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ABSTRACT 
 
Directing antibodies against CD4, the primary receptor for HIV entry on its host T-cells, has 
been explored as an alternative way of inhibiting viral infection. Here, a panel of 40 CD4 
targeting monoclonal antibodies (MAbs) were generated from mice immunized with bacterially 
expressed recombinant 2-domain CD4 (2dCD4). Firstly, the first two individual domains of 
CD4, termed D1 and D2, were generated. Whilst the mutant D1 generated was based on a 
previous work, the expression and characterisation of individual wild-type domain D2 has not 
yet been reported in detail. D1 and D2 cassettes were cloned and expression in E.coli was 
optimised. After the establishment of an optimised purification protocol, the purified protein 
were assessed by means of basic biophysical analyses (analytical SDS-PAGE, CD 
Spectroscopy), which allowed us to gain insights into the structural and functional integrity of 
the purified products. Recombinant D1 and D2 were then used to define the domain specificities 
of the MAbs by ELISA. We also demonstrated the ability of the MAbs to inhibit CD4-gp120 
binding in vitro by ELISA, and inhibit viral infection by a pseudovirion inhibition assay. These 
preliminary results reinforce the potential of CD4-directed MAbs as candidate anti-HIV agents, 
and provide a solid platform for further pre-clinical development of this class of antiviral 
compounds. 
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1.1. INTRODUCTION 
 
1.1.1. Epidemiology 
 
According to the World Health Organisation, nearing the end of 2013, approximately 36 million 
people globally were infected with the Human Immunodeficiency Virus (HIV) 
(WHO_Media_Centre, 2014). The official report from the UNAIDS (2013) estimated that 
approximately 35.3 million [32.2– 38.8] individuals were living with the disease. The number of 
new HIV infections in 2012 was 2.3 million [1.9 – 2.7], which represented a 33% decrease in the 
incidence since the turn of the millennium. This corresponds to the improved accessibility to 
antiretroviral (ARV) therapy in the low- and middle-income countries 
(World_Health_Organisation, 2013). As a result, a decrease in the number of Acquired 
Immunodeficiency Syndrome (AIDS)-related deaths from 2.3 million [2.1– 2.5] in 2005, to 1.6 
million [1.6– 1.9] at the end of 2012, was observed. In spite of the optimistic figures, HIV/AIDS 
remains the leading cause of death worldwide by an infectious disease 
(World_Health_Organization, 2014). 
The prevalence of HIV/AIDS remains very high globally (World_Health_Organisation, 2013). 
The global burden of the disease is however unequally distributed. As reported in the 2013 
UNAIDS Global Report, the Sub-Saharan African region, representing only 12% of the world’s 
population, bears approximately 70% of the population infected with HIV. By the end of 2012, it 
was estimated that Sub-Saharan Africa was comprised of 25 million [23.5 – 26.6] people living 
with HIV, with an annual incidence of 1.6 million [1.4 – 1.8] and AIDS-related death tending to 
1.2 million [1.1 – 1.3]. 
Nevertheless, as from 2004 – 2005, sub-Saharan Africa, amongst other low income countries, 
witnessed a significant decrease in AIDS-related deaths. With reduced new infections and 
greater access to ARV therapy, the mortality due to HIV/AIDS declined by over 50% from 2004 
– 2012. For example, following introduction of ARVs in the public health system  in KwaZulu-
Natal (South Africa) in 2003, the adult life expectancy of the population cohort under 
observation (over 101,000 individuals) was increased from 49.2 to 60.5 years by 2011 (Bor et al., 
2013). Behavioural changes towards safe sex (Gregson et al., 2006), voluntary medical male 
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circumcision (Bailey et al., 2007, Auvert et al., 2005) and most importantly, increased 
accessibility to treatment and ARV drugs, enlist some of the few factors that have certainly 
contributed towards the reversal of the trend. 
 
1.1.2. Basics of HIV 
1.1.2.1. Pathophysiology of HIV and AIDS 
 
Infection with HIV is the cause of AIDS. The disease is characterised by the interference with 
the normal function, and the eventual ablation of the immune system. More specifically, the 
canonical hallmark of HIV/AIDS is the gradual destruction of the CD4+ T-cell population – the 
main HIV host cell (Douek et al., 2003). Following primary infection with HIV, the high viral 
load and significant reduction of peripheral blood T-cell counts correlate with an acute 
symptomatic phase. With restoration of the T-cell population and the maturation of an HIV-
targeting immune response within the following few weeks, the virus is remarkably cleared from 
the peripheral blood. The period of low viraemia, during which there is the establishment of a 
viral reservoir, is an asymptomatic or chronic phase, with the dynamics of viral load and T-cell 
count determining the outcomes. Throughout, the trending decrease in peripheral T-cell count 
and increase in viraemia translates into the disease progression to AIDS. As defined by the 
WHO’s clinical staging, with the CD4+ counts falling below 350 cell/µL, the progression of HIV 
infection becomes increasingly associated with the array of AIDS-related afflictions 
(World_Health_Organisation, 2007). 
In the immuno-compromised state the infected person is at open risk to a multitude of severe and 
chronic opportunistic infections and diseases (Holmes et al., 2003). In 1981, when the first cases 
of AIDS were being reported in homosexual men and intravenous drug abusers in the U.S., the 
patients presented with a form of pneumonia caused by Pneumocystis carinii, a fungal infection 
which typically affects only severely immuno-compromised individuals (Gottlieb, 2006). 
Tuberculosis, caused primarily by Mycobacterium tuberculosis, is heavily associated with 
HIV/AIDS, particularly in developing countries like South Africa (Corbett et al., 2003). As well 
as increasing the risks of developing the disease, the positive HIV/AIDS status significantly 
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contributes to the reactivation of latent tuberculosis (McShane, 2005), and rapid disease 
progression (Daley et al., 1992). The African continent is faced with a worsening dual disease 
burden as nearly 93 % of new TB cases occurred in patients with an underlying HIV infection 
(World_Health_Organisation, 2011). Additionally, the HIV/AIDS condition is marked with 
increased susceptibility to Salmonella enteritis and acute diarrhoea, pneumococcal infections, 
cryptococcal meningitis, oral and oesophageal candidiasis, herpes zoster and cytomegalovirus 
infections (Holmes et al., 2003). Malaria, yet another Africa-biased burden, indicates poor and 
severe prognosis in HIV immunosuppressed patients (Grimwade et al., 2004). In fact, population 
studies in Kenya have shown that regular malaria infections results in repeated in increases viral 
loads in HIV-infected patients, which is likely to contribute to the spread of HIV (Abu-Raddad et 
al., 2006). Karposi’s Sarcoma and Non-Hodgkin Lymphoma, as well as several non-AIDS 
defining cancers, further contribute to the extensive list of diseases associated with HIV/AIDS 
(Frisch et al., 2001). 
 
1.1.2.2. Viral Classification and Diversity 
 
HIV is a member of the Lentivirus genus and part of the Retroviridae family. HIV is one of the 
most genetically diverse species. Screening samples that were collected between the years 2000 
– 2007 from across the globe illustrates its extreme diversity (Hemelaar et al., 2006, Hemelaar et 
al., 2011). The HIV type 1 (HIV-1) strain can be categorised into four genetic groups: M (major), 
O (outlier), N (non-M, non-O) and P. Subsequently, the M-group, primarily responsible for the 
AIDS epidemic, can be re-classified into 9 subtypes (A – D, F – H, J and K). However, it is 
interesting to note that subtype C corresponds to almost 50 % of the global distribution, and 
nearly exclusively all of Sub-Saharan HIV-1 infections. Within a single subtype, genetic 
diversity can range between 15 – 20 %, whilst between the subtypes, the corresponding figure is 
25 – 35 %. Worsening the scenario, as result of genomic intermingling between subtypes, 19 
recombinant forms of the virus have been identified during the survey and to date, 72 circulating 
recombinant forms (CRFs) have been identified (http://www.hiv.lanl.gov). Nevertheless, HIV-1, 
as opposed to the rarer HIV-2 which remains confined to West Africa, is the predominant strain 
responsible for the pandemic (McCutchan, 2006). 
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1.1.2.3. Viral Genome and Structure 
 
The genetic composition and morphology of HIV-1 has been extensively studied. HIV consists 
of two copies of positive-strand RNA. The relatively short genome (~10 kb), capped by LTRs 
(Long Terminal Repeats), can be divided into three main segments encoding key proteins: the 
structural components; gag (encoding the p24, p17, p7, p6, p2 and p1), pol (encoding the viral 
enzymes protease, reverse-transcriptase, RNAse H and integrase), and env, the gp120-gp41 
envelope precursor gp160 (Ratner et al., 1985). Also present are regulatory (tat and rev) and 
accessory protein encoding genes (nef, vif, vpu, and vpr). As described from electron 
micrographs, the typical viral particle is spherical and approximately 145±25 nm in diameter 
(Briggs et al., 2003). It consists of a shortened electron dense cone-shaped core (capsid) 
surrounded by a host derived lipid bilayer. The lipid bilayer is studded with about 70 – 80 
“spikes”, consisting of knobs connected to the membrane by stalks (Gelderblom et al., 1987). 
Respectively, the knobs and the stalks represent trimeric gp120 and gp41 (Ozel et al., 1988). 
These, as described later, play vital roles in viral entry into its host cell. The most external layer 
of the core, made up of matrix protein (p17), is associated with the inner side of the bilayer. 
Capsid protein (p24), arranged as rings of hexamers, forms the capsid. The capsid encapsulates 
the two RNA copies. Binding tightly to the RNA, the nucleocapsid protein (p7) is important for 
the stabilisation of the RNA and viral assembly (Dawson and Yu, 1998). Localised within the 
capsid are the enzymes reverse-transcriptase, integrase and protease, critical for viral replication. 
Additionally, the capsid encloses several accessory proteins (Vpu,Vif, Vpr and Nef) which are 
involved in a multitude of roles that ensure viral survival, replication and maturation (Malim and 
Emerman, 2008). 
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Figure 1: Diagram of HIV particle (copied from http://www.niaid.nih.gov/factsheets/graphics/howhiv.jpg) 
 
1.1.2.4. Life-Cycle and Replication 
 
HIV infection begins with the attachment of the viral envelope glycoprotein gp120 to host cell 
CD4 receptors, and subsequent interaction between gp120 and host cell co-receptors (CCR5 or 
CXCR4). As discussed more extensively in the following section, a series of events involving the 
viral envelope – host cell receptors’ interaction lead to viral entry into the host cell. Within the 
cytoplasm, following the dismantling of the virion core, viral reverse transcriptase (RT) reverse 
transcribes and converts the viral RNA into linear double-stranded cDNA (Sarafianos et al., 
2009). Assisted by integrase, the proviral cDNA is transported into the nucleus, and is inserted 
into gene-rich regions of the host genome (Schroder et al., 2002). Initially transcribed along with 
host transcription events, the gradual accumulation of accessory protein Tat (Trans-Activator of 
Transcription) directs the intensive transcription of the viral DNA (Debaisieux et al., 2012). 
Subverting the host cell transcription and translation machinery, all the viral proteins and 
genomic RNA are produced. Throughout, accessory proteins participate in a number of tasks that 
ensure the survival and assembly of the virion particle. A function of Vpu (Viral protein U) 
involves the formation of conductive ion pores on the host cell surface membrane to favour viral 
release and budding (Schubert et al., 1996). Viral proteases cleave the Gag-Pol polypeptide into 
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its functional components, and therefore participate in the finalisation of the mature virion 
(Nicholson et al., 1995). 
After integration of viral DNA into the host cell genome, HIV is capable of entering the so called 
‘latent’ state, a state of viral dormancy during which active viral replication is interrupted 
(Siliciano and Greene, 2011) Following immune activation by antigen-presenting cells, a small 
number of activated CD4+ T-cells revert to the resting (Go) state, and persist as long-lived 
memory cells. HIV contained within memory cells in the form of stably integrated DNA escapes 
canonical humoral and cell-based immune surveillance mechanisms, and these provide an 
important reservoir that sustains the emergence of viral quasi-species (Chun et al., 1997, Chun et 
al., 1995, Spina et al., 1997) 
 
1.1.2.5. Viral Entry 
 
The first step of HIV infection of host cells involves the attachment of the viral envelope gp120 
to its primary receptor, CD4. As correctly presumed from early electron microscopy studies, 
“knob on stalk” structures coating the virion are the envelope glycoproteins gp120-gp41 trimeric 
heterodimers (Ozel et al., 1988, Gelderblom et al., 1987). With recent cryo-electron tomography 
analysis, the arrangement of trimeric gp120-gp41 heterodimers with the surface glycoprotein 
gp120 attaching non-covalently to the membrane spanning glycoprotein gp41 was reinforced 
(Liu et al., 2008, White et al., 2010). The structure of gp120 consists of five constant (C1-C5) 
and five variable regions (V1-V5) (Kwong et al., 1998). The core structure of gp120 (lacking V1 
– V3), folding into a globular structure, comprises 25 β-strands, 5 α-helices and 10 loop 
segments. The overall structure is considered as an inner and outer domain, linked by a four-
stranded “bridging sheet”. The depression located at the interface of the two domains with the 
bridging sheet forming the CD4 binding site. Closer inspection of the binding site indicates two 
cavities into which the CD4 molecule inserts. The placement of CD4 into its binding site 
consequently leads to the occlusion of the gp120 binding site by Phe
43
 of CD4, which critically 
assists in stabilising the CD4-gp120 interaction. 
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Following the binding of the CD4 to its corresponding binding site, the gp120 undergoes 
conformational changes leading to exposure of several conserved sites on the gp120 termed 
CD4-induced binding sites (CD4i), including the highly-conserved co-receptor binding site 
(either CCR5 or CXCR4) (Rizzuto et al., 1998). Conformational changes occurring in CD4 as 
well, lead to the approach and re-orientation of the gp120 co-receptor binding site to its target 
(Yachou and Sekaly, 1999). The protruding N-terminus and extracellular loops of the 
transmembranal co-receptor procure the contact points for the gp120 interaction (Lee et al., 
1999a). Additionally, the negatively charged nature of the N-terminus of the coreceptor is 
suspected to participate in electrostatic interactions with the positively charged residues of the 
V3 loop of gp120 (Kwong et al., 1998). 
The core structure of gp41 consists of a bundle of three α-helical strands organised as a trimeric 
rod (Weissenhorn et al., 1997). From proximal to distal of the viral membrane, each of the 
strands in turn contains a regular α-helix and leucine zipper-like region. Capping the extremity of 
the latter, are the fusion domains. Upon co-receptor binding, conformational changes induced in 
the gp120 exposes the gp41. HIV entry at this stage is suggested to follow a similar mechanism 
as that of the “spring-loaded” fusion in Influenza (Carr and Kim, 1993). The fusion domains of 
the gp41 are extended towards the host cell membrane where contacts are made. Subsequently, 
the α-helices and leucine zipper-like domains complex to each other and form a six-helix bundle. 
In the process, as the result of the overall contraction of the structure the viral and host 
membranes are brought close to each other. Several such gp41 interactions eventually lead to the 
fusion of membranes, and hence the formation of fusion pores. The viral core can therefore 
access the host cell cytoplasm. 
 
1.1.3. Current Antiretroviral Treatment and Prevention Strategies 
1.1.3.1. Approved Anti-HIV Drugs 
 
The multistage life-cycle of HIV offers a number of targets for drug-induced disruption. Since 
Zidovudine, the first antiretroviral drug approved for HIV treatment in 1987, at least 25 other 
anti-HIV drugs have been approved for clinical use (De Clercq, 2009, AIDSinfo, 2014). 
22 
 
The different drugs operate by various modes of actions. Several of them inhibit the normal 
functioning of viral reverse transcriptase (RT). These are consequently re-categorised as 
nucleoside RT inhibitors (NRTIs), nucleotide RT inhibitors (NtRTIs) and non-nucleoside 
(NNRTIs). NRTIs (zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and 
emtricitabine) and NtRTIs (tenofovir), when converted to the active forms, essentially act as 
competitive inhibitors of dideoxynucleotides, the building blocks of viral DNA. The use of the 
analogues results in the premature termination in the elongation of the viral DNA. The NNRTIs 
(nevirapine, delavirdine, efavirenz and etravirine) bind to a non-catalytic site, which 
consequently due to an allosteric effect, leads to the inactivation of RT. As expected, integrase 
inhibitors (INIs; raltegravir, elvitegravir) and protease inhibitors (PIs; saquinavir, ritonavir, 
indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir) 
target the corresponding enzymes. The fusion inhibitor Enfuvirtide, that blocks viral entry by 
interfering with the functionality of gp41, provides another mechanism of viral inhibition 
(Matthews et al., 2004). 
Maraviroc is CCR5-specific antagonist which inhibits infection of CCR5-dependent (R5) viruses 
(Dorr et al., 2005). Functional and structural studies of CCR5 chemokine receptor in complex 
with Maraviroc provided further evidence of the role of the drug  as a viral fusion inhibitor (Dorr 
et al., 2005, Tan et al., 2013). It is being suggested the small molecule Maraviroc, acting as a 
non-competitive inhibitor, binds to a region of CCR5 that is distinct from the binding site of viral 
gp120 (Garcia-Perez et al., 2011, Tan et al., 2013). Thus, Maraviroc is of particular interest in 
this project as it provides a certain proof of concept in finding an equivalent antibody against (the 
host factor) CD4, which is non-toxic and capable of inhibiting HIV infection. 
 
1.1.3.2. Antibody Development against HIV 
 
HIV vaccine research has focused extensively on raising antibodies against exposed, structurally 
conserved epitopes on the envelope glycoprotein. A key research tactic (reverse vaccinology) 
involves the identification of broadly neutralising antibodies (bNAbs) that can inhibit conserved 
functional epitopes of the viral envelope glycoprotein across all of the clinically relevant HIV 
strains (Trkola et al., 1995).  The epitope of IgG1b12, the first bNAb to be recognised (Burton et 
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al., 1994, Burton et al., 1991), was found to overlap the CD4 binding site on gp120 (Roben et al., 
1994). As visualised from the crystal structure of b12, a protein loop of the antibody (termed 
CDRH3) is capable of occupying the depths of the CD4 binding site (Saphire et al., 2001). 
Another bNAb, 2G12 recognises a carbohydrate-enriched region on the outer surface of gp120 
(Calarese et al., 2005). The 447 – 52D monoclonal antibody targets the GPGR residues of the 
gp120 V3 loop (Stanfield et al., 2004). By contrast, the antibody 2F5 targets a conserved epitope 
on the gp41 (Muster et al., 1993). Further anti-gp41 monoclonal antibodies such as Z13 and 
4E10 have been generated and characterized (Zwick et al., 2001). Exposure of CD4i epitopes  
provides additional binding targets for antibodies. The crystal structure of the Fab fragment of 
the 17b antibody in conjunction to CD4-bound gp120, showed that its binding site on gp120 is 
located on the bridging sheet and V1 – V2 loops (Kwong et al., 1998). The region closely 
corresponds to the co-receptor binding site. In vivo experiments involving passive immunisation 
with several of such antibodies, have provided strong evidence that the correct anti-HIV antibody 
present in sufficient quantity would be able to protect against HIV infection (Shibata et al., 1999, 
Gauduin et al., 1997, Mascola et al., 2000). 
Within the last five years, there has been an explosion in the number of newly identified bNAbs 
(Eroshkin et al., 2014). PG9 and PG16, two somatically-related bNAbs which target V1 – V3 
region of g120, were recognised from an infected individual and could neutralise 70 – 80% of 
viral isolates (Walker et al., 2009, Doores and Burton, 2010). VRC01, acting as a CD4 mimic, 
binds to the CD4bs of gp120 and thus sterically restricts viral attachment to CD4 (Zhou et al., 
2010). The PGT group of antibodies, similarly to 2G12, targets glycans of gp120 (Pejchal et al., 
2011). BNAbs develop in a HIV-infected individual (Richman et al., 2003, Doria-Rose et al., 
2009), and thus thanks to the advancement of high-throughput screening technology, these could 
be identified. As well as identifying new bNAbs, high-throughput screening, coupled with 
sequencing and mathematical models, are being used to understand the development of the 
antibodies (Simek et al., 2009, Sather et al., 2009, Wu et al., 2011, Doria-Rose et al., 2010). By 
regression of the somatic hypermutation pathway, it would be possible to identify the HIV 
immunogen that elicited the bNAb. Thus, such studies would assist in the rationale vaccine 
design (Stamatatos et al., 2009). 
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1.1.3.3. The Problems with Antibody-Based HIV Treatments 
 
It has been nearly 30 years since the discovery of HIV/AIDS and yet, no efficient vaccine has 
been developed. Several reasons, pertaining to viral biology, the immune system, and the 
interplay of the two, have been described for the failure. An excellent review which by D. R. 
Burton et al.(2012) provides the extensive details on issues relating to HIV vaccine development 
(Burton et al., 2012a). Here, a brief overview of the main problems associated with the 
development of vaccines and antibody treatments against HIV shall be described. 
 
1.1.3.3.1. HIV Diversity and Rapid Mutation Rates 
 
As mentioned previously, HIV is extremely diverse. The different HIV strains, subtypes and 
CRFs, display variable immunogenicities, pathogenesis and transmission characteristics. 
Consequently, this poses major obstacles in the diagnostics, prognostics, and most importantly, 
vaccine and drug development (Boutwell et al., 2010). The highly imprecise nature of the reverse 
transcriptase (RT) is considered as a main cause of such diversity (Korber et al., 2001). Coupled 
with a rapid replication rate, from a single homogenous HIV population following infection, a 
wide-distribution of genetically varied quasispecies arises. A study involving the monitoring of 
the C2 – V5 region of gp120 during the course of HIV infection, exemplified such divergence 
and diversification of a founder HIV population, to the point that there was the establishment of 
CXCR4 co-receptor-dependent HIV population (Shankarappa et al., 1999). In fact, it is being 
shown that most HIV clinical infections occur due a single founder virus (Keele et al., 2008, 
Salazar-Gonzalez et al., 2008). Ultra-deep sequencing provided further evidence of viral 
diversification which arises from a single virus within the only few weeks following infection 
(Fischer et al., 2010). It can be theorised that under the selective pressure of the immune system, 
micro-evolution pushes HIV towards resistant strains (Wolinsky et al., 1996). For instance, by 
tracking the changes in the genome of HIV during early infection in patients, it was observed 
that low neutralising antibody titres allowed for selection and escape of HIV resistant strains 
(Bar et al., 2012). Similarly, neutralising antibodies produced by HIV-infected patients drove the 
emergence of resistant strains for as long as 10 years after of initial infection (Chaillon et al., 
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2012). Such mutations, translated as amino acid changes in the viral envelope, imply that critical 
epitopes can subsequently go unrecognised by cellular and humoral immune responses. 
 
1.1.3.3.2. Inaccessible Neutralizing Epitopes on the Envelope Glycoprotein 
 
Another important mechanism of immune evasion involves the inaccessibility of neutralising 
epitopes on Env (Johnson and Desrosiers, 2002). Several such epitopes remain buried at the core 
of the viral envelope and are only exposed transiently during the course of viral entry as a result 
of induced conformational changes. Whilst antibodies are produced in HIV-infected patients, 
these generally however target the exposed variable regions, rather than the conserved, recessed 
regions on gp120, leading to very restricted strain-specific neutralisation   (Burton et al., 2012b).  
Furthermore, the heavily glycosylated variable loops of gp120, often blamed for concealing the 
more conserved regions (Poignard et al., 2001, Johnson and Desrosiers, 2002), are therefore a 
reason for the inability to develop efficient bNAbs. It is estimated that 50 % of the gp120-gp41 
molecular weight is attributed to the associated carbohydrates. In effect, the viral envelope is 
coated with a dense “glycan shield” that blocks antibody interaction with underlying epitopes 
(Wei et al., 2003). It is interesting to note that the CD4-binding site of gp120 lacks 
oligosaccharides (Kwong et al., 1998). It is however protected by the shielding variable loops, 
which in addition, are glycosylated. Artificially altering the positions or removal of the 
oligosaccharides of the V1 or V3 loop dramatically increased the sensitivity of the virus to 
antibody neutralisation (Back et al., 1994, Overbaugh and Rudensey, 1992, Koch et al., 2003). 
Certain antibodies, such as 2G12, however, can actually recognise and bind to the carbohydrates 
on gp120 (Calarese et al., 2003). More recently, the PGT group of antibodies could bind directly 
to the glycans and many within this group are capable of potent, cross-clade neutralisation 
(Pejchal et al., 2011). Nevertheless, it has been shown that the glycan layer is not static, but 
changes throughout the course of viral infection (Overbaugh and Rudensey, 1992, Moore et al., 
2012, Wei et al., 2003). To illustrate this, a study demonstrated that within 6 months of infection, 
a shift in the position of a critical glycan molecule on gp120 resulted in HIV resistance to 
PGT128 (Moore et al., 2012).   
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1.1.3.3.3. The Envelope Glycoprotein as an Immune Decoy 
 
Many vaccine studies have focused their attention on monomeric forms of recombinant gp120. A 
large number of antibodies binding to gp120 have been generated in small animals, non-human 
primates as well as humans, but very few, if any, have a neutralising effect against clinically 
relevant HIV. One of the reasons for this is the existence of two “faces” on gp120: termed the 
‘neutralising’ and  ‘non-neutralising’ face (Moore and Sodroski, 1996). As their name suggests, 
the neutralizing face contains conserved epitopes which could elicit bNAbs, while no known 
bNAb epitopes exist on the non-neutralizing face. Further studies eventually lead to the 
conclusion that the neutralising and non-neutralising characteristics of gp120 relate to the 
positioning of its faces in the native state (Poignard et al., 2001, Johnson and Desrosiers, 2002). 
Considering that the gp120-gp41 heterodimer exists as a trimeric structure in the native state (Liu 
et al., 2008) it is now known that the neutralising face represents the exposed surface of the viral 
envelope, whereas the non-neutralising face represents the surface hidden within the trimer. 
Based on gp120 dissociation after co-receptor binding and the establishment of the gp41 fusion-
hook, it is interesting to note that both the neutralising and non-neutralising faces are exposed 
(Parren et al., 1997). Hereafter, any antibodies directed towards the shed gp120 will unlikely 
target the conserved bNAb epitopes on the virion, since the conformations and exposed sites are 
different. Thus, the shed gp120 acts as an immune decoy, and these antigenic baits provide 
another mechanism of HIV escape from neutralising antibodies. 
 
1.1.3.3.4. Extensive Somatic Hyper-mutation 
 
With increasing usage of high-throughput antibody screening and sequencing approaches, a 
number of novel bNAbs have been identified in HIV-infected individuals (Walker et al., 2009, 
Zhu et al., 2013, Johnson et al., 2009). However, these mature bNAbs only come to existence 
after extensive somatic hypermutation in some of the chronically infected HIV individuals 
(Haynes et al., 2012, Verkoczy et al., 2011). Understanding the development of the antibodies 
and recognising the immunogen precursor that elicited such response would be of immense help 
in rationale vaccine design (Simek et al., 2009, Sather et al., 2009, Wu et al., 2011, Doria-Rose et 
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al., 2010). However, directing guided evolution of the antibody remains a complex task due to 
the number of variables that affect somatic hyper-mutation evolution (Gray et al., 2009, 
Piantadosi et al., 2009, Sather et al., 2009). For instance, following an analysis of over a hundred 
patient sera against several clinical features, it was shown that neutralisation breadth correlated 
only with viraemia, and 20% of these sera could be qualified as bNABs (Doria-Rose et al., 
2010). Elsewhere, it is indicated that additionally, the generation of potent bNABs is influenced 
by length of time since the patient was infected and the binding avidity of the early antibodies 
against viral envelope (Sather et al., 2009). Moreover, it has also been suggested the 
development of bNABs has to be triggered during early infection (Piantadosi et al., 2009). Taken 
together, a number of studies suggest that the generation of bNABs in a patient begins from an 
early unmutated germline antibody with strong affinity to CD4-binding site of viral envelope that 
goes through a lengthy and complex maturation process, whilst being continuously exposed to 
heterogeneous viral antigens (Zhou et al., 2010, Xiao et al., 2009, Wu et al., 2010, Wu et al., 
2011, Kwong and Mascola, 2012, Liao et al., 2013). Recently, the evolution and structure 
determination of mature CD4-binding site CH103 antibody, which could neutralise about 55% of 
HIV-1 strains, provides critical information on the pathway for maturation and the structural 
characteristics that bNABs require (Liao et al., 2013).In the future, with more studies, it might be 
possible to indentify the exact requirements for the development of potent bNABs against HIV 
(Burton et al., 2012a). 
 
1.1.4. Project objectives 
 
Targeting the HIV envelope glycoprotein with vaccine induced neutralizing antibodies has 
remained a major focus of biomedical preventative HIV research. The identification of novel 
neutralising antibodies through the mass screening of HIV infected sera, has provided a recent 
boost of optimism in the field individuals (Walker et al., 2009, Zhu et al., 2013, Johnson et al., 
2009). However, it still remains that with the evolving nature of HIV and due to the extensive 
degree of somatic hyper-mutation required for the generation of mature bNAb, the development 
of a successful HIV vaccine remains difficult. An alternate school of thought to overcome this 
issue and prevent viral entry involves targeting the host cell receptors and co-receptors that are 
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employed by the virus during entry. Accordingly, in this project we have generated a panel of 
monoclonal anti-CD4 antibodies that are capable of inhibiting HIV infection, and defined their 
binding specificities at the domain level. 
In chapter 2, after a detailed description of CD4, we describe the generation of recombinant 
bacterially expressed individual domains 1 and 2 of CD4. We began by designing the expression 
cassettes encoding the respective domains and proceeded to express, purify and characterise 
purified proteins biochemically. Here, we showed that proteins were stable and exhibited correct 
disulphide pairing. In chapter 3, using the purified individual domains of CD4 as part of ELISA 
assays, we were able to define the domain-specificities of a panel of anti-CD4 monoclonal 
antibody-containing hybridoma supernatants. We then confirmed the antiviral properties of the 
hybridoma supernatants in vitro using recombinant gp120, and finally, in cell culture using 
pseudovirus inhibition assays. 
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CHAPTER 2:         
THE CD4 RECEPTOR 
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2.1. INTRODUCTION 
 
Human CD4 plays a canonical role in the infection of HIV as the primary receptor for the viral 
surface glycoprotein gp120.  Recent structural and biophysical data have suggested that CD4 
plays a more active role in HIV entry than simply acting as a viral docking site. These data have 
revealed that CD4 is a dynamic and conformationally-active molecule that plays a major role in 
viral infection. In this chapter we introduce the structure, biophysics and basic biology of CD4, 
before describing the production of a panel of recombinant CD4 variants, which have been used 
as tools for generating novel candidate therapeutic monoclonal antibodies against HIV. 
 
2.1.1. General Overview 
 
The human T-cell surface glycoprotein cluster of differentiation 4 (CD4; previously T-cell 
surface antigen T4/Leu-3), is encoded by the CD4 gene, which is located on the forward strand 
of chromosome 12 (Ensembl Transcript ID: ENST00000011653). The 3114 base transcript is 
spliced into 10 exons, which upon translation produces a polypeptide of 485 amino acid residues 
(Ensembl Protein ID: ENSP00000011653). The polypeptide precursor has a molecular weight of 
51,110.54 g/mol (~51 kDa), and an average residue weight of 111.595 g/mol. The unprocessed 
CD4 polypeptide contains a signal peptide (hydrophobic NH2 – terminal domain, residues 1 – 
25) while the mature CD4 polypeptide comprises residues 26 – 458. The actual polypeptide can 
be further divided into three regions: the extracellular (residues 26 – 396), transmembranal 
(residues 397 – 418), and cytoplasmic (residues 419 – 458) regions. Starting most distal from the 
cell surface membrane, the extracellular region contains four distinct domains: domain 1 (D1, 
residues 26 – 125), domain 2 (D2, residues 126 – 203), domain 3 (D3, residues 204 – 317) and 
domain 4 (D4, residues 318 – 374). Post-translational modifications include two lipidation sites 
(S-palmitoyl cysteine; Cys
419
, Cys
422
), two glycosylation sites (N-linked acetylglucosamine; 
Asn
296
, Asn
325
), and critically, as will be described in detail in subsequent sections, three 
potential disulphide linkages (Cys
41
 – Cys109, Cys155 – Cys184, Cys328 – Cys370). Following post-
translational modifications, CD4 has a relative molecular weight of 55,000 g/mol (~55 kDa). 
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2.1.2. Function of CD4 
 
Although canonically located on CD4+
 
T-cells (Maddon et al., 1985), the CD4 receptor is also 
present on dendritic cells (Patterson et al., 1995), macrophages (Lee et al., 1999b) and natural 
killer cells (Bernstein et al., 2006). The role of CD4 on non-T-cells remains largely unknown. 
However, recent evidence indicates that CD4 on non-T-cells are involved in roles other than the 
‘immunological synapse’. For instance, following ligation of CD4 on activated natural killer 
cells, CD4 has been shown to mediate the migration of the cells towards CD4-specific 
chemotactic factor IL-16, and induce cytokine expression (Bernstein et al., 2006). 
Under normal physiology, the CD4 receptor located on T-cells, plays a fundamental role in the 
formation of the immunological synapse between the antigen presenting cells (APCs) and T-cells 
(Sweet et al., 1991, Bromley et al., 2001). During infection, as part of the innate immune 
response, APCs such as macrophages and dendritic cells phagocytose the invading pathogen. 
The phagocytosed material is digested intracellularly, with constituent proteins being cleaved to 
small peptides. These peptides associate with major histo-compatibility complex class II 
(MHCII) molecules, which are transported to the cell surface where the MHCII is 
embedded/inserted into the cell surface membrane. The MHCII thereby presents the peptide to 
circulating T-cells. T-cells bind to peptide-MHCII complexes via the T cell receptor (TCR), and 
recognise the peptide as foreign. This interaction and the resulting transduced signal is however 
weak. The immunological synapse is stabilised and transduced signal reinforced by the CD4, 
which binds to MHCII following the initial, kinetically ‘loose’ association between the TCR and 
MHCII. The co-stimulatory effect can be explained by the activation of tyrosine kinase p56
lck
, an 
enzyme which is associated with the cytoplasmic domain of the CD4. The phosphorylation 
events initiated by the p56
lck
 lead to a molecular cascade, which in turn ultimately results in 
activation of the T-cell and the release of immunostimulatory cytokines. Amongst their various 
targets, the cytokines activate β-cells into the production of antibodies, a defining feature of the 
adaptive immune response. For an extensive description on the role of CD4 T-cell in antigen 
recognition, the review by Merwe and Davis should be consulted (van der Merwe and Davis, 
2003). 
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2.1.3. Structure of Extracellular CD4 
 
The structure of the extracellular domain of CD4 has been extensively investigated.  The crystal 
structure of the first two domains (2dCD4, Figure 2), which wholly contains the contact points 
for both MHCII and HIV-1 gp120, revealed a rod-shaped structure comprising two distinct but 
closely associated immunoglobulin-like domains linked by a flexible β-strand. (NOTE: Residue 
numbers are with reference to the 2dCD4 and NOT full length CD4) (Ryu et al., 1990, Wang et 
al., 1990). The surfaces of the relatively large solvent inaccessible interdomain regions are 
essentially hydrophobic. 
 
 
 
 
 
 
Intracellular 
Extracellular 
Domain 3 
Domain 2 
Domain 1 
Domain 4 
 
Figure 2: Molecular Structure of the first 2 N-
terminal domains of Human CD4 (2dCD4) 
(PDB ID: 1CDJ) (Wu et al., 1996) 
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CD4 domain 1 (D1, residues 1 – 98) is made up of nine anti-parallel β-strands organised as a two 
β-sheet layer sandwich with Greek key topology (Ryu et al., 1990, Wang et al., 1990). In this 
way, D1 - and indeed all 4 extracellular domains of CD4 – are structurally homologous to 
variable immunoglobulin (IgV) domains, and the β-strands are defined accordingly:  strands A, 
C, C’, C”, F and G form the one layer of the β-sheet sandwich, whilst strands B, D and E form 
the other layer (Figure 2). An extensive network of hydrogen bonds link the anti-parallel strands, 
which encapsulate a hydrophobic core. In D1, as for the typical IgV domain, the presence of the 
disulphide bond between Cys
16
 – Cys84 and the conserved Try28 (tryptophan) is noted. 
Conversely, there are two important differences in the structure of D1 and a typical IgV 
structure. Firstly, the C’C” loop of D1, corresponding to the complementarity-determining region 
2 (CDR2) of antibodies is abnormally long. Secondly, the loops CC’ and FG of D1, 
corresponding respectively to the CC’ and CDR3, are on the other hand, shortened. This second 
difference correlates with the function of the loops in heavy- and light- chain (VH - VL) 
association, a feature which is relevant only for antibodies. 
Domain 2 (D2), as a direct continuation of D1 from residues 99 – 173, is in turn made of seven 
anti-parallel β-strands (Ryu et al., 1990, Wang et al., 1990). The folding pattern of D2 follows a 
topology resembling that of constant immunoglobulin domain (IgC). Similarly, the strands of β-
sheets are ascribed the same nomenclature. The strands A, B and E comprise one of the β-sheet 
sandwich layers, and strands C, C’, F and G form the other (Figure 3). However, several striking 
differences are noted in D2 when contrasted to the typical IgC domain. The most apparent 
feature is the small size of D2 (75 residues), as opposed to the IgC or the other domains of CD4 
(~100 residues). As a result, the lengths of the β-strands are considerably shorter. Another 
difference is that the C’ strand of D2, corresponding to the D strand of IgC, is contained in the β-
sheet that comprises of strands C, F and G. The D strand in the typical IgC is by contrast found 
in the β-sheet that includes itself (the D strand), E, B and A strands. In that regard, the hydrogen 
bond association between C’ and C of D2 in the corresponding β-sheet layer resembles the IgV 
instead of IgC (Figure 2). Finally, a critical difference between D2 and the typical 
immunoglobulin-fold structure is the presence of respective intra- as opposed to inter sheet 
disulphide linkages. The disulphide bond formed by the residues Cys
130
 – Cys159 interlinks 
strands C and F of the same sheet. In subsequent sections, a more elaborate discussion of the 
nature, importance and possible functional implication of this disulphide bond will be discussed. 
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Figure 3: Schematic 
representation of the 
organisation of the β-strands in 
D1 and D2 (Taken from (Ryu 
et al., 1990) 
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The crystal structure of full length sCD4 (1WIO) reveals an elongated, rod-like structure 
comprised of 4 distinct domains (Wu et al., 1997). As expected, a single strand, the direct 
continuation of strand G of D2 into strand A of D3, links the two domains. Similarly to the 
interface of D1 – D2, surfaces forming the D2 – D3 interface are solvent inaccessible and highly 
hydrophobic. Significantly, an obtuse angle of 140
o
 is observed between the D1D2 (domain 1, 
domain 2) and D3D4 (domain 3, domain 4). Such a wide angle is suggested to be related to 
junctional flexibility between D1D2 and D3D4. 
 
2.1.4. The CD4-Gp120 Interaction 
 
As the primary complex formed during contact between HIV and host target cells, the CD4-
gp120 interaction has been studied extensively (Kwong et al., 1998). CD4 inserts into a 
depression in the gp120 formed at the interface of the inner and outer domains, with the bridging 
sheet on gp120 stretching in between (Figures 4a, b). The depression can be divided into two 
cavities. The larger of the two cavities (279 Å
3) fits the CC’C” strands of domain 1 of CD4, 
whereas the smaller cavity is occluded by the large ring structure of residue Phe
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(phenylalanine, position 43) of CD4. In general, there is good electrostatic complementarity 
between the contacting surfaces of CD4 and gp120, with the electro-positive apex of D1 fitting 
into the electro-negative cavity of gp120. Despite the relatively large surface area that is 
occupied during this interaction (742 Å
2
 of CD4, 802 Å
2
 of gp120), only 22 CD4 residues make 
direct contact with 26 gp120 residues. These interactions include stabilising Van der Waal’s 
forces and hydrogen bonds. Residues 25 – 64 of CD4 provide the bulk of the binding surface on 
CD4 and interact with several segments of gp120. The most critical residues on CD4 are Phe
43
 
and Arg
59
. These are involved in a number of contacts with well-conserved residues of gp120: 
Asp
368
 (Aspartic acid, position 368), Glu
370
 (Glutamic Acid, position 370) and Trp
427
 
(Tryptophan, position 427). To exemplify, 63 % of all of the bond interactions between CD4 and 
gp120 result from the short stretch of residues 40 – 48 (of the CC’C” strands of domain 1 of 
CD4). Furthermore, 23 % of these bond interactions between CD4 and gp120 arise due to Phe
43
. 
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Presumably, sterically inhibiting those aforementioned critical residues would directly prevent 
the gp120-CD4 interaction. 
  
Figure 4a: Diagrammatic 
representation of the crystal structure 
of core gp120 (from Kwong et al, 1998, 
PDB 1GC1) 
Figure 4b: Crystal structure of the 
gp120-2dCD4 complex shown in ribbon 
format. (PDB 1GC1) 
D1 of CD4 fits into the larger pocket 
created by the inner and outer domains of 
gp120. Phe43 and Arg59 of CD4 (shown) 
are involved in the most critical contacts 
with gp120. 
 
 
Figure 4a 
Figure 4b 
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2.1.5. Conformational Changes in CD4 
 
Upon comparison of the crystal structures of CD4 in the unbound (Ryu et al., 1990, Wang et al., 
1990) and gp120 bound states (Kwong et al., 1998), CD4 did not seem to undergo 
conformational changes. In terms of thermodynamics, the CD4-gp120 interaction results in 
significantly large enthalpy and entropy changes (Myszka et al., 2000). This suggests that the 
majority of conformational changes that occur during CD4-gp120 binding occur on gp120. Such 
data coincide with the exposure of CD4-induced (CD4i) epitopes on the gp120 that are 
recognised preferentially by certain anti-gp120 antibodies (17b, 48d, A32) following gp120-CD4 
complex formation (Wyatt et al., 1995). 
However, it has been shown that just as with gp120, CD4 undergoes conformational changes 
upon gp120 binding (Denisova et al., 1997). Analogously, there is the exposure of previously 
concealed epitopes on CD4 that are recognised by anti-CD4 antibodies in the gp120-CD4 
complex (Denisova et al., 1997). In order for the gp120 to make contact with the co-receptor, it 
has long been theorised that upon binding to gp120, CD4 must undergo considerable 
conformational change. A particularly interesting feature in that regard is the wide angle between 
the D1D2 and D3D4 (Wu et al., 1997). With a single strand connecting the two domains, a 
potentially large “jack-knife” rotation about the D2 – D3 junction could be possible (Ashish et 
al., 2008). It has therefore been proposed that the D2 – D3 junction acts as a hinge which serves 
to bring the entire virion closer to the host cell following CD4-gp120 binding. However, with the 
depiction of CD4 as a rigid molecule in X-ray crystallographic images of full length CD4 in the 
ligand-bound state, the “jack-knife” rotation about D2 – D3 remains questionable (Freeman et 
al., 2010). A more likely hinge region may be located at the base of the CD4, between D4 and 
the transmembranal portion of CD4. In support of this, deletion of the termed D4-TM 
(Transmembrane) was shown to reduce the capability of subsequent viral entry and fusion (Moir 
et al., 1996). 
 
 
Outer Domain Arg59 
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2.1.6. Redox Changes in CD4 
 
A key aspect of the CD4 molecule that has been under investigation relates to dynamic redox 
changes incurred on resident CD4 disulphides. These redox changes are increasingly thought to 
represent a fundamentally important component of CD4 function, both with respect to its 
participation in T-cell activation and HIV entry. 
 
2.1.6.1. The Role of Disulphide Bonds 
 
The disulphide bond in proteins is a covalent bond between two cysteine residues. Under general 
circumstances, disulphide bonds are known to favour protein folding into the correct 
conformation. The presence of the disulphide bond lowers the entropy of the unfolded protein 
and thereby restricts folding towards the native form (Noiva, 1994, Thornton, 1981). Disulphides 
bonds are also canonically known to stabilise the structure of protein structure. For such roles, 
with the high bond energy associated, disulphide bonds were typically considered as stable and 
inert. In certain proteins however, disulphide bonds undergo cleavage and reformation as part of 
the normal physiology. These disulphide bonds, termed catalytic bonds, have long been 
identified as critical components of the function of thiol-disulphide oxidoreductases. The protein 
disulphide isomerase (PDI) involved in disulphide bond pairing during protein folding contains 
an alternating thiol-disulphide pair which allows corresponding disulphide bond formation or 
cleavage in substrate proteins (Sevier and Kaiser, 2002, Darby et al., 1994). Recent studies have 
put forward the possibility that another type of ‘functional’ disulphide bond, termed ‘allosteric’ 
disulphide bonds exists. Allosteric disulphide bonds are those which upon redox change are 
capable of initiating functionally important conformational changes in the protein (Chen and 
Hogg, 2006). 
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2.1.6.2. The Role of Disulphide Bonds in CD4 
 
The disulphide bonds of cell surface receptors of lymphocytic populations have been shown to 
be susceptible to redox alterations depending on the cellular state. Activated lymphocytes, 
particularly B-cells, display significant increases in thiols (Lawrence et al., 1996). PDI, known to 
be secreted on the surfaces of B-cells (Tager et al., 1997), was effectively shown to participate in 
the reduction of the surface thiols (Lawrence et al., 1996). 
To this end, CD4 itself has been shown to exist as both monomers and dimers on cell surfaces 
(Lynch et al., 2003, Matthias et al., 2002, Moldovan et al., 2002, Lynch et al., 1999), and redox 
exchanges involving the CD4 D2 disulphide is thought to play a critical role in regulating this 
isomerisation. The significance of disulphide-dependent CD4 oligomerisation is reflected by the 
observation that dimeric forms of CD4 are required for T-cell activation (Moldovan et al., 2002), 
and such dimeric forms of CD4 are linked by intermolecular disulphide bonds (Lynch et al., 
1999). This suggests that active thiol-disulphide interchanges in the CD4 must occur in order to 
enable oligomerisation. Several reports, and most importantly from the four-domain CD4 crystal 
structure, suggested that the disulphide linkage arose from domain 4 of the CD4 (Lynch et al., 
1999, Wu et al., 1997, Moldovan et al., 2002). More recent studies, however, have described the 
occurrence of the intermolecular disulphide bond between domain 2 cysteines of CD4 (Matthias 
et al., 2002). 
 
2.1.6.3. Redox Changes in CD4 and HIV infection 
 
It was also observed that lymphocytes, namely CD4+ T-cell and CD19+ B-cell populations that 
were derived from HIV infected patients exhibited a marked increase in reduced cell surface 
thiols (Lawrence et al., 1996). Whilst the over-expression of reduced thiols on the cell surface of 
HIV-infected lymphocytes could essentially be as a result of the activation of those cells, further 
studies revealed that the reduced state of thiols has critical significance in viral infectivity. 
Reduced, monomeric forms of CD4 have been shown to be the preferred state of the receptor for 
HIV entry (Matthias et al., 2010). The predominant explanation for this observation is that CD4 
occurs in a conformation that enhances viral entry. Although, the detailed intricacies of these 
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conformational changes are remain elusive, there is strong evidence that they arise from redox 
alterations in the disulphide bond of domain 2 of CD4 (Matthias et al., 2002, Cerutti et al., 
2014).The importance of the state of the disulphide bond of CD4 for gp120 binding was most 
recently demonstrated in our laboratory using recombinant two-domain CD4 fragment 2 (Cerutti 
et al., 2014).  
 
2.1.7. Project Objectives for this Chapter 
 
CD4 appears to be a highly dynamic molecule whose state can have implications for both normal 
physiology and viral infectivity. For this part of the project, we generated the individual domains 
1 (D1) and 2 (D2) of CD4. We began by designing the expression cassettes encoding the 
individual domains. Once generated, the codon optimised, histidine-tagged encoding cassettes 
were cloned into plasmid vector pET15b, which were then used to transform E.coli expression 
hosts. Once expression of the protein was optimised, the proteins were then extracted from the 
bacterial harvest. Upon confirming the insolubility of the proteins, chaotropic solubilisation 
buffer was used to complete protein extraction. Proteins were then isolated using Ni/NTA 
agarose and washed accordingly. Following elution, proteins were refolded extensively. Purified 
protein in PBS buffer was characterised using biophysical methods in order to provide an 
indication on structural integrity of the purified, refolded products. Reducing and non-reducing 
SDS-PAGE gels confirmed correctly formed disulphide bonds. Far-UV CD analysis indicated 
the integrity of the secondary structure of the proteins. Finally, we showed by means of ELISA 
that D1 could bind to recombinant gp120. 
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2.2. MATERIALS AND METHODS 
 
For detailed recipes, please consult Appendix A. 
 
2.2.1. Design of CD4 Variants Cassettes 
 
The wild-type DNA sequence of the four-domain T-cell surface glycoprotein CD4 molecule 
(Homo sapiens) was obtained online from the UniProtKB/Swiss-Prot database (P01730). Based 
on a previous publication, mutant domain 1 of CD4, termed D1 (m1.1), the following amino 
substitution were introduced: L5I, A55V, I76P, L96I and F98L (Chen et al., 2011). Since no 
previous study exclusively described individual domain 2, wild-type D2 was selected as default. 
The mutant four-domain CD4, termed 4dCD4 (D2A), consisted of alanine mutations of cysteine 
residues Cys130 and Cys159 in domain 2. The 3D crystal structure of the entire four-domain 
extracellular (PDB ID: 1WIQ) and the two-domain CD4 fragment (PDB ID: 1CDJ) were 
obtained from the RCSB Protein Data Bank. The visualisation, assessment and comparison of 
the wild-type and mutant CD4 domains were carried out using the Swiss-PDB Viewer v. 4.04. 
The sequences of the two domains were generated and aligned against corresponding wild-type 
sequencing using the vector NTI® software. Start and stop codons capped the DNA sequences. 
In frame 6xHis fusion tags encoding sequences were added to the C-terminus of the CD4 
variants. The D1 (m1.1) DNA cassette was encoded between BspHI (N-terminal) and XhoI (C-
terminal) restriction sites; D2 (WT) between NcoI (N-terminal) and XhoI (C-terminal) restriction 
sites and the 4dCD4 variants between XhoI (N-terminal) and XbaI (C-terminal) restriction sites. 
The sequences of CD4 variants were codon optimised for bacterial (E.coli) expression. The 
required DNA cassettes were synthesised by GenART® (Regensburg, Germany) and delivered 
in the vehicle pMA vector. First distal two-domain CD4 variants (plasmid vector and purified 
protein), which had previously been expressed in our laboratory, were kindly provided by N. 
Cerutti. These included wild-type (2dCD4-Wt) and the following variants Cys/Ala variants: 
C16A/C84A, C130A/C159A and C16A/C84A/C130A/C159A. These were respectively termed 
2dCD4 (D1A), 2dCD4 (D2A) and 2dCD4 (CΔA). All of the cassettes/proteins used in this study 
included a 6xHis fusion tag at the C-terminus (Table 1). 
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CD4 
Cassettes 
First cloned 
and produced 
by 
Description 
D1 (m1.1) 
Chen et al. 
(2011) 
Individual domain 1, C-terminal 6x His-tag, Stable mutant 
based on the work of Chen et al. (2011) 
D2 Original work Individual domain 2, wild-type, C-terminal 6x His-tag,  
2dCD4(Wt) 
Cerutti et al. 
(2014) 
Distal two-domain CD4, wild-type, C-terminal 6x His-tag,  
2dCD4(D1A) 
Cerutti et al. 
(2014) 
Distal two-domain CD4, C16A/C84A, C-terminal 6x His-tag,  
2dCD4(D2A) 
Cerutti et al. 
(2014) 
Distal two-domain CD4, C130A/C159A, C-terminal 6x His- 
2dCD4(CΔA) 
Cerutti et al. 
(2014) 
Distal two-domain CD4, C16A/C84A/C130A/C159A, C-
terminal 6x His-tag 
4dCD4(Wt) Original work 
Extracellular Four-domain CD4, Wild-type, C-terminal 6x His-
tag  
4dCD4(D2A) Original work 
Extracellular Four-domain CD4, C130A/C159A, C-terminal 6x 
His-tag 
 
Table 1: Description of CD4 variants (and abbreviations) used in this study 
 
2.2.2. Preparation of Competent E. coli DH5α and BL21 
 
Derived from frozen glycerol stocks of E.coli DH5 or BL21* (Life Technologies, CA U.S.A), 5 
µL of overnight starter cultures were used to inoculate 40 mL of Luria-Bertani (LB) Broth (1% 
w/v tryptone (Sigma-Aldrich, MO, U.S.A),  1% w/v yeast extract (Sigma-Aldrich, MO, U.S.A), 
0.5% w/v NaCl (Sigma-Aldrich, MO, U.S.A)) in sterile 50 mL capped Falcon tubes. With caps 
tightly closed and tubes placed at a tilt, the samples were incubated on a rotary plate at 37
o
C until 
the culture OD600
 
reached approximately 0.4±0.1. The cells were collected by centrifugation (800 
g, 10 minutes). The cells were re-suspended in 10 mL of ice cold transformation buffer and 
incubated on ice for 20 minutes. The cells were collected again by centrifugation (450 g, 4
o
C, 10 
minutes) and re-suspended in 1 mL of fresh ice cold transformation buffer (100 mM CaCl2.2H2O 
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(Sigma-Aldrich, MO, U.S.A), 10 mM PIPES-HCl (Sigma-Aldrich, MO, U.S.A), 15% Glycerol 
(Sigma-Aldrich, MO, U.S.A), pH to 7.0 with NaOH). Aliquots (50 µL per microtube) of 
competent E.coli were stored at -80
o
C. 
 
2.2.3. Bacterial Cloning 
 
Five microgram of each of the lyophilised plasmids pMA-D1 (m1.1), pMA- D2, pMA-4dCD4 
(Wt) and pMA-4dCD4 (D2A) (Regensburg, Germany) were dissolved in 50 µL of high-quality 
Millipore® distilled water, respectively. The plasmids were correspondingly transformed into 
competent E.coli DH5α using a heat-shock bacterial transformation protocol. To the respective 
50 µL aliquot of thawed E.coli in 1.5 mL capped microtubes, 50 - 100 ng of plasmid vector was 
added. The samples were mixed by pipetting and incubated on ice for 20 minutes. Heat-shock 
transformation was conducted by incubating the samples on a heating block at 42
o
C for 90 
seconds. The samples were incubated on ice for another two minutes. Transformed bacterial 
suspension was then plated onto ampicillin-containing (100 µg/ml) Luria-Bertani (LB) agar (1% 
w/v Tryptone (Sigma-Aldrich, MO, U.S.A), 1% w/v Yeast Extract (Sigma-Aldrich, MO, U.S.A), 
0.5% w/v NaCl (Sigma-Aldrich, MO, U.S.A), 1.5% w/v agar (Sigma-Aldrich, MO, U.S.A)) 
plates. The plates were incubated overnight at 37
o
C. Plates with colonies were sealed and stored 
at 4
o
C. 
 
2.2.4. Plasmid Extraction 
 
One colony of transformed E.coli DH5α was picked and inoculated into 4 mL of ampicillin-
containing (100 µg/mL) LB broth (LB) in sterile capped 5 mL tubes. The LB was incubated 
overnight on a rotary plate at 37
o
C. Plasmid extraction was conducted from 4 mL aliquots of the 
overnight culture using a plasmid extraction kit (GenElute
TM
 Plasmid Miniprep Kit, Sigma-
Aldrich, MO, U.S.A), according to the manufacturer’s instructions (Appendix B.b.). The 
plasmids were eluted in 100 µL of elution buffer. The concentration and purity of the eluted 
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plasmids were assessed by UV-spectrophotometry and agarose gel electrophoresis (1% agarose, 
1x Tris-Acetate EDTA (TAE) buffer; Appendix A.a.iii.). Purified plasmids were stored at -20
o
C. 
 
2.2.5. Molecular Cloning of DNA Cassettes into Host Expression Vectors 
 
CD4-encoding DNA cassettes optimised for expression in bacterial were subcloned into pET-
15b (Novagen/Merck, Darmstadt, Germany) expression vectors. 
All enzymes and buffers used during restriction digestion were from ThermoScientific
TM
, 
Fermentas Life Science (MA, U.S.A). Purified pET15b, pMA-D1 (m1.1) and pMA-D2 (WT) 
plasmid vectors were digested using Ncol/XhoI, BspHI/XhoI and NcoI/XhoI restriction enzymes, 
respectively. Purified pMA-4dCD4 (Wt) and pMA-4dCD4(D2A) plasmid vectors, as well as 
pET-15b, were digested using XhoI and XbaI restriction enzymes. 
Restriction reactions consisted of 2.0 µg of plasmid, 8.0 µL of 10x FastDigest® buffer  and 2.0 
µL (20 U) of each enzyme, made up to a final volume of 80.0 µL with high-quality Millipore® 
distilled water. These were incubated at 37
o
C for 1h on a heating block. Digestion reactions were 
stopped by adding 3.0 µL of green FastDigest® loading buffer. The restriction fragments were 
resolved by agarose electrophoresis. 
The corresponding D1 (m1.1), D2 and 4dCD4-encoding cassettes, as well as digested pET15b, 
were isolated by cutting the band out from the gel. The DNA fragments were purified using a 
High Pure PCR product purification kit (Roche®, Germany) according to the manufacturer’s 
instructions (see Appendix B,ii). The concentration and purity of the eluted DNA fragments were 
assessed by UV-spectrophotometry and agarose gel electrophoresis. 
Ligation reactions comprising digested pET-15b and corresponding inserts in a 1:1 
(insert:vector) molar ratio were set up. Control ligation mixes contained only the linearised 
vector without insert. Ligation reactions contained 1.0 u/µL of T4 DNA ligase 
(ThermoScientific
TM
, MA, U.S.A), 2.0 µL of 10x ligation buffer (ThermoScientific
TM
, MA, 
U.S.A) and were made up to 20.0 µL with pure water. The reaction mixes were incubated for 1h 
at 22
o
C in a water bath. The ligase was deactivated by incubating the ligation mix for 5 minutes 
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at 70
o
C on a heating block. Five microlitres of the reaction mix was added to 50.0 µL of 
competent E.coli DH5α and transformation was conducted using the standard heat-shock 
protocol. Transformed E.coli was plated onto ampicillin-containing (100 µg/mL) LB agar plates. 
The plates were incubated overnight at 37
o
C. Plates carrying colonies were sealed and stored at 
4
o
C. 
 
2.2.6. Restriction Enzyme Analysis, Molecular Screening and Isolation of Pet-
15b-D1 (M1.1), Pet-15b-D2, Pet-4dcd4 (Wt) and Pet-4dcd4 (D2A) 
 
Colonies from the corresponding overnight incubated plates were picked and inoculated into 4.0 
mL of ampicillin-containing (100 µg/mL) LB broth in sterile 5.0 mL capped tubes. With caps 
loose and maintained at a tilt (for optimum aeration and stirring), the samples were incubated 
overnight at 37
o
C with vigorous agitation. Plasmids were purified using a GenElute
TM
 Plasmid 
Miniprep Kit (Sigma-Aldrich, MO, U.S.A).The concentration and purity of eluted plasmids were 
assessed by UV-spectrophotometry and agarose gel electrophoresis. 
Restriction mapping was then performed to identify recombinant plasmids with successfully 
ligated inserts. Samples of purified pET15b-D1 (m1.1) and pET15b-D2 (WT), as well as pET15b 
control vector, were linearised with BamHI, while the CD4 domain-encoding inserts were 
excised using XbaI and EcoRI. PET-4dCD4 (WT), pET-4dCD4 (D2A) and control pET15b were 
linearised with XhoI, and the inserts excised using XhoI and XbaI. In addition to the 
corresponding plasmid DNA (~100ng) and enzymes (5U per reaction), the reaction mixes 
included the 10x FastDigest® buffer. The samples were made up to 20.0 µL with pure water and 
incubated at 37
o
C for 1h. The reaction was neutralised by the addition of 3.0 µL of green 
FastDigest® loading buffer. Agarose gel electrophoresis was conducted and DNA bands were 
visualised under UV transillumination (NB: For restriction analysis figure, please see appendix 
C.f.) 
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2.2.7. Bacterial Expression of CD4 variants 
2.2.7.1. CD4 Expression 
 
The recombinant plasmids containing the 1- and 4-domain CD4-encoding inserts optimised for 
expression in E. coli were transformed into E. coli BL21 using the standard heat-shock protocol. 
Transformed E.coli BL21 with their corresponding plasmids were picked and inoculated into 5.0 
mL of ampicillin-containing (100 µg/ml) LB broth. The samples were incubated overnight at 
37
o
C with vigorous agitation. One millilitre of each culture was diluted into 100 mL of fresh 
ampicillin-containing LB broth in sterile 250 mL flasks (two flasks per inoculant). The loosely 
closed flasks were incubated on a rotary plate at 37
o
C. Upon reaching an OD600 of 0.6-0.7, one of 
the flasks was transferred to a shaking incubator set to 20
o
C, while the other was maintained at 
37
o
C. After overnight incubation, samples of bacterial cultures were collected and added to an 
equal volume of 2x SDS-PAGE loading buffer (0.125M tris-cl (Sigma-Aldrich, MO, U.S.A), 4% 
SDS (Sigma-Aldrich, MO, U.S.A), 20% v/v glycerol (Sigma-Aldrich, MO, U.S.A), 0.2 M DTT 
(Sigma-Aldrich, MO, U.S.A), 0.02% bromophenol blue (Sigma-Aldrich, MO, U.S.A), pH6.8). 
The samples were placed in boiling water for 10 minutes, vortexed and stored at -20
o
C. 
SDS-PAGE of samples was conducted (See Appendix B.a). Once resolved, the gel was allowed 
to equilibrate in transfer buffer (Appendix A) (20 min) and then transferred onto a nitrocellulose 
membrane (Hybond C, Amersham Bioscience, UK) by standard Western Blotting procedures. 
The membrane was incubated on a rotary plate in 10 mg/mL of Bovine Serum Albumen (BSA; 
Sigma-Aldrich, MO, U.S.A) in 1% Tris-Buffered Saline containing 0.05% Tween (Sigma-
Aldrich, MO, U.S.A) (1% BSA T-TBS) for 1h at room temperature, washed twice with T-TBS 
(5 minutes per wash), incubated with an anti-His-HRP conjugated probe (ThermoScientific, MA, 
U.S.A) in T-TBS (1:2000) for 1h, and finally washed 4 times with T-TBS (10 minutes per wash). 
His-tagged CD4 proteins were detected by chemiluminescence using the SuperSignal West Pico 
substrate system (Thermo-Fisher, MA, U.S.A) on a Chemi-Doc imaging instrument (Bio-Rad, 
CA, U.S.A). 
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2.2.7.2. Protein Solubility Analysis 
 
An overnight bacterial culture of E.coli BL21 expressing the relevant recombinant proteins was 
diluted (1:100) into 1 L (in 2L flasks) of ampicillin-containing (100 µg/mL) LB broth. The 
bacteria expressing D1 (m1.1) and D2 were incubated overnight at 37
o
C on a rotary plate 
(vigorous stirring), whereas those expressing 4dCD4 were incubated at 20
o
C. The cultures were 
centrifuged (4000g, 30min, 4
o
C) to collect cells, the spent medium discarded, and the cell pellet 
re-suspended in 20 ml of 1x Phosphate Buffered Saline (PBS, 1/20
th
 volume of culture) (Sigma-
Aldrich, MO, U.S.A). Lysozyme (0.5mg/ml) (Sigma-Aldrich, MO, U.S.A) was added to re-
suspended cells and the suspension was incubated on ice on a rotary plate with gentle shaking for 
1h. The BL21 E.coli suspension was transferred to a 50.0 mL Falcon tubes, and the samples were 
snap-frozen in dry ice/acetone and thawed twice. The lysed bacterial cells were sonicated 
(HD3100, MS73, Bandelin Sonopuls, Berlin, Germany) a minimum of three times (4500 kJ per 
L; 1 minute, 80% amplitude, 1.0 s pulse on, 0.5 s pulse off), or until viscosity of lysates was 
reduced. The total cell fraction (TCF) was centrifuged (10000 g, 4
o
C, 30 minutes) and the 
supernatant collected as the soluble fraction (sol). The cell pellet was re-suspended in 20 ml of 
solubilising buffer (8M Urea (VWR International), 50mM Glycine (Sigma-Aldrich, MO, U.S.A), 
0.5 M NaCl (Sigma-Aldrich, MO, U.S.A), 20 mM Imidazole (Sigma-Aldrich, MO, U.S.A), 2 
mM β-mercaptoethanol (Sigma-Aldrich, MO, U.S.A), pH 7.4) and incubated for 20 minutes at 
room temperature with vigorous agitation. The re-suspension was centrifuged (10000 g, 4
o
C, 30 
minutes), and the supernatant was collected as the insoluble fraction (Insol). Fifty microlitre of 
TCF, Sol and Insol were collected and boiled for 10 minutes with an equal volume of 2x loading 
buffer. Samples were stored at -20
o
C and analysed by SDS-PAGE and Western Blotting as 
described previously. 
 
2.2.7.3. Protein Isolation and Purification 
 
Recombinant CD4 proteins were purified from the insoluble fractions by nickel-chelate affinity 
chromatography. Ni
2+
-charged NTA beads (a gift from Dr W. Prinz) were added to the insoluble 
fractions extracted from the overnight cultures. The suspensions were incubated overnight with 
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stirring at 4
o
C. Overnight suspensions were transferred to centrifugation tubes and the beads 
were harvested (3200 g, 2min, 4
o
C). The supernatant was carefully decanted and discarded. The 
protein-bound beads were sequentially resuspended and washed by centrifugation (3200 g, 2min, 
4
o
C) with 50.0 mL of wash buffers (8M Urea (VWR International), 50mM Glycine (Sigma-
Aldrich, MO, U.S.A), 0.5 M NaCl (Sigma-Aldrich, MO, U.S.A), 2 mM β-mercaptoethanol 
(Sigma-Aldrich, MO, U.S.A), pH 7.4) of increasing imidazole concentration (for D1 and D2: 5x 
20 mM, 5x 50 mM; for 4dCD4: 3x 20 mM, 3x 50 mM, 3x 75 mM). The His-tagged proteins 
were eluted with 10.0 – 20.0 mL (depending on the original volume of bacterial culture extracted 
from) of elution buffer (500 mM Imidazole). The purified proteins were analysed by standard 
SDS-PAGE procedures. 
 
2.2.7.4. Protein Re-folding 
 
The 2dCD4 re-folding protocol, previously developed in our laboratory to facilitate formation of 
canonical disulphide bonds in proteins expressed in E coli, involves slow dialysis in glutathione-
containing buffers (Cerutti et al., 2014, Cerutti et al., 2010). Briefly, the insoluble proteins were 
extracted from inclusion bodies by solubilisation with strongly denaturing (8M urea) buffer. The 
extensive re-folding protocol allows the gradual removal of solubilisation buffer and its 
replacement with PBS at physiological pH of 7.4. The slow removal of denaturant, at cold 
temperature, is important to promote the renaturation and correct refolding of the protein into its 
native conformation, and to limit precipitation. Sucrose and glycine act as stabilisers, and 
enhance the refolding process, whilst also limiting precipitation (Tsumoto et al., 2003).  
Additionally, with the inclusion of glutathione and glutathione disulphide in the refolding buffer, 
an appropriate redox system is setup to encourage correct formation of disulphide bonds (Singh 
and Panda, 2005). The following references should be consulted for extensive reviews on protein 
refolding (Sorensen et al., 2003, Middelberg, 2002, Tsumoto et al., 2003, Singh and Panda, 
2005). 
The eluates were respectively placed into pre-wet dialysis tubes (MWCO 10,000, Thermo 
Scientific SnakeSkin
TM 
Pleated Dialysis Tubing, MA, U.S.A). For three consecutive days, the 
purified proteins were sequentially dialysed overnight at 4
o
C with stirring in 1 L of pre-chilled 
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folding buffer A (50 mM Glycine (Sigma-Aldrich, MO, U.S.A), 10% Sucrose (Sigma-Aldrich, 
MO, U.S.A), 1 mM Glutathione (Sigma-Aldrich, MO, U.S.A), 1 mM Glutathione disulphide 
(Sigma-Aldrich, MO, U.S.A), 4 M Urea (VWR International), 1 mM EDTA, pH 9.6, 4
o
C), 
folding buffer B (15 mM Na2CO3 (Sigma-Aldrich, MO, U.S.A), 35 mM NaHCO3 (Sigma-
Aldrich, MO, U.S.A), 10% Sucrose (Sigma-Aldrich, MO, U.S.A), 0.1 mM Glutathione (Sigma-
Aldrich, MO, U.S.A), 0.01 mM Glutathione disulphide (Sigma-Aldrich, MO, U.S.A), 1 mM 
EDTA (Sigma-Aldrich, MO, U.S.A), pH 9.6, 4
o
C) and 1x PBS. The two final rounds of dialysis, 
were carried out for 2 hours in each case in 1 L of pre-chilled 1x PBS. The dialysed solution was 
collected and centrifuged (3200 g, 4
o
C, 2 min) to pellet any precipitate formed. The supernatant 
was decanted, syringe filtered (0.45 µm filter) and stored at 4
o
C. 
 
2.2.7.5. Protein Analysis 
 
The purified proteins were concentrated to 0.5 – 1.0 mg/ml using a centrifugal filter unit (10 kDa 
cut-off, Amicon Ultra-15, Millipore-Merk, Darmstadt, Germany), and final concentrations 
determined using a BSA protein quantification kit (Thermo Scientific, Pierce Protein Research 
Products, MA, U.S.A) as per the manufacturer’s instructions. The refolded, concentrated CD4 
proteins were analysed by reducing- or non-reducing SDS-PAGE in the presence or absence of 
50 mM Dithiothreitol (DTT) (Sigma-Aldrich, MO, U.S.A), respectively. 
. 
2.2.7.6. Assessing Functionality of Bacterial Expressed CD4 variants 
a. D1 (m1.1) and 2dCD4 variants 
 
In the case D1 (m1.1), a sandwich ELISA was used since gp120 binding to directly coated 
protein is hindered as it abuts the plate’s surface. CD4 variants and gp120 were allowed to 
complex before being added to the plate wells that had been coated with capture antibody. 
Gp120 bound CD4 undergoes conformational changes such that there is the exposure of CD4-
induced binding sites (CD4i). These can be probed using antibodies directed to CD4i epitopes 
such as the well-characterised 17b monoclonal antibody. The 17b monoclonal antibody was 
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obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 
gp120 monoclonal antibody (17b) from Dr James E. Robinson (Moore et al., 1993, Wyatt et al., 
1995, Trkola et al., 1996, Sullivan et al., 1998, Wyatt et al., 1998, Kwong et al., 1998). The anti-
gp120 capture antibody, D7324 (Aalto BioReagents Ltd, Dublin, Ireland or Cliniqa Inc., 
Fallbrook, CA, U.S.A) (1ug/ml in PBS, pH 7.4) allows the capture and orientation of gp120-CD4 
complex that enhances the exposure of CD4i to the subsequent 17b antibody (Gram et al., 2002). 
Purified recombinant 2dCD4 variants (WT, D1A, D2A and CΔA) were a kind gift from Mrs. N. 
Cerutti. One hundred microlitres (100 µl) of D7324 antibody (Aarto, UK, 1ug/ml in PBS, pH 
7.4) was added to wells of 96 well-plates (Flat-bottom/ MaxiSorp, Nunc®, Denmark). PBS blank 
controls were included. Overnight coating at 4
o
C was allowed. The coating antibody was 
aspirated and 250 µl of blocking solution (1% BSA (Sigma-Aldrich, MO, U.S.A) in 1x 
Phosphate Buffer Saline (PBS, Sigma-Aldrich, MO, U.S.A) containing 0.05% Tween-20 
(Sigma-Aldrich, MO, U.S.A) (1% BSA T-PBS) was added to wells. Blocking was allowed for 
90 minutes. Serial dilutions of D1 (m1.1) and 2dCD4 variants in PBS were prepared, following 
which gp120bal in PBS was added. Gp120bal was obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH: HIV-1BaL gp120 from DAIDS, NIAID. Final 
concentration of mixes of 2dCD4 and gp120bal were respectively 1 – 0 µg/ml and 100 ng/ml. 
Samples were allowed to incubate for 1 hour at room temperature. Block solution was aspirated 
and 100 µl of sample mix was added to the wells in triplicates, as well as to the PBS control. 
Incubation of the samples in the plate was allowed for 1h. Plates were then washed 5x with 1x T-
PBS. Primary monoclonal antibody, 17b in 1x T-PBS, was added to corresponding wells (100 
µl) at 0.3 μg/ml in PBS-T. One hour incubation was allowed, after which plates were washed 5x 
with 1x T-PBS. Secondary goat anti-human HRP-linked antibody (GE Healthcare, UK) in 1x T-
PBS was added to wells and incubation was allowed for 1h. Plates were washed five times with 
T-PBS. TMB Ultra Substrate (Thermo-Pierce, U.S.A) equilibrated to room temperature was 
added to all wells (100 µl). The plates were then incubated for 30 min respectively at 37
o
C on a 
shaker. An equal volume of sulphuric acid (1 M) was added to the wells to stop the reaction. 
Absorbencies of wells were measured on a plate reader at both 450 nm and 570 nm (Bio-Rad 
Model 650 Microplate reader, CA, U.S.A; fast read, 450 nm measure filter, 37
o
C). 
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b. 4dCD4-WT 
 
In order to confirm the conformation and functionality of 4dCD4-WT derived from bacterial 
expression, the binding ability to gp120bal was addressed. Using 100 µL per well, the bacterial 
expressed 4dCD4-WT was coated at 1 µg/ml in 1x PBS into a 96-well plate (Flat-bottom/ 
MaxiSorp, Denmark) for 1h. Control wells were coated with 100 µL of 1x PBS. The coating 
solution was removed and 250 µL of blocking reagent (1% BSA in T-PBS) was added for 1h. 
Blocking buffer was removed and 100 µL of gp120bal (500 – 7.8125 ng/ml in T-PBS) were 
added to wells for 1h. The gp120 was removed and wells were washed 5x with T-PBS. The 
2G12 antibody at 100 µL at 0.1ug/mL was added to wells for 1 hour. Primary antibody was 
removed and wells were washed 5 times with T-PBS. Secondary anti-human goat HRP-linked 
antibody was added to wells and incubation for 1h allowed. Wells were washed 5 times with T-
PBS before 100 µL of TMB-Ultra substrate (Thermo-Pierce, U.S.A) was added. Plate was 
incubated for 20 min at 37
o
C on a rotary plate. Sulphuric acid, 100 µL at 1 M, was added to 
wells to quench the reaction. The absorbance values for all the wells were determined using a 
plate reader (Fast read, 450 nm measure filter, 37
o
C; Bio-Rad Model 650 Microplate reader; CA, 
U.S.A). 
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2.3. RESULTS 
 
2.3.1. In silico analysis of CD4 variants 
 
The published crystal structures of CD4 and the extracted domains variants were visualised using 
DeepView/Swiss-PDBViewer (Swiss Institute of BioInformatics, v4.0.4). References from 
previous authors who have successfully expressed of D1 and D2, and how were they expressed, 
is provided in Appendix C.f. 
 
2.3.1.1. D1 
 
The first domain of CD4 (D1) comprises residues 1 - 98 (Figure 6) and displays typical 
immunoglobulin topology, consisting of nine anti-parallel β-strands arranged as a two-layered β-
sheet sandwich. A hydrophobic core is encapsulated within D1 whilst hydrophilic residues are 
localised at the surface. Extensive hydrogen bonds between the strands stabilise the structure. 
The disulphide bond between Cys
16
 – Cys84 links the two sandwich sheets. In contrast to 2dCD4 
or full length sCD4, the first attempts at expression and purification of soluble WT D1 were 
unsuccessful (Chen et al., 2011, Sharma et al., 2005, Saha et al., 2011). The lack of D2 and the 
exposure of the highly hydrophobic D1 surface to the aqueous in vitro environment are often 
considered as the main reason for this. Accordingly, Chen et al. reported the CD4 domain variant 
designated D1 (m1.1), which contains the following substitutions: L5I, A55V, I76P, L96I and 
F98L (Chen et al., 2011). Upon isolation, D1 (m1.1) occurs as a highly soluble, monomeric 
protein, which acquires the native CD4 D1 fold and binds recombinant gp120 with high affinity 
(Chen et al., 2011). These mutations involve the replacement of residues having large 
hydrophobic side chains to ones with smaller, but still hydrophobic, side chains. Contrasting 
wild-type (WT) and mutant D1 (m1.1), it was seen that the mutations were mainly located on the 
D1/D2 interface. The interface of D1 and D2 consists of a largely hydrophobic surface formed 
by amino acids in each domain. A reduction in the hydrophobicity of the surface of mutant D1 
can therefore improve the protein stability and limit aggregation whilst exposed to aqueous 
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solvent. Additionally, the substitution of isoleucine to proline at position 76 could also enhance 
the stability of D1 by firmly “kinking” the backbone of the polypeptide against the overall 
domain (MacArthur and Thornton, 1991). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: In silico analysis of D1 (PDB ID: 1CDJ; Swiss-PDB Viewer v. 4.04.).  
3D backbone trace of wild-type (A) and mutant D1 (m1.1) (B), showing hydrogen bonds 
between strands (green lines) is depicted. Red residues indicate the mutated amino acids. 
Yellow residues show the disulphide Cys
16
 – Cys84 bond. For a simplified view, the ribbon 
diagrams of wild-type (C) and mutant D1 (m1.1) (D) are shown as well. N- and C- termini 
are denoted by Lys
1
 and Phe
98
, respectively. 
 
 
A B 
C D 
54 
 
2.3.1.2. D2 
 
The structure of the second N-terminal CD4 domain (D2) comprises residues 99 – 178, (Figure 
7). CD4 D2 is directly linked to D1 via a β-strand on the C-terminus of D1. The topology of D2, 
consisting of seven anti-parallel β-strands organised into a two sheet-sandwich, is analogous to 
the constant immunoglobulin domain. Extensive hydrogen bonding arises between the β-strands. 
As for D1, hydrophobic residues are localised at the core of D2 whereas hydrophilic ones are 
exposed at the surface. The surfaces of D2 at the interface of D1 and D3 bear hydrophobic 
patches which abut against the respective domains (Wu et al., 1997, Ryu et al., 1990). Based on 
the fact that the 2dCD4 has been successfully expressed in previous work and in our laboratory, 
it was reasoned that the hydrophobic surface of D2 adjoining D3 would not have a deleterious 
impact on the stability or solubility of a recombinant domain 2 mini-protein. Since no previous 
work has described the expression of recombinant D2 in detail, the influence of the exposure of 
the surface D2 that directs towards D1 on the solubility and re-folding of the protein is unknown. 
While it is possible that the exposure of this hydrophobic patch to the aqueous in vitro 
environment could result in protein misfolding or protein aggregation that may compromise the 
ability to produce correctly folded recombinant forms of D2, we reasoned that the extensive 
hydrogen bonding network between the β-strands in D2 could facilitate folding into the native β-
barrel-like structure, and the decision was made to assess the feasibility of producing a 
recombinant, natively folded CD4 D2 protein empirically. 
The structure of D2 is atypical in comparison to CD4 domains 1, 3 and 4 or the conventional 
constant immunoglobulin domain topology. In particular, D2 is shorter by approximately 25 
residues than the conventional Ig domains (which normally comprise approximately 100 amino 
acid residues). Another striking feature is that the D2 disulphide bond (Cys
130
 – Cys159) links β-
strands within the same sheet (as opposed to strands across sheets typical of the Ig-fold). 
Moreover, the Cα - Cα distance between the cysteine residues of D1 and D2 was found to be 
respectively 6.38 Å and 3.84 Å. The shorter bond length between the D2 cysteines is believed to 
increase the torsional strain on this disulphide bond (Wu et al., 1997, Ryu et al., 1990), that is 
suggestive to enable its facile reduction. 
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2.3.2. Protein Expression Studies 
 
2.3.2.1. IPTG Induction and Temperature Optimisation for Protein Expression 
 
DNA cassettes encoding full-length (4-domain) CD4 (sCD4) and CD4 domains 1 (D1 (m1.1) 
and 2 (D2) were codon-optimized for expression in E coli and synthesised by Geneart 
(Regensburg, Germany). These were sub-cloned into the prokaryotic expression vector pET15b 
(Novagen/Merck, Darmstadt, Germany). Cassettes encoding 2dCD4 (wild-type and mutants) 
were synthesized and cloned into pET15b previously by others in our laboratory (Cerutti et al., 
2010). Following transformation of E .coli BL21 with the indicated expression vectors, SDS-
PAGE and Western blots revealed optimum yields of recombinant D1 (m1.1) and D2 in the 
whole cell lysates following overnight incubation of the cultures at 37
o
C cultures (Figure 8). D1 
 
 
A B 
Figure 6: In silico analysis of D2 (PDB ID: 1CDJ; Swiss-PDB Viewer v. 4.04.) 
3D backbone trace of wild-type (A), showing hydrogen bonds between strands (green lines) is 
depicted. Red residues indicate the mutated amino acids. Red and blue indicate oxygen of 
carboxyl and nitrogen of imino groups. Yellow residues show the disulphide Cys130 – Cys159 
bond. For a simplified view, the ribbon diagram of wild-type D2 (B) is shown as well. N- and C- 
termini are denoted by Gly99 and Ala178, respectively. 
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(m1.1) and D2 migrated electrophoretically to positions consistent with their respective 
molecular weights (~12.4 kDa and 10.4 kDa). Pre-purified 2dCD4 (~22 kDa), was used as a 
control. The amount of protein present increased gradually with time and reached maximum 
yields following overnight incubation. Addition of IPTG at 1 mM had no apparent added effect 
on the yield of protein in either case. This is attributable to the “leakiness” of the T7 promoter 
under which expression of heterologous proteins is controlled in pET15b. The expression of 
recombinant proteins was significantly affected by temperature. At 37
o
 C, expression was highly 
stimulated in either case. On the other hand, expression of proteins at 20
o
 C was significantly 
reduced. 
 
 
 
 
 
 
 
 
 
2.3.2.2. Protein Solubility analysis 
 
SDS-PAGE and Western blots of the soluble and insoluble cellular fractions revealed the D1 
(m1.1) and D2 was localised almost exclusively in an insoluble fraction (Figure 9). Being in the 
Figure 7: Western Blot of D1 and D2  
Anti-His antibody probed Western blots showed that His-tagged D1 and D2 were 
effectively being expressed in E. coli BL21 whole cell lysate that was derived 
from overnight cultures. Reflecting on their corresponding molecular weights, the 
2dCD4 control (~22kDa), D1 (~12kDa) and D2 (~10kDa) localised at different 
positions. Repeated experiments indicated that the maximum amount of protein 
was obtained after overnight culture. Whilst IPTG had no effect on the 
expression of the recombinant proteins, the higher temperature (37
o
C) was 
stimulatory. Expression of proteins at the lower temperature (20
o
C) was almost 
negligible in the case of D2. Neg.: Negative control, T0: T0 sample, +: IPTG 
included, --: IPTG-free. 
   
 
              2dCD4                         D1                                               D2   
                                       20oC           37oC                              37oC        20oC 
                          To    --     +      --       +         Neg.   To    --       +       --       + 
                       
                      
 
10kDa 
35kDa 
25kDa 
15kDa 
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insoluble fraction, it is highly probable that the recombinant proteins were localised in the host 
bacteria as inclusion bodies. The exposure of the hydrophobic surfaces that abut the D1/D2 
interface could be a strong factor influencing the insoluble nature of D1 (m1.1) and D2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.2.3. Protein Isolation and Purification 
 
Following optimization of D1 (m1.1) and D2 expression, and confirmation that these proteins 
localized almost exclusively in the insoluble fraction, the recombinant proteins were purified by 
Figure 8: Protein Solubility Analysis of D1 and D2 
Anti-His antibody probed Western blots show that the His-tagged D1 and 
D2 were effectively being expressed in the insoluble cellular fraction.  
Neg: Negative control, 2dCD4: two-domain CD4/positive control, TCF: 
Total Cell Fraction, Sol.: Soluble Cell Fraction, Insol.: Insoluble cell 
Fraction 
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Ni
2+
-chelate chromatography following chaotropic extraction from inclusion bodies. SDS-PAGE 
analysis of the purified products showed that these were purified to near homogeneity (Figure 
10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 9: Protein Washes  
Coomassie Blue stained SDS-
PAGE (15 % polyacrylamide 
Tricine gel) A: D1; B: D2,  
ML: Molecular weight ladder 
(BR spectra Multicolour Protein 
Ladder, ThermoScientific
TM
, 
MA, U.S.A); D1/D2 Insol.: 
Insoluble cell fractions of D1 
and D2 as positive controls; 
Ovn: Sample from overnight, 
upscaled culture; Insol.: 
Insoluble cell fraction; Harvest: 
supernatant sample from first 
bead harvest; P.Elution: Sample 
from previous eluate.  
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2.3.3. Protein Analysis: Structural 
 
2.3.3.1. SDS PAGE Gels 
 
Following denaturing, affinity purification of D1 (m1.1) and D2, the proteins were folded via an 
oxidative refolding protocol to facilitate formation of the canonical CD4 D1 and D2 disulphide 
bonds. The refolded proteins were analysed in the first instance by conventional standard SDS-
PAGE gel electrophoresis followed by Coomassie Blue staining. However, improving the 
resolution of separated bands was deemed necessary for D1 (m1.1) and D2, and Tricine 
polyacrylamide gel electrophoresis was subsequently used for further analysis of these refolded 
proteins. In order to gain insights into whether disulphide bonds had been established in D1 
(m1.1) and D2 following refolding, the purified proteins were analysed by reducing- and non-
reducing SDS-PAGE. By default, the loading buffer used contains DTT which reduces 
disulphide bonds. The elimination of disulphide bonds in the presence of SDS allows the protein 
to completely unfold. In general, unfolded proteins have a greater hydrodynamic volume than 
their folded counterparts, and the former thus migrate with higher apparent molecular weight 
during electrophoresis. The upper bands in DTT-treated samples therefore represent the slower 
moving, fully denatured, disulphide-free proteins. Lower bands represent the proteins which 
have not been reduced. 
Upon comparison with the non-reducing gel, D1 (m1.1) produces the expected increase in 
apparent molecular weight when disulphide bonds were reduced (Figure 11). In contrast, DTT-
treatment of D2 resulted in the occurrence of an isomer with a lower apparent molecular weight. 
It could thus be reasonably speculated that reduction of the D2 disulphide gives rise to a more 
condensed CD4 domain 2 structure. This unusual consequence of disulphide reduction may, in 
turn, represent an important component of the biological function of CD4. 
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Figure 10: Reduced (DTT+) and non-
reduced (DTT-) gels of D1 (m1.1) and 
D2.  
Reduced D1 (m1.1), produced a single 
band at the expected higher apparent 
molecular weight. Reduced D2 however 
resulted in a band with lower apparent 
molecular weight as compared to the non-
reduced sample. This unusual feature is 
indicative of the occurrence of a more 
compact structure in D2 when the 
disulphide bond in D2 is reduced. 
Figure 11:  Reduced (DTT+) and non- 
reduced (DTT-) gels of 2dCD4 variants 
(WT, D1A, D2A, CΔA). Copied from 
(Cerutti et al., 2014). 
Reduction of 2dCD4 variants resulted in 
localisation of variants at a single molecular 
weight corresponding to that of NR CΔA. With 
the exception of D1A which remained 
unchanged, NR WT and D2A displayed lower 
apparent molecular weight as compared to 
reduced samples. Dimeric bands in WT, 
corresponding to all disulphide being formed 
and reduced D2 disulphide bond, represent the 
two redox state in which the protein exists.  
 
ML                              D1(m1.1)              D2 
                                DTT+   DTT-   DTT+  DTT-     
10kDa 
35kDa 
25kDa 
15kDa 
 
             WT    D1A      D2A       CΔA 
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2.3.4. Protein Analysis: Low resolution Structure/Function analysis 
 
As mentioned, D1 (m1.1) is based upon previously published work (Chen et al., 2011). Chen and 
colleagues showed that the stabilising mutation inserted into D1 (m1.1) allowed its purification 
following expression in E coli, and that this protein had native structure, bound to HIV-1 gp120, 
and competitively inhibited CD4-gp120 binding. 
 
2.3.4.1. Analysis of interaction between D1 (m1.1) and D2 and a CD4 antibody 
(Mt310) 
 
To assess the integrity of the D1 and D2 proteins purified in our laboratory, we performed an 
ELISA assay to check whether the CD4 domain proteins were reactive with a well-established 
monoclonal anti-CD4 antibody (mt310) whose conformational epitope is known to reside in CD4 
domain 1 (Healey et al., 1990a, Qin L., 2001, Helling et al., 2015). D1 (m1.1) and D2 were 
coated onto the ELISA plate and probed using mt310. ELISA analysis revealed that D1 (m1.1) 
was recognised by D1-specific antibody mt310 (Fig. 13), while D2, serving as a control, 
displayed only low intensity non-specific recognition. We could not at this point gain insights 
into the structural integrity of D2 in terms of antibody recognition, as D2-specific antibodies are 
not commercially available. Later in Chapter 2, we however provide evidence that D2 - 
recognisable by supernatants from hybridoma cell lines generated following immunization of 
mice with a native 2dCD4 – has native structure. 
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2.3.4.2. Far-Field CD Analysis of D1 (m1.1) and D2 
 
To obtain insights in the nature of the secondary structures formed in D1 (m1.1) and D2, far-field 
circular dichroism was performed (Figure 14). Incomprehensible, flat spectra or CD spectra with 
a significant negative trough between 195 – 200 nm - characteristics of misfolded, disordered or 
denatured proteins (Sreerama et al., 2000, Wu et al., 1992) - were not observed. Instead, both 
proteins had spectra that were consistent with the presence of significant β-sheet secondary 
structure, suggesting that these domains are able to acquire Ig-fold-like structures when 
expressed independently of the adjoining domains (Figure 14). 
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Figure 13: Far-UV CD Analysis 
The top figure depicts the far-
field CD curve profiles of D1 and 
D2 at two different 
concentrations. The signature 
profile of D2 is observed to 
closely follow that of reference 
2dCD4. Relative to 2dCD4, a 
shift of the minima towards the 
right was observed for D1 (from 
~214 – ~225 nm). The signature 
profile of D1 was consistent with 
data obtained from previous work 
(left, (Chen et al., 2011).  
For voltage versus wavelength 
plots, see appendix C. d. 
  
 
 
Far-Field CD analysis 
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The D2 spectrum closely followed that of 2dCD4, and almost overlapped when at equal 
concentration. Noticeably, with a peak and trough at respectively ~195 nm and ~214 nm, D2 
produced a profile which tends to resemble that of a the typical β-strand enriched Fab fragment 
of γ-immunoglobulin G (Doi and Jirgensons, 1970).  This observation correlates with the 
structure of D2, which as predicted from in silico visualisation, Ramachandran plot (see 
Appendix D) and X-ray crystallography (Ryu et al., 1990), assumes an immunoglobulin 
topology with abundant β-strands. CD spectra of purified D1 (m1.1) were consistent with the 
original work on this protein published by Chen and colleagues (Chen et al., 2011) (Figure 14), 
with the peak and trough profile of a typical β-strand enriched protein observed at approximately 
225 nm. However, relative to the 2dCD4 reference, the trough was shifted to the right, with 
minima at approximately 225 nm. This observation, also consistent in the original work, could be 
explained by the occurrence of α-helices/loops in D1 which was predicted by the Ramachandran 
plot (see Appendix C.d). 
 
2.3.4.3. Gp120 Binding Ability of CD4 variants 
 
The functionality of D1 (m1.1) was confirmed by demonstrating robust binding to gp120 along 
with several other CD4 variants (Figure 15). It was observed that all CD4 variants, with the 
exception of the 2dCD4-CAΔ, bound gp120. Since both 2dCD4-D1A and 2dCD4-D2A bind 
gp120, at least one of the disulphide bonds is required for the preservation of the gp120 binding 
site. 
As described by Chen and al., attributable to its small size and higher solubility, D1 (m1.1) had 
significantly greater affinity for gp120 as compared to two-domain CD4 variants (Chen et al., 
2011). Comparison of equimolar amounts of D1 (m1.1) to 2dCD4 variants (mass ratio D1 to 
2dCD4 is approx. 1:2) in our experiments served to confirm the observation. 
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Figure 14: Gp120 Binding of CD4 variants 
Gp120 binding to CD4 variants confirm their functionality. Gp120 bound to CD4 undergoes conformational 
changes that reveal the CD4i epitopes. CD4i can be probed subsequently using the 17b monoclonal antibody, 
and hence confirms the gp120-CD4 complex. With the exception of 2dCD4-CAΔ, all of the variants allowed for 
gp120 binding. As defined by Chen et al. (2011), mutant D1 (m1.1) showed high binding to gp120. 
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2.4. DISCUSSION 
 
The focus of the first part of this study was to express and characterise individual single domains 
CD4 D1 and D2. These were successfully expressed in bacterial host cells. As described from 
previous work, initial attempts to express wild-type D1 were unproductive (Chen et al., 2011, 
Sharma et al., 2005, Chao et al., 1989). The exposure of the hydrophobic surface which normally 
abuts D2 in the native state (Ryu et al., 1990), is considered the primary factor leading to poor 
solubilisation and heavy aggregation of D1. Based on previous work (Chen et al., 2011), a 
mutant D1 (m1.1) with substituted residues at the D1/D2 interface was stably expressed, thus the 
same protein was expressed in this study. D2 has also been expressed previously (Matthias et al., 
2010). While the potential for a recombinant D2 to be poorly soluble was acknowledged, 
considering that 2dCD4-WT is readily purified in native, soluble form despite exposure of the 
D2 surface which abuts D3, it was reasoned that the production of a native, soluble form of CD4 
D2 would be possible. 
In this study however, C-terminal His-tagged D1 (m1.1) and D2 (WT) were expressed in 
transformed E.coli BL21 cell cultures that were incubated overnight with vigorous stirring at 
37
o
C. Overexpression of certain recombinant proteins in E.coli can interfere with bacterial 
metabolism and result in either bacteriostatic or bacteriocidal effects. Abundant expression of 
either D1 (m1.1) or D2 (WT) in E.coli did not have any such negative effects. Localisation of 
both of the recombinant proteins in the insoluble cellular fraction suggested that both proteins 
were sequestered in inclusion bodies. Following solubilisation and extensive refolding, the 
reducing/non-reducing SDS-PAGE and far-field CD analyses indicated that the purified, 
refolded recombinant CD4 D1 and D2 proteins contained oxidized disulphide bonds and native 
β-sheeted secondary structures. 
Stable and soluble D1 could only be obtained after the introduction of amino acid changes 
located at the interface of D1/D2 (Chen et al., 2011, Sharma et al., 2005, Saha et al., 2011). This 
indicates that there exist strong interactions between D1 and D2 in native CD4 or recombinant 
two-domain 2dCD4. The presence of the large hydrophobic patches at the D1/D2 interface 
implies hydrophobic interactions and Van-der-Waals’ forces contribute mainly to the 
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maintenance of the structure of D1 in the native state (Ryu et al., 1990). Based on the solvent 
accessible surface area calculations, five critical residues on D1 that interact strongly with D2 
were identified in a previous study (Sharma et al., 2005). The residues, all located at the D1/D2 
interface, possessed hydrophobic side chains (V3, L5, I76, L96 and F98). Mutation of the 
residues to either threonine or alanine served to reduce the hydrophobicity of the D1 surface and 
therefore eliminate its dependence on D2. Although this version of mutant D1 was successfully 
expressed and purified in soluble form, biophysical characterisation revealed that the protein did 
not mimic the natively folded structure: the protein had poor stability at physiological pH (7.4), a 
three-fold lower affinity for gp120 in comparison to recombinant 2dCD4 and a far-UV CD 
sprectra indicative of short irregular β-strands. The reference study (Chen et al, 2011) on which 
the recombinant CD4 domain 1 protein (CD4-D1 (m1.1) used in this study is based, showed that 
this mutant folded more readily into the native state. As shown in this study by SDS-PAGE and 
CD analyses, D1 (m1.1) was highly soluble and had stable β-sheeted secondary structure at pH 
7.4. Previous studies on D1 (m1.1) showed that this protein was able to bind to both soluble 
gp120 and MHCII expressing human B-cells, and interfere with HIV infection (Chen et al., 
2011).  In addition to confirming the robust binding of D1 (m1.1) to recombinant gp120, in this 
study it was further shown that D1 (m1.1) binds specifically to the monoclonal anti-CD4 
antibody mt310, whose epitope is contained wholly within the first domain of CD4. Taken 
together, these tests further confirmed the structural and functional integrity of D1 (m1.1) 
purified in this study. The critical residues that had to be mutated to facilitate purification of a 
soluble CD4 domain 1 protein were established after an intense screen of a large D1 mutant 
library. D1 (m1.1) was selected from this library based on its stability, solubility and cross-
reactivity against different HIV envelopes, and is thus likely to resemble the native structure of 
CD4 domain 1 as it occurs in the context of the full-length protein. The sites of mutation in D1 
(m1.1) (L5I, A55V, I76P, L96I and F98L) overlapped with those from the above mentioned 
study. Minimising the influence of the largely hydrophobic residues remained the dominant 
strategy. The mutation to proline could contribute additionally by “kinking” and locally 
stabilising the polypeptide backbone against the overall globular domain (MacArthur and 
Thornton, 1991). 
Previous studies considered the expression and purification of soluble histidine-tagged D1 from 
the periplasm of E.coli and from the supernatant of mammalian cell cultures (Chen et al., 2011). 
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Individual wild-type D2 was efficiently expressed, purified and refolded, and the preservation of 
native CD4 secondary structure was strongly indicated from the CD analyses. Whilst the 
preliminary studies conducted in this chapter suggested that D2 had attained native β-sheeted 
secondary structure, further compelling evidence for this would be confirmed by the work 
described in Chapter 3, which demonstrated that D2 was a target for CD4-specific antibodies. 
The yield of refolded D2 however, compared to D1 (m1.1), was lower. The exposure of the 
hydrophobic patch of D2 that normally touches D1 could certainly be the main factor leading to 
a relatively large amount of protein precipitation observed during the refolding process. 
Introducing stabilising mutations to improve the solubility and yield of D2 could be considered 
in the future. However, this would imply the risk of compromising the integrity of the structure 
and disrupting potential antibody epitopes. 
Previous studies have described the use of the E. coli expression system for the expression and 
purification of mutant D1 as insoluble inclusion bodies (Sharma et al., 2005, Saha et al., 2011). 
Although the use of commercially available recombinant E.coli expressed was mentioned 
(Matthias et al. 2010), the eleborate details for its expression and purification were not described. 
Whilst the use of mammalian cell culture for recombinant protein expression provides the ideal 
microenvironment for protein folding and includes post-translation modification, it remains a 
costly and tedious task. Our laboratory, with much experience with recombinant protein 
expression in E.coli, demonstrated that mutant D1(m1.1) and D2 could be produced in high 
yields from inclusion bodies, and subsequently purified following solubilisation and extensive 
refolding process. Aside from the disulphide bonds, domain 1 of CD4 does not include any other 
post-translation modification (glycosylation, lipidation…). With the established in-house GSH-
GSSG containing refolding protocol, and as indicated by SDS-PAGE gels, correct disulphide 
pairing could be confirmed D1(m1.1)  and D2. Furthermore, with the CD- and binding studies 
that were conducted in this study, the maintenance structural and functional integrity of the 
recombinant protein is suggested. 
The disulphide-reducing and non-reducing treatments followed by SDS-PAGE analysis of D1 
(m1.1) and D2 provided insights into the formation of disulphide bonds in D1 and D2. Attention 
was however focused on the peculiar behaviour of D2. As opposed to D1 (m1.1), treatment with 
disulphide reducing agent led to the observation of an isomer which migrated faster than the 
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unreduced form. As evidenced from D1 (m1.1), the expectation was that the fully denatured and 
disulphide reduced protein resolves at a higher apparent molecular weight due to increased 
hydrodynamic volume, and proportionally lower electrophoretic mobility. 
The structure of D2, and in particular its Cys
130
 – Cys159 disulphide link, is contrary to the other 
CD4 domains or the typical immunoglobulin topology. Rather than inter-bridging the two β-
sheets, the disulphide bond links strands within the same sheet (Ryu et al., 1990). Thus, as 
compared to D1, the Cα - Cα distance between cysteine residues in D2 is usually short (3.84 Å vs. 
6.38 Å). Moreover, the orientation of the disulphide bond in D2 is right handed and has high 
dihedral strain energy (Matthias et al., 2002). High dihedral strain energy coincides with ease in 
reduction of the bond (Katz and Kossiakoff, 1986). Explaining the unusual behaviour of D2 to 
disulphide reduction is difficult without further analyses. Investigating the effect of thioredoxin, 
a redox protein that has been shown to assist in the reduction disulphide bonds of D2 in native 
CD4 (Matthias et al., 2002, Cerutti et al., 2014), is an area of ongoing research in our laboratory. 
Further assessment of the individual D2 domain would not only provide further evidence on 
structural integrity, but also provide insights on the functional role played by the disulphide 
bond. 
Without further investigations, accounting for the presence of the unusual conformation of 
reduced D2 can be tentatively suggested. The formation of a more condensed structure as a result 
of the direct or consequent effect of disulphide reduction could be speculated. Rather than acting 
as a molecular tether that prevents uncoiling of the protein, the disulphide bond could instead act 
as a separating ‘pillar’ which prevents the collapse of the structure into a more condensed form. 
The observed high strain energies associated with the disulphide bond in D2 (Matthias et al., 
2002, Katz and Kossiakoff, 1986), could in fact be a reflection of the compression of the bond. 
Alternatively, as a consequence of denaturation and disulphide reduction, as yet undefined 
interactions in D2 could lead to the occurrence of a more condensed structure, a phenomenon 
which may represent an important component of the biological function of CD4. 
In addition to stabilizing protein structures or acting as catalytic sites for mediating thiol-
disulphide interchange reactions, redox active thiol-disulphide elements can induce 
conformational changes which affect the function of the protein (Schmidt et al., 2006). An 
intricate understanding of the biochemistry of the disulphide bonds is crucial as they were shown 
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to be redox active in native CD4 in CD4-expressing cells in culture (Matthias et al., 2002). The 
presence of free thiols in CD4 on the cell surface of activated T-cells was furthermore 
demonstrated. Secreted upon activation of the T-cell (Rubartelli et al., 1992), thioredoxin 
localises at the surface membrane (Wollman et al., 1997) and modulates the disulphide 
reduction. Interestingly, only the disulphide bond of D2, but not those of D1 and D4, was 
reduced. In another study which puts forward the domain-swapped CD4 dimer model, the ability 
of cell-surface CD4 to form dimers due to disulphide cross-linking between D2 domains is 
described (Maekawa et al., 2006). In the same instance, the elimination of disulphide bonds and 
prevention of the formation of dimers, were found to critically hinder binding of CD4 to MHCII 
(Maekawa et al., 2006). Therefore, it can be proposed that activated T-cells secrete thioredoxin 
which mediates the cleavage of intramolecular disulphide bonds within D2 before intermolecular 
CD4 linkages can occur (Cerutti et al., 2014). However, it should be stressed such dimers were 
formed following drastic conformational changes in D2 which led to the swapping of domains 
(Maekawa et al., 2006). 
It was shown that the redox state of the disulphide bond in D2 affected gp120 binding and HIV 
entry (Matthias et al., 2002, Matthias et al., 2010, Cerutti et al., 2014). In this study, we also 
attempted to confirm the importance of the redox state of disulphide bonds in recombinant 
2dCD4 in terms of gp120 binding. As described in previous sections, 2dCD4 variants were 
available in our laboratory (Cerutti et al., 2014), and included wild-type (2dCD4-Wt) and the 
following variants Cys/Ala variants: C16A/C84A, C130A/C159A and 
C16A/C84A/C130A/C159A. These were respectively termed 2dCD4 (D1A), 2dCD4 (D2A) and 
2dCD4 (CΔA). By means of ELISA, the ability of 2dCD4-Wt, -D1A, -D2A, but not -CA, to 
bind to gp120 was confirmed (Cerutti et al., 2014). This indicates that complete ablation of both 
disulphide bonds, or complete reduction of both disulphide bonds, does not allow for gp120 
binding. Previous evidence of viral entry inhibition was demonstrated when either the dithiols of 
CD4 or the active site of thioredoxin were maintained in a reduced state by trivalent arsenic 
(Matthias et al., 2002). Trivalent arsenicals, known to react with thiols that are close to each 
other but not distant ones (Donoghue et al., 2000), prevented further modulation of the redox 
state of the dithiols. The later study by the same author however described the preference of HIV 
for disulphide reduced monomers of CD4 during viral entry (Matthias et al., 2010). Rather than 
chemically inhibiting the redox-activity of the D2 thiol-disulphide, mutants of CD4 with 
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cysteines of D2 replaced by alanine were expressed on T-cells. HIV infection of these host cells 
was remarkably enhanced. Taken together, these data underscore the importance of the thiol-
disulphide interaction in CD4 D2 for HIV entry. 
The next phase of this study involved the generation of a panel of novel anti-CD4 monoclonal 
antibodies as novel candidate anti-HIV therapies. We also attempted to verify whether such 
antibodies bound preferably to specific CD4 conformations. Recently, an antibody directed 
against HER3 (Human Epidermal Growth factor Receptor 3), a critical receptor that when 
overexpressed leads to oncogenesis, could lock HER3 into an inactive conformation (Garner et 
al., 2013). In the same analogy, we sought to verify whether certain anti-CD4 antibodies may 
mediate inhibitory effects by antagonizing specific conformations of CD4 that are required for 
viral entry.  
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CHAPTER 3:       
ANTI-CD4 ANTIBODIES AS 
ALTERNATIVE HIV 
THERAPIES 
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3.1. INTRODUCTION 
 
Whilst the need for eliciting efficient broadly neutralising antibody (bNAb) responses against 
HIV following vaccination remains critical, alternative forms of antiretroviral therapy exist. An 
alternative approach to the problem of viral escape that leads to drug resistance involves 
shielding the CD4 receptor against HIV by means of an anti-CD4 antibody. In this chapter, we 
introduce the concept of CD4-targeting monoclonal antibodies as a potential novel class of 
potent antiviral therapeutic ligand, using Ibalizumab, a recently developed monoclonal anti-CD4 
antibody with broad and potent anti-HIV activity, as a prototypical example. We then describe 
the generation of a new panel of CD4-binding antibodies, and our preliminary data 
characterizing the domain and isomer specificities of these antibodies, along with their potential 
therapeutic efficacy in cell culture. 
 
3.1.1. Anti-CD4 Antibodies against HIV 
3.1.1.1. Early Development 
 
As early as 1984, shortly after the identification of HIV virus as the aetiological agent of AIDS, 
it was recognised that the CD4 receptor is a critical requirement for HIV infection (Dalgleish et 
al., 1984). Faced with difficulties in finding a cure for HIV/AIDS by directly targeting the viral 
envelope glycoprotein, the idea of inhibiting viral entry by targeting CD4 quickly emerged 
(Sweet et al., 1991, Capon and Ward, 1989, Auffray et al., 1991). Early experimental anti-CD4 
monoclonal antibodies provided very optimistic results in inhibiting viral entry (Healey et al., 
1990b, Zeira et al., 1990). Subsequently, as well as developing new anti-CD4 antibodies with the 
view of inhibiting viral infection, the antiviral activities of existing anti-CD4 antibodies were 
investigated (Peterson and Seed, 1988). In one example, it was found that the well-established 
anti-CD4 antibody Leu3a, the epitope for which resides in CD4 domain 1, inhibited viral 
infection in monocytic cells (Zeira et al., 1990), consistent with the fact that Leu3a binds to an 
epitope on CD4 that overlaps with the gp120 recognition site. Two other anti-CD4 antibodies 
(Q425 and Q428), which bind to CD4 D3, were found to inhibit HIV infectivity despite allowing 
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gp120-CD4 binding (Healey et al., 1990). These antibodies most likely inhibit conformational 
changes that occur in the receptor complex after initial contact between CD4 and gp120 is made. 
 
3.1.1.2. Immune Suppressive Effects 
 
It is reasonable to suspect that the placement of an antibody on CD4 may compromise the natural 
role of the receptor in immune modulation. Before the notion of blocking HIV using anti-CD4 
antibodies was acknowledged, such antibodies were predicted/known to interfere with immune 
function, and ultimately lead to T-cell depletion (Cobbold et al., 1984, Goronzy et al., 1986, 
Dalgleish et al., 1984). In parallel, anti-CD4 antibodies targeting the distal portion of CD4 
domain 1 were verified as immune suppressive/modulating agents in the treatment of rheumatoid 
arthritis (Herzog et al., 1989), a disease that results from aberrant autoimmune responses. Upon 
treatment of patients with the antibodies, CD4 T-cell counts dropped drastically, but eventually, 
recovered to normal levels (Herzog et al., 1989). OKT4A, whose epitope was mapped onto 
domain 1 of CD4 (Peterson and Seed, 1988) is likely to cause viral inhibition by blocking the 
gp120 binding of CD4. However, once amongst the list of potential therapeutic anti-CD4 mAbs 
that could possibly inhibit HIV infection, it was soon found that OKT4A is in fact a potent 
immunosuppressant that can be used during organ transplantation procedures (Delmonico et al., 
1993, Cosimi et al., 1990). OKT4A therefore binds to CD4 in a way that prevents the receptor 
from coupling to MHCII during formation of the CD4-MHCII-TCR antigen presentation 
complex. An alternate mechanism of immune suppression, as demonstrated whilst using the 
GK1.5 antibody that targets the analogous mouse CD4 receptor, suggests that a negative signal is 
transduced from CD4 to directly inhibit T-cell activation, irrespective of whether there is 
effective antigen presentation or not (Tite et al., 1986). In this scenario, immune suppression 
arises not directly due to T-cell depletion, but its dysfunction (Carteron et al., 1988). (Anderson 
et al., 1997) 
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3.1.2. Description of MHCII-TCR-CD4 interaction 
 
3.1.2.1. MHCII 
 
As far as the intricate interactions between CD4 and MHCII are concerned, it is important to be 
reminded of the general structure of MHCII (Figure 16). The cell surface molecule MHCII is a 
heterodimer, consisting of α- and β-monomers. Each monomer is made up of extracellular, 
transmembranal and cytoplasmic portions. The extracellular portion of each of the monomers is 
divided into two domains: with respect to the cell surface membrane of the APC (antigen 
presenting cell), α1 and β1 domains are most distal, while α2 and β2 are most proximal. The 
association of the α1 and β1 domains form the cusp into which the peptide that is being presented 
inserts. The α2 and β2 abut the unexposed domains of α1 and β1, and form the length of the 
extracellular portion of MHCII. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Depiction of MHCII 
MHCII is a heterodimer, consisting of monomers α- and β. The α1 and β1 domains, which are 
most distal, form the cusp in which processed antigen is presented to the CD4
+
T-Cell.  
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3.1.2.2. MHCII-CD4 interaction 
 
In order to understand the implications in terms of immune suppression as a result of the 
placement of an antibody on CD4, an overview of the CD4 interaction in the immunological 
synapse is necessary. Depicting the elaborate interactions, the crystal structure of a two-domain 
CD4 (2dCD4) in association with MHCII (Wang et al., 2001) provides invaluable information on 
the potential sites on CD4 that if blocked, could lead to immunosuppressive effects. 
The crystal structure of the 2dCD4 – MHCII complex shows the interaction of CD4 with the α2 
and β2 domains of MHCII (Figure 17) (Wang et al., 2001). With respect to CD4, all direct 
contacts between the two molecules arise from D1. D2 is placed away from the interaction point 
and does not contribute to any contact. The portion of D1 comprising Phe
43
, the C” strand, and 
the short α-helical segment between strand D and E defines the MHCII contact surface of CD4. 
Intriguingly, the observed interaction between CD4 and MHCII nearly resembles that between 
CD4 and gp120 (Kwong et al., 1998). This part of CD4 inserts into the cognate CD4-binding site 
on gp120. The Phe
43
 inserts into a conserved hydrophobic pocket formed between the α2 and β2 
domains of MHCII. This interaction saliently resembles the interaction of CD4 with gp120, 
whereby the aromatic ring of Phe
43
 inserts into a hydrophobic pocket formed at the interface of 
the inner and outer domains. Besides Phe
43
, other critical residues in the interaction between 
CD4 and MHCII include Lys
35
, Lys
46
 and Arg
59
, and the latter also plays a fundamentally 
important role in stabilizing the CD4-gp120 interaction. Seemingly, the near identical mimicry in 
the mechanisms by which CD4 binds to MHCII and to gp120, poses a major limitation to the 
generation of anti-CD4 antibodies. Whilst these can effectively inhibit HIV infection, they are 
likely to have immunosuppressive effects by preventing normal CD4 – MHCII interactions. 
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3.1.2.3. MHCII-CD4-TCR Interaction 
 
The crystal structure of the TCR-MHCII-CD4 complex procured the visualisation of the 
interaction (Figure 18, 19) (Yin et al., 2012). The complex forms a V-shaped structure. 
Extending from the apex, one of the arms of “V” is defined by the peptide-presenting MHCII 
bound to the distal domains of the TCR. The other arm is represented by the elongated four-
domain CD4, which associates with the proximal portion of MHCII via its N-terminal domain 1. 
From this picture, if a horizontal line representing the cell surface membrane of the T-cell is 
drawn to complete the “V” into a triangle, the angles between TCR – horizontal, CD4 – 
horizontal, and CD4 – MHCII are 60o, 70o and 50o, respectively. Despite not directly binding to 
the MHCII binding site of D1, the potential for anti-CD4 antibodies to impose physical 
constraints that prevent the formation of the triangular immunological synapse is appreciable. 
Logically, with widening of the triangular space from the apex to the imaginary T-cell surface 
membrane, it can be presumed that the degree of steric restriction lessens if an antibody is 
Figure 16: Crystal 
structure of the MHCII-
CD4 interaction, from 
Wang et al., 2001 (PDB 
1JL4) 
 Strictly the domain 1 of 
CD4 forms contact with 
MHCII at the junction of 
the α1 and β2. Interaction of 
D1 includes Phe
43, C” 
strand, and the short α-
helical segment between 
strand D and E.  
Green: α2 domain of 
MHCII 
Blue: β2 domain of MHCII 
White: 2dCD4 
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directed towards the more proximal domains of CD4.  A superimposition of the MHC-bound 
CD4 over unbound CD4 showed minimal angular variations between the domains (Wu et al., 
1997). This is suggestive of the rigid nature of CD4, with flexibility only potentially occurring at 
the base of CD4 between D4 and the transmembrane domain (Moir et al., 1996). In this case, an 
antibody directed towards the most proximal domains (D3/D4) could interfere with the tilt 
required by CD4 to make contact with MHCII. 
 
 
 
Figure 17: Crystal structure of CD4, MHCII and TCR complex, from Yin et al., 2012 (PDB 3T0E) 
Green: α2 domain of MHCII; Blue: β2 domain of MHCII; White: 2dCD4; Orange: T-Cell Receptor 
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3.1.3. Ibalizumab: Model Anti-CD4 Antibody against HIV 
 
3.1.3.1. Drug Discovery and Development 
 
Out of one of the early experiments in the development of HIV-inhibitory anti-CD4 antibodies 
emerged the anti-CD4 murine monoclonal antibody 5A8 (Mu5A8 mAb) (Burkly et al., 1992) - 
the precursor to Ibalizumab. The epitope for Mu5A8 mAb, generated by immunising mice with 
CD4+ CHO cell transfectants, was mapped to domain 2 of CD4 and could potently hamper HIV 
infection. Most importantly, the antibody Mu5A8 was unique in that its antiviral effect was 
observed despite allowing for gp120-CD4 binding both in T-cells and sCD4 (Burkly et al., 1992, 
Moore et al., 1992). The antiviral effect, as indicated when observing the failure of Fab 
fragments of Mu5A8 to inhibit viral infection, was attributed to the ability of Mu5A8 to 
sterically block the conformational changes in either CD4 or gp120 required for viral entry 
following gp120-CD4 binding
1
. Upon further investigation however, a “hetero-antibody” 
                                                     
1
 Such effect was in fact an artifact arising from the limited number of viral strains used. See section 3.1.3.3 
Figure 18: Immunological 
Synapse 
Diagrammatic representation 
of the immunological synapse 
comprising the TCR-MHCI-
CD4 complex. The elongated 
CD4 makes contact with 
MHCII as it presents the 
antigen to the TCR. This 
synergy allows the 
reinforcement of the 
transduction signal to initiate 
the T-cell response.   
Antigen Presenting Cell 
Processed 
Antigen 
TC
R 
MHCII 
CD4 
CD4+ T-Cell 
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(antibody comprising of two different Fab) consisting of 5A8 and an irrelevant control Fab could 
not inhibit viral infection despite binding to CD4, as opposed to bivalent Mu5A8 (Burkly et al., 
1992)
2
. This could suggest that steric constraints are insufficient to explain the inhibitory effect 
of this antibody. In fact, it was shown that upon incubation of sCD4 and Mu5A8 mAb with virus, 
as opposed to the domain 1 binding 6H10 antibody that caused gp120 dissociation, a ternary 
structure consisting of gp120-CD4-Mu5A8 can actually exist (Moore et al., 1992). As suggested, 
it is possible that Mu5A8 functions by blocking conformational changes in CD4 that are critical 
for viral entry. 
 
Most importantly, shortly after its discovery, Mu5A8 mAb was tested in vivo and was found to 
have no immunosuppressive effects (Reimann et al., 1993). After the initial in vitro test 
confirming that Mu5A8 mAb was capable of binding to rhesus macaques CD4 with comparable 
affinity to that of human CD4, and could inhibit simian immunodeficiency virus (SIV) 
replication in vitro, Mu5A8 was administered intravenously into animals. CD4 T-cells were 
effectively coated by Mu5A8 and throughout the experiment, CD4+ cell numbers were 
maintained at normal physiological levels. The functionality of the cell-mediated and the 
humoral immune responses as a whole was confirmed by verifying proliferation of extracted 
peripheral blood mononuclear cells (PBMCs) and maintenance of the level of anti-tetanus toxoid 
antibodies. These promising results obviously were surprising as previous studies have described 
general ablation of the immune system in mice models treated with an anti-CD4 analogue 
antibody as result of CD4 T-cell clearance (Goronzy et al., 1986, Alters et al., 1990). In fact, 
upon administration of Mu5A8 in the monkeys, an almost immediate peak in circulating CD4+ 
T-cells was observed prior to a steady drop to adequate levels (Reimann et al., 1995, Reimann et 
al., 1993). 
 
As expected, the study was extended to confirm actual viral clearance in non-human primates 
(Reimann et al., 1995). Rhesus macaques that had been chronically infected with SIVmac 
displayed drastic decreases in provirus levels following Mu5A8 mAb treatment, as opposed to 
controls which received irrelevant antibody. Interestingly, viral clearance correlated to initial 
CD4+ T-cell levels: monkeys having higher levels of T-cells were able to eliminate SIV provirus 
                                                     
2
 Possible artefact as well. See section 3.1.3.3 
81 
 
much more rapidly. However, the functionality of the T-cells also drove the clearance of the  
Mu5A8 mAb due to the strong anti-murine response encountered, resulting in rapid clearance of 
the antibody (Reimann et al., 1993, Reimann et al., 1995). Hu5A8, a humanised form of Mu5A8, 
displaying much lower antigenicity, and was able to remain in circulation for weeks prior to viral 
detection and clearance (Reimann et al., 1997). Moreover, Hu5A8 maintained identical 
properties to the murine version in terms of binding affinity to human or monkey CD4, inhibition 
of both HIV and SIV, and non-immunosuppressive effects. From there, it was indicated that 
Hu5A8 would be tolerated in humans. Pharmaceutical grade Hu5A8 mAb was produced and 
used as part of an official good-laboratory practice pre-clinical trial demonstrated tolerability and 
safety of the antibody in chimpanzees (Boon et al., 2002). 
 
Hu5A8, termed TNX-355, as antiviral therapy in the treatment HIV infected patients mirrored 
the optimistic results obtained from previous in vitro and non-human primate studies (Kuritzkes 
et al., 2004). Cohorts of HIV-1 infected patients (T-cell count >100 cells/mm
3, viraemia ≥ 5000 
RNA copies/mL), treated with increasing amounts TNX-355 (0.3 – 25 mg/kg), showed 
significant dose-dependent decreases in HIV-1 plasma RNA, which were maintained as long as 
the CD4+ T-cells remained coated with TNX-355. CD4+ T-cell levels immediately peaked 
following treatment and no immunosuppressive effects were observed. TNX-355 was not 
immunogenic in humans, and was well-tolerated with minimal adverse effects. Under the current 
name Ibalizumab (TaiMed Biologics), respective decreases and increases in viraemia and CD4+ 
T-cells have been observed and verified, whilst safety and tolerance in both healthy and infected 
subjects of the drug was confirmed  (Jacobson et al., 2009, Norris D, 2006, Khanlou H, 2011, 
TaiMed_Biologics_Inc, 2011). 
 
3.1.3.2. Epitope Mapping of Ibalizumab 
 
From the initial studies describing the discovery of the anti-CD4 antibody currently known as 
Ibalizumab, it was found by means of mutagenic expression of chimeric human/mouse CD4 
molecules, that the antibody was directed towards the stretches of residues 121 – 124/ 127 – 134  
in domain 2 of CD4 (Burkly et al., 1992). With the progression of Ibalizumab into phase II 
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human clinical trials, parallel studies sought to gain further insight on the mechanism of action of 
the mAb by refining the definition of its epitopes. Extending the use of mouse/human chimeric 
CD4 molecules, point mutations that were introduced into domains 1 and 2 were found to be 
important for Ibalizumab binding to CD4 (Song et al., 2010). These residues were located at the 
interface of CD4 domain 1 and 2. As well as being located in domain 2 (Leu
96
, Pro
121
, Pro
122
, 
Gln
163
), two of the 6 identified residues were found in domain 1 (Glu
77
, Ser
79
). While not directly 
involved in making contact with the antibody, certain of these residues may play a role in 
maintaining the conformation of Ibalizumab’s binding epitope. 
Recently, the crystal structure of the Fab fragment of 5A8/Ibalizumab bound to two domain CD4 
(2dCD4) was solved (Figure 20) (Freeman et al., 2010). The overall picture depicted the binding 
of the Fab fragment to an epitope spanning D1 and D2. Consistent with the original mutagenesis-
based epitope mapping studies (Burkly et al., 1992), Ibalizumab was found to interact primarily 
with residues 121 – 125 of the BC-loop of D2 through an extensive hydrogen bonding network. 
Additionally, structural analysis showed the insertion of the tip of the BC loop of CD4 D2 
between the light and heavy chains of the CDR (complement determining region) of Ibalizumab, 
in which Pro
122
 makes extensive contact with the light-chain. The residues 164 – 165, located on 
the short FG loop of D2, were confirmed as further key contacts interacting with the heavy chain 
of Ibalizumab. Contacts in domain 1 were confirmed, with residues Ser
79
 and Glu
77
 in the EF 
loop interacting with the tip of the light-chain. 
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3.1.3.3. Mechanism of Action of Ibalizumab 
 
The mechanism of action of Ibalizumab as a viral entry inhibitor and non-immunosuppressive 
agent is still poorly understood. From the recent crystal structure of the Ibalizumab Fab fragment 
coupled to 2dCD4, it is clear that the binding site of Ibalizumab on CD4 does not correspond to 
the binding site of gp120 or MHCII (Freeman et al., 2010). Consistent with this, Ibalizumab 
presence on CD4 does not prevent gp120 binding (Burkly et al., 1992, Moore et al., 1992). 
Several theories have been proposed to explain these favourable properties of Ibalizumab. 
Figure 19: Crystal Structure of the Ibalizumab Fab Fragment bound to 2dCD4, from Freeman et al., 
2010 (PBD: 3O2D). 
Depiction shows interaction of the Fab Fragment with the BC-loop of D2 (Green). Other interactions with D2 
include residues 164 and 165 of the FG loop (Red). Ser79 and Glu77 of D1 also seem to be involved in the 
interaction (Orange). It should be noted that Phe43 and Arg59 of D1 (Yellow), critical in gp120 and MHCII 
binding, are located distant and are not involved in the interaction. 
H-chain of Fab: dark blue; L-chain of Fab: Light Blue 
Ibalizumab Fab Fragment 
CD4 
D1 
D2 
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Firstly, based on preliminary work on Mu5A8, it was indicated that through the inability of Fab 
fragments to inhibit viral infection as opposed to IgG, steric restriction preventing post-binding 
events was at play (Burkly et al., 1992). However, new studies elaborating on the matter describe 
both the Fab fragment and IgG as capable of blocking viral infection, dependent on the viral 
strains tested (Freeman et al., 2010). Additionally, full-length bivalent Ibalizumab antibody, 
which showed equivalent ability to inhibit viral infection as a Fab fragment, was determined not 
to be absolutely required. The previous observations could therefore have been due to an artefact 
arising from the limited number of viral strains used (Moore et al., 1992, Burkly et al., 1992). 
Nevertheless, steric restriction of conformational events post gp120-CD4 binding may still be a 
valid explanation for those viral strains where the IgG form inhibits viral entry more effectively 
than the Fab fragment. 
The second suggestion relates to the ability of Ibalizumab to either a) trigger conformational 
changes in the CD4 molecule that limit viral entry, or b) prevent subsequent conformational 
changes in CD4 that allow viral entry. Interestingly, it was observed that the binding of 
Ibalizumab to CD4 induced a flip in the peptide bond between Asn
164
 and Gln
165
 in domain 2 
(Freeman et al., 2010). This resulted in only a local conformational change that led to the 
stabilisation of hydrogen bonds between the Fab fragment and the corresponding residues of 
CD4 domain 2. Such a change however, might be insufficient to explain the mechanism of viral 
entry inhibition. 
Furthermore, major conformational changes are visualised in gp120 that is bound to CD4 
(Kwong et al., 1998), whereby there is exposure of CD4-induced binding sites and gp41. No 
such drastic changes are observed in CD4 in the gp120-CD4 crystal structure, although inducible 
conformational changes in bound CD4 have been suggested (Denisova et al., 1997). As 
mentioned in the previous chapter, in order that CD4 bound virus might enter the host cell, the 
CD4 molecule needs to be able to drastically flex towards the T-cell surface membrane. The 
mechanism of this is still largely unknown (see chapter 1), but it is an intriguing possibility that 
Ibalizumab exerts its antiviral effects by inhibiting such changes in CD4. 
Finally, studies by others and in our laboratory have shown that the redox state of 
thiol/disulphide bond Cys130-Cys159 of CD4 domain 2 plays a critical role in gp120-CD4 
binding and viral entry (Matthias et al., 2002, Cerutti et al., 2014), and that significant 
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conformational differences exist between reduced and oxidised isoforms of CD4 (Cerutti et al., 
2014). In particular, these studies have shown that HIV only binds efficiently to CD4 containing 
reduced D2 cysteines. It is thus notable that Cys125 is located within Ibalizumab’s epitope and 
an intriguing possibility that Ibalizumab exerts its antiviral effects by interfering with the 
dynamic redox regulation of the CD4 D2 disulphide that is required for viral entry. 
 
3.1.3.4. Resistance to Ibalizumab 
 
During phase II clinical trials, Ibalizumab has shown considerable promise as a viral entry 
inhibitor in the treatment of HIV infection (Jacobson et al., 2009, Norris D, 2006, Khanlou H, 
2011, TaiMed_Biologics_Inc, 2011). By binding to CD4 instead of the hypervariable regions on 
HIV gp120, Ibalizumab may provide a greater barrier to viral escape than ligands that are 
targeted to gp120. Nevertheless, viral resistance to Ibalizumab did eventually emerge in several 
of the pre-clinical and clinical trials mentioned above. SIV isolated from rhesus macaques before 
and after treatment with hu5A8 showed clear reduction in neutralisation sensitivity (Reimann et 
al., 2002), and reports from a phase II clinical trial described viral RNA in plasma increasing to 
baseline levels within about two months despite continuous Ibalizumab treatment (Jacobson et 
al., 2009). When tested in vitro, the isolated virus was effectively shown to have significantly 
reduced sensitivity to Ibalizumab. It was determined that resistance correlated to viral mutations 
entailing the loss of asparagine-linked glycosylation sites in the variable region 5 (V5) of gp120 
(Toma et al., 2011, Pace et al., 2013). Resistance to Ibalizumab in patients is likely due to 
negative selection and propagation of the viral strains that naturally had the variation beforehand 
(Pace et al., 2013). The mechanism by which such mutations allow viral escape is still yet to be 
confirmed. 
 
3.1.4. Project Objectives 
 
Despite the demonstrable potential of anti-CD4 antibodies as alternative HIV therapies, 
Ibalizumab is currently the only acknowledged existing anti-CD4 antibody that inhibits viral 
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entry without resulting in immunosuppression. However, with resistance to Ibalizumab being 
reported, it is critical to begin looking for alternatives. 
In this chapter, we sought to develop novel Ibalizumab-like anti-CD4 antibodies that could 
inhibit HIV whilst being non-immunosuppressive. Following the immunization of mice with 
recombinant mammalian 2dCD4, supernatants from a panel of 40 monoclonal antibody-
generating hybridomas, were screened for such properties. Using the panel of recombinant CD4 
variants described in Chapter 2, we determined firstly the domain specificities of the antibody 
supernatants. Due to the importance of the redox state of the disulphide bonds in CD4, we also 
attempted to verify whether antibodies had altered binding affinity for disulphide defective 
mutants. We then established the gp120 inhibition properties of the antibody supernatants in 
vitro. Finally, we then confirmed such observations using pseudovirion inhibition assays. 
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3.2. MATERIALS AND METHODS 
 
For detailed recipes of standard buffers and solutions, please see Appendix A. 
 
3.2.1. Generation of Monoclonal Anti-CD4 Antibodies Producing Hybridomas 
 
The production of monoclonal anti-CD4 antibodies was outsourced to ProMab Biotechnology, 
Inc (California, U.S.A). Purified 2dCD4-WT (expressed in E. coli) was used to immunise 
BALB/C mice. Following immunisation, hybridoma selection and propagation, 1 ml samples of 
supernatants derived from 40 cultures were received and stored at -80˚C for further analyses. 
These 40 antibody-containing supernatants samples were selected by the manufacturer based on 
the strengths of their reactivities with 2dCD4, a number defined per contract prior to 
immunization.   The hybridoma supernatants were designated CD4MAb1 – 40. 
 
3.2.2. Detection of Anti-CD4 Antibodies in Hybridoma Supernatants 
 
3.2.2.1. Screening against Recombinant Expressed 2dcd4 (WT) 
 
A preliminary ‘broad-screen’ ELISA was conducted in order to confirm the presence of CD4-
specific antibodies in 40 hybridoma supernatants received from ProMab Biotechnologies. In 
order to assess data statistically, triplicates of experimental wells were used. Using 100 µL per 
well, recombinant 2dCD4 (Wt) in 1 x PBS (Sigma-Aldrich, MO, U.S.A) was coated onto a 96-
well plate (Flat-bottom/ MaxiSorp, Nunc®, Denmark) at 1.0, 0.5 and 0.2 µg/mL for 1h at room 
temperature. Control wells were coated with 100 µL of 1 x PBS. The coating solutions were 
removed and 250 µL of blocking reagent (1% BSA in T-PBS) (Sigma-Aldrich, MO, U.S.A) was 
added to each coated well, and the plate was incubated for 1 hour at room temperature. Blocking 
buffer was removed and 100 µL of each hybridoma supernatant (1:2 – 1:15625 dilutions in T-
PBS) was added to 2dCD4-coated wells for 1 hour at room temperature. The supernatants were 
removed and wells washed 5 times with T-PBS. A goat anti-mouse HRP-linked antibody (100 
µL at 1:2000 in PBS-T; GE Healthcare, UK) was added to each well and the plate was incubated 
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for 1 hour at room temperature. Wells were washed 5 times with T-PBS before the addition of 
100 µL of TMB-Ultra chromogenic substrate (Thermo-Pierce, U.S.A). The plate was incubated 
for 20 minutes at 37
o
C on a rotary plate (600 rpm). To stop the chromogenic reaction, 100 µl of 
sulphuric acid solution (2 M) was added to each well. The absorbencies of the wells at 570 nm 
(A570) were determined using a plate reader (Fast read, 570/450 nm measure filter, 37
o
C Bio-Rad 
Model 650 Microplate reader, CA, U.S.A). 
 
3.2.2.2. Low-Resolution Epitope Mapping: Elucidation of CD4 Antibody Domain 
Specificities 
 
Bacterially expressed D1 (m1.1), D2, 4dCD4-WT and 4dCD4-D2A, as well as 2dCD4 (WT), 
mutant 2dCD4 (D1A), mutant 2dCD4 (D2A) and mutant 2dCD4 (CΔA), were used to determine 
the domain specificities of each monoclonal antibody-containing hybridoma supernatant. In 
order to assess data statistically, triplicates of experimental wells were used. One hundred 
microlitres (100 µL) of each recombinant CD4 variant at 1.0 µg/mL in PBS was used to coat the 
wells of 96-well plates (Flat-bottom/ MaxiSorp, Nunc®., Denmark) for 1h at room temperature. 
In order to exclude the possibility that any of the antibodies were directed to a His-tag epitope 
(present on the C-terminus of the immunogen), a recombinant His-tagged gp41 protein, was 
additionally coated in parallel. Control wells (blanks) were coated with 100 µL of 1x PBS 
(Sigma-Aldrich, MO, U.S.A). Thereafter the plates were processed as described above to detect 
CD4-bound antibodies, with 100 µL of each supernatant (1:50 µg/ml in T-PBS) used in the first 
probing step. 
 
3.2.2.3. CD4-Gp120 Binding Assay 
 
An ELISA assay was used to verify whether the antibodies could potentially inhibit binding of 
gp120 to CD4 binding in vitro. In order to assess data statistically, triplicates of experimental 
wells were used. One hundred microlitres (100 ul) of 4dCD4 (WT) (1 µg/mL in 1x PBS) was 
coated onto 96-well plates (Flat-bottom/ MaxiSorp, Nunc®, Denmark) for 1h at room 
temperature. Control wells were coated with 100 µL of 1x PBS. The coating solutions were 
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removed and 250 µL of blocking reagent (1% BSA in T-PBS) (Sigma-Aldrich, MO, U.S.A) was 
added to each well. Plates were incubated overnight at 4
o
C. The blocking reagent was removed 
and 50 µL of each supernatant (1:50, 1:500 1:5000 dilutions in T-PBS) were added to 
corresponding wells. Following a 1 hour incubation, 50 µL of recombinant HIV-1 gp120bal (400 
ng/mL) in T-PBS was added to wells, which were incubated for a further 1 hour at room 
temperature. The wells were washed 5 times with T-PBS and 100 µL of the monoclonal anti-
gp120 antibody 2G12 (0.1ug/ml) was incubated in each well for 1 hour. The following reagent 
(2G12) was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
HIV-1 gp120 Monoclonal Antibody (2G12) from Dr Hermann Katinger (Buchacher et al., 1994, 
Trkola et al., 1996, Mascola et al., 1999, Etemad-Moghadam et al., 1999, Crawford et al., 1999). 
Wells were washed 5 times with T-PBS and 100 µL of a secondary HRP-conjugated sheep anti-
human antibody (GE HealthCare, UK) was added to wells. Following 1h incubation, the wells 
were washed 5 times with T-PBS before adding 100 µL of TMB-Ultra substrate (Thermo-Pierce, 
U.S.A). The plate was incubated for 20 min at 37
o
C on a rotary plate (600 rpm), and 100 µl of 
sulphuric acid solution (2 M) was added to wells to stop the reaction. The absorbencies of the 
wells at 570 nm (A570) were determined using a plate reader (Bio-Rad Model 650 Microplate 
reader; fast read, 570/450 nm measure filter, 37
o
C). 
 
3.2.3. HIV-1 Pseudovirion Inhibition Assay 
 
3.2.3.1. Determination of Working Viral Dilution 
 
The inhibitory effects of the anti-CD4 antibodies on HIV replication were assessed by an HIV-1 
pseudovirion inhibition assay. ZM53M.PB12, SF162.LS and TZM-bl cells were kindly provided 
by Dr Mark Killick. 
TZM-bl cells stably express large amounts of CD4 and CCR5 (NIH AIDS Reagent Program, 
Cat. 8129), making it a recommended cell-line for assessment of HIV infection in vitro. TZM-bl 
cells have also been genetically modified to allow for the detection of HIV infection and 
replication using luciferase as a reporter. During viral integration in the host DNA, the viral 
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promoter drives the overexpression the luciferase, which can be subsequently detected using 
luciferase detection methods. 
 
ZM53M.PB12 (obtained from Drs E. Hunter and C. Derdeyn) and SF162.LS (obtained from Dr 
D. Monefiori, Laboratory for AIDS Vaccine R&D, Duke University Medical Center) were 
produced using pSG3
Δenv
 (Dr John C. Kappes and Xiaoyun Wu) backbone and complementing 
Env(gp160)-expressing plasmids. Throughout, as short handedness, we shall refer to 
ZM53M.PB12 and SF162.LS as ZM53 and SF162 respectively. 
 
In 25 cm
2
 Nunc culture flasks, TZM-bl cells were grown in growth media (DMEM; 10% FCS 
(Biochrom Heat Inactivated FCS, UK), 1x Glutamax, 100 units of Penicillin and 0.1 mg/ml of 
Streptomycin) (Sigma-Aldrich, MO, U.S.A) until they reached approximately 90% confluence. 
Cells were gently washed with 1 x PBS, trypsinized (0.05% Trypsin-EDTA) (Sigma-Aldrich, 
MO, U.S.A) and resuspended in growth media. Following counting with a haemocytometer and 
Trypan Blue (Gibco©, LifeTechnologies, CA, U.S.A), cells were seeded into a 96-well culture 
plate (ThermoScientific
TM
 Nunc
TM
 MicroWell
TM
 96-Well Microplate/ Nunclon
TM
-D, Denmark) 
at 10
5
 cells per well in 100 µL of media. The initial concentrations of ZM53 and SF162 were 
respectively 1.95 x 10
6
 and 8.75 x 10
5
 TCID50. In order to determine working concentrations of 
SF162 and ZM53 pseudovirions (TCID50), a 10 X serial dilution of pseudovirus stocks (1:10 – 
1:10000) was prepared in growth media supplemented with 80 µg/mL of DEAE-Dextran 
(Sigma-Aldrich, MO, U.S.A). Fifty microlitres of the diluted virus samples were added per well. 
Cell control wells received virus-free growth medium. Volumes of wells were made up to a total 
of 200 µL with growth media. Plates were incubated for 48 hours at 37
o
C/5% CO2, following 
which the culture medium was aspirated and discarded. Wells were washed once with 1x PBS 
(Sigma-Aldrich, MO, U.S.A), one hundred microlitres (100 µL) of Glo-Lysis buffer (Promega, 
WI, U.S.A) was added per well and with occasional gentle rocking, and the plate was incubated 
for 5 minutes at room temperature. Fifty microlitres (50 µL) of the lysate was extracted per well 
and transferred to white luminometer plates (Promega, WI, U.S.A). An equal volume of 
reconstituted Bright-Glo
TM
 Assay reagent (Promega, WI, U.S.A) was then added to the cell 
lysate and the reactions were incubated for a further 5 minutes at room temperature. 
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Luminescence was recorded using a luminometer (Veritas Microplate Luminometer, Promega, 
WI, U.S.A) calibrated for the Bright-Glo
TM
 assay protocol. 
 
3.2.3.2. Viral Assay 
 
As described above, 10
5
 of resuspended TZM-bl cells in 100 µL media were seeded per well of a 
96-well culture plate (ThermoScientific
TM
 Nunc
TM
 MicroWell
TM
 96-Well Microplate/ 
Nunclon
TM
-D, Denmark). In order to assess data statistically, triplicates of experimental wells 
were used. Concentrated hybridoma supernatants of samples were added to corresponding wells 
at a dilution of 1:15 in a total of 150 µL per well. Positive control anti-CD4 antibody (mt310) 
was added to final concentration of 1.33 µg/mL in 150 µL per well. A serum sample (M79) 
derived from rabbits immunized with a recombinant gp120-CD4 complex, which shows potent 
antiviral effects in vitro, was kindly provided by Dr Mark Killick. This would be used as positive 
control for comparison with the panel of CD4MAbs. Wells free of antibody/supernatant/serum 
served as negative controls. Plates were incubated for 2 h at 37
o
C/5% CO2 to allow for anti-CD4 
antibody binding, following which 50 µL of virus in DEAE-Dextran (Sigma-Aldrich, MO, 
U.S.A) supplemented media was added to experimental and viral control wells. Cell controls 
without virus were made to 200 µL with DEAE-supplemented media. The final dilutions of virus 
and DEAE-Dextran per 200 µL volume were respectively 1:500 (3900 TCID50 for ZM53; 1750 
TCID50 for SF162) and 20 µg/mL (For TCID determination, see Appendix F). Plates were 
incubated for 48 h at 37
o
C/5% CO2, and luciferase activity measured by the procedures described 
above. 
 
 
 
  
92 
 
3.3. RESULTS 
 
3.3.1. Screening Supernatants 
 
3.3.1.1. Preliminary Binding to 2dCD4-WT 
 
One millilitre samples of supernatants derived from 40 hybridoma cell lines, which were 
generated from mice immunized with purified, native 2dCD4, were obtained from Promab 
Biotechnologies (Richmond, U.S.A). Screening ELISAs were then performed in order to 
characterize the binding specificities of antibodies in each of the 40 hybridoma supernatants. We 
first carried out a direct ELISA in which CD4MAb-1 was incubated on a 96-well microtiter plate 
that had been coated with purified wild-type 2dCD4. This approach confirmed that CD4MAb-1 
bound recombinant 2dCD4 robustly (Figure 20). Probing and detection was conducted using 
anti-mouse secondary antibody linked to HRP. Increasing amounts of either 2dCD4-WT or 
concentration of supernatant resulted in increased binding. This approach established the optimal 
concentration ranges of the 2dCD4 coating solution and hybridoma supernatant dilution levels, 
and provided a platform for screening CD4Mab-2-40. 
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Figure 20: Preliminary 
Trial of Supernatant 1 
against 2dCD4-WT (at 
570nm readout) 
It was observed that 
supernatant effectively 
bound to bacterially 
expressed 2dCD4-WT. 
Increasing either the 
amounts of CD4 coated 
in each well or the 
concentration of 
supernatant used allowed 
for increased binding.  
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3.3.1.2. Interaction of CD4-MAbs with Recombinant CD4 variants 
 
We next sought to characterize the ability of the antibody clones to bind a range of CD4 variants, 
including 2dCD4 and 4dCD4. In each case both wild-type CD4s and variants containing Cys/Ala 
substitutions in domain 2 were used (2dCD4-Wt, 2dCD4-D2A, 4dCD4-WT and 4dCD4-D2A). 
Additionally, we also included the Cys/Ala substitution variant (2dCD4-CΔA) as a further 
control to validate the importance of the preservation of the disulphide bond in epitope 
recognition. This control includes the C130A/C159A mutation in domain 2, as well as the 
C16A/C84A mutation in domain 1. All 40 antibody clones bound with various levels of 
efficiency to the wild-type and Cys\Ala variants of both 2dCD4 (Figure 21a, b) and 4dCD4 
(Figure 22a, b). Once again, due to unknown and variable antibody concentration in 
supernatants, characterization of the relative antibody-binding affinities of CD4MAbs at this 
stage was not possible. However, it was qualitatively evident that supernatants bind robustly to 
2dCD4-WT and 2dCD4-D2A. Most samples had significantly reduced binding to the control 
2dCD4-DΔA variant, suggesting that the epitopes to which these antibodies are directed are 
dependent on secondary or tertiary structural conformations. In contrast however, several D2-
specific antibodies (22 – 36) were able to bind 2dCD4-DΔA, albeit at lower levels than to the 
WT and D2A variants. This suggests that the epitopes of these antibodies are not strictly 
conformation-dependent, and are likely to be comprised primarily of continuous linear amino 
acid sequences within the second domain of CD4. 
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Figure 21: Binding of hybridoma supernatant against 2dCD4 variants (450 nm readout). 
All CD4 variants, with the exception of 2dCD4-CΔA, allowed for binding. By approximately 50% less than with the other CD4 variants, supernatants 23 – 
36 (D2-specific) could bind 2dCD4-CΔA. Triplicates of experimental data were used for calculating means; error bars represent standard deviation (µ±1sd). 
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Figure 22: Binding of hybridoma supernatant against 4dCD4 variants (450 nm readout). 
Both variants of 4dCD4 allowed for binding of the CD4-Mabs, with no significant difference whether against wild-type or mutant 4dCD4. Triplicates of 
experimental data were used for calculating means; error bars  represent standard deviation (µ±1sd). 
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3.3.1.3. Binding towards Hexahistidine Tag 
 
Before proceeding with further analyses, we determined whether supernatants had any affinity 
for the hexahistidine tag, since the immunogen used to raise the 40 hybridoma clones was a his-
tagged recombinant 2dCD4, raising the possibility that a significant number of the antibody 
clones were directed towards a polyhistidine epitope. The use of an irrelevant hexahistidine 
tagged protein - 6xHis-gp41 produced by others in our laboratory coated on ELISA wells 
confirmed that none of the supernatants were directed towards the tag (Figure 24). 
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Figure 23: Binding of hybridoma supernatants to irrelevant hexahistidine-tagged gp41 
Grey bars reflect the interactions between the indicated CD4-MAb and a 6XHis-tagged HIV gp41 protein. CD4-
MAb 2 bound to coated 2dCD4 ( shown  in green) was used as a positive control to demonstrate antibody 
binding to non-histidine tag epitope. 
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3.3.1.4. Domain Specificity 
 
We next sought to establish the domain specificities of CD4MAbs 1 – 40 by coating ELISA 
plates with CD4 D1 (m1.1) or D2 and probing these with each hybridoma supernatant (Figure 
24). It was found that of the 40 supernatants tested, 24 were specific for D1, while the remaining 
16 clones bound specifically to D2. Interpreting the binding affinity of supernatants relative to 
each other was difficult as the amount of antibody present in supernatant is likely to be highly 
variable. To do so accurately, antibody purification from supernatant and quantification would be 
necessary (beyond the scope of this study).  Moreover, robust binding of a significant number of 
the CD4MAbs to D2 suggested that bacterially expressed D2 refolds into a structure that 
reconstitutes at least some of the native Ig-fold-like CD4 secondary structure. 
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Figure 24: Domain Specificity of MAbs in the hybridoma supernatants 
Coating ELISA plates with either D1 or D2 (1 µg/ml) followed by incubation with the indicated hybridoma 
supernatant (1:100) allowed for identification of domain specificity (in blue: D1; in green: D2). Due to the 
variability and unknown antibody concentration in supernatants, it was not possible to effectively compare 
binding affinities. 
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3.3.1.5. Analysis of CD4MAb-mediated inhibition of CD4-gp120 binding in vitro 
 
After characterizing the binding specificities of the 40 anti-CD4 antibody clones, we next set out 
to establish to what extent each of these were able to block binding of gp120 to CD4. The ELISA 
plate was coated with 4dCD4-Wt in order to represent native physiological extracellular CD4. 
CD4-MAbs were then incubated with the coated 4dCD4-Wt in order to allow for binding. Gp120 
was added to the wells, probed and detected. Whether the presence of the CD4-MAb bound to 
4dCD4-Wt could inhibit gp120 binding was thus determined. It was found that all of the 
supernatants inhibited recombinant gp120 binding to 4dCD4-WT. For clarity of presentation, the 
results of four of the 40 CD4-MAbs (Figure 25) are shown in this chapter. The remaining 36 
antibodies showed qualititatively similar levels of inhibition – these results are shown in 
Appendix E. At an antibody dilution of 1:10, all of the 40 antibody supernatants were capable of 
inhibiting gp120 binding, which was almost completely ablated. For every 10 fold dilution of the 
CD4-MAb, gp120 binding was roughly doubled. The epitopes of D1-specific mAbs present in 
the supernatants are likely to overlap with the gp120 binding site on CD4, while the inhibitory 
effects of the D2-specific mAbs on CD4-gp120 binding could be due to steric inhibition due to 
the antibodies’ Fc portion. To confirm these suggestions, further characterisation is required 
(beyond the scope of this project). Studies have confirmed that Ibalizumab binding to CD4 does 
not prevent gp120 binding despite inhibiting subsequent viral entry. The mechanism of action of 
Ibalizumab is therefore suggested to involve the inhibition of a series of events that lead to viral 
entry following gp120-CD4 engagement. In contrast, the domain 2 specific Mabs identified in 
this study all prevented gp120 binding. Potentially, this indicates a novel class of D2-specific 
antibodies that could inhibit viral entry by directly preventing the gp120-CD4 interaction. 
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3.3.2. Pseudovirus Inhibition Assay 
3.3.2.1. Establishing working TCID50 of pseudovirus 
 
Both ZM53 and SF162 pseudoviruses were capable of infecting TZM-bl cells. SF162 however 
had greater infectivity as compared to ZM53. This preliminary viral inhibition assay allowed for 
the determination of the working concentration of pseudovirus to be established (Figure 26). The 
working dilution of pseudovirus was established and selected to be 1:500, at which adequate 
luminescence (10
5
 – 106 RLU) for observation was obtained. This represented 3900 TCID50 for 
ZM53 and 1750 TCID50 for SF162 (For further description of TCID50 calculation, see 
Appendix F). 
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Figure 25: CD4MAb-
mediated inhibition of 
CD4-gp120 binding in 
vitro.  
Inhibition of gp120 (200 
ng/ml) binding to 4dCD4-
Wt following pre-incubation 
with CD4-Mab-containing 
supernatants at dilutions of 
0.1, 0.01, 0.001 and negative 
control (PBS). Absorbance 
readings reflect the level of 
gp120 binding. The data has 
been normalised to the 
negative control. 
Supernatants 17 and 39 are 
D1-specific; 1 and 25 are 
D2-specific.  Triplicates of 
experimental data were used 
for calculating means; error 
bars represent standard 
deviation (µ±1sd). For 
remaining CD4MAbs, 
consult Appendix E. 
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3.3.2.2. Preliminary Analysis of Pseudovirus Inhibition Assay 
 
At a concentration of 1ug/ml, mt310 showed potent inhibition of pseudoviral infection that was 
comparable to the cell control (Figure 27). The rabbit m79 serum, at 1:100 dilution, showed 
inhibition of viral infection, although to a lesser extent compared to mt310 (Figure 28). This 
pseudovirus inhibition assay would serve as the reference for further experiments dealing with 
the panel of CD4MAbs. 
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Figure 26: 
Preliminary Viral 
Assay 
TZM-bl cells, 
plated out into 96-
well culture plate 
(10
5
 cells/well), 
were incubated 
with pseudovirus 
SF162 and ZM53 
(Dilution range: 
0.1 – 0). Viral 
infection and 
replication was 
confirmed and 
quantified using 
the luciferase 
reporter detection 
system.  
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3.3.2.3. CD4MAb-mediated inhibition of HIV-1 pseudovirus replication 
 
The first attempts to demonstrate the inhibitory effects of the CD4-MAbs in pseudovirus 
inhibition assays failed to show any significant inhibition mediated by any of the 40 clones. 
Considering that these antibodies mediated robust inhibition of CD4-gp120 in vitro, the reasons 
for their inability to inhibit viral replication efficiently in cell culture is unclear. A strong 
possibility is that the concentration of the antibodies in the hybridoma supernatants is relatively 
low. We therefore decided to concentrate the hybridoma supernatants prior to setting up the 
pseudovirion inhibition assays, such that the concentrations used would be approximately 20-
fold higher than those employed in the preliminary screening assay. Due to limited amount of 
supernatant we received (~ 1.0 mL), we limited ourselves to testing inhibitory effects on a single 
pseudovirus strain, ZM53. In this experiment, viral inhibition was observed in 22 of the 39 tested 
supernatants (supernatant 25 was compromised and had to be discarded) (Figure 28).  
Figure 27: Preliminary 
Analysis of CD4MAb-
mediated inhibition of HIV-1 
pseudovirus replication 
Serum m79, which was 
derived from a rabbit 
immunized with a gp120-CD4 
complex, had shown 
significant viral inhibition 
against both SF162 and ZM53. 
Control mt310 antibody 
completely ablated viral 
infection. Triplicates of 
experimental data were used 
for calculating means; Error 
bars represent standard 
deviation (µ±1sd). * indicate 
significant reduction in viral 
infectivity relative to viral 
control (t-test, p<0.05) 
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Effectively, all 40 supernantants could inhibit gp120 binding to CD4 in the ELISA. However 
only 12 of the CD4 supernatants showed significant ability to prevent viral infection and viral 
infection to varying degrees. A plausible explanation for this observation could be due the 
unknown, but certainly varying concentration of antibodies present in the supernatants. 
Supernatants having lower MAb concentration, whilst being able to inhibit gp120 binding to 
CD4 in the ELISA, could be insufficient to saturate CD4 molecules present on TZMBls in order 
cause observable reduction in the infection during the viral assay. Another explanation could be 
due to the occurrence of gp120-gp41 (gp140) trimers in the viral assay (Ozel et al., 1988), 
instead of recombinant monomeric gp120 which was present in the ELISA. As compared to 
monomeric gp120, native trimeric gp140 could bind to CD4 in such a way that it is not sterically 
hindered by the anti-CD4 – thus allowing viral entry and infection. It is also possible that 
mammalian expressed CD4 is functionally different to that CD4 expressed from bacteria when it 
concerns viral binding and entry. For instance, mammalian CD4 has glycosylated residues in 
domains 3 and 4 (Spellman et al., 1991), and these could reduce binding affinity of MAbs to the 
CD4 molecule by imposing steric constrains. Interestingly, CD4MAb-20 enhanced viral 
infection and therefore, it would be interesting to further characterise the antibody responsible 
for such observation. 
It is difficult to interpret the relative inhibitory potencies of each antibody clone, and the above 
explanation the observed differences remains highly suggestive without further investigation.  
This study however positively identifies a panel of CD4-specific antibodies that have inhibitory 
effects on HIV replication, and provides a platform for further selection of specific antibody 
clones for further characterization and development. This will involve expansion of selected 
hybridoma cultures and purification/quantification of corresponding antibodies for detailed 
kinetic and anti-HIV activity analysis (not the scope of this project). 
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3.3.2.4. PBMC Assay (See Appendix D) 
 
Activated PBMCs express a wide-range of cytokines, one of which is Interferon-gamma (Fan et 
al., 1998, Vaquero et al., 1986, Sullivan et al., 2000). Interferon-gamma (INF-γ) is a critical 
secreted cytokine that is involved in further lymphocyte and macrophage activation during an 
immune response (Schroder et al., 2004). In our study, we wished to examine the activation of 
PBMC by PHA by assessing the levels of INF-γ secreted into the cell culture media. We 
reasoned that this might provide some rudimentary insights into whether any of the CD4-MAbs, 
had any negative effects on lymphocyte proliferation and activation during PHA stimulation As 
shown in Appendix D, ii, none of the antibodies appeared to exert significant inhibitory effects 
on PHA-mediated IFN-γ secretion. While the results of this rudimentary assay establish a basic 
platform for analysing potential immunosuppressive effects of the CD4 antibodies on T-cell 
activation, and suggest that many of those identified in this study may not exert significant 
inhibition in this regard, we acknowledge that far more detailed and rigorous cellular and 
biochemical analyses, beyond the scope of this work, will need to be performed in order to 
address this important question satisfactorily. 
 
Figure 28: CD4MAb-mediated inhibition of HIV-1 replication 
Viral Inhibition due to CD4-MAbs. By means of Luciferase assay, pseudoviral infection of TZMbls were 
assessed. The TZMBls cells were incubated with concentrated CD4-MAbs supernatant prior (2h) to addition of 
pseudovirus (ZM53). Viral infection was allowed for 48 h. Triplicates of experiments were used and average 
luminescence was determined. Error bars represent standard deviation (µ±1sd).  
VC: Viral Control CC: Cell control 
Two tail t-test relative to viral control (VC, in blue). Green: Reduced Infection (P<0.05); Grey: No significant 
difference (P>0.05); Red; Enhanced Infection (P>0.05). 
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3.4. DISCUSSION 
 
In this chapter we described the generation of a panel of anti-CD4 monoclonal antibodies that 
could potentially serve as novel candidate anti-HIV therapies. These were derived from mice 
immunized with purified recombinant 2dCD4-WT. Supernatants derived from 40 anti-CD4 
monoclonal antibody hybridomas that had been selected and expanded were collected and 
characterised. Using purified CD4 D1 (m1.1) and D2 we were thus able to define the domain 
specificity of each of the CD4-Mabs, and this data provided further evidence for the structural 
integrity of recombinant CD4 D2. We also verified and confirmed the inhibitory potential of the 
Mab-containing supernatants against HIV-1 in vitro by a CD4-gp120 competition ELISA assay, 
and in cell culture by an HIV-1 pseudovirion inhibition assay. 
Recombinant individual D1 (m1.1) (Chen et al., 2011), wild-type D2 and 4dCD4 variants were 
generated using bacterial host cells. A major disadvantage of expressing mammalian proteins in 
E. coli is the inability of these host cells to effect post-translational modifications, which may be 
important for the structure and function of the protein (Yin et al., 2007). Furthermore, the lack of 
chaperones and presence of a heavily reducing intracellular microenvironment prevent proper 
protein folding and disulphide bond formation. (Baneyx, 1999). Our laboratory, and part of this 
project, addresses the redox state of the expressed CD4 (Cerutti et al., 2010, Cerutti et al., 2014). 
Therefore, structural and functional integrity of the protein is critical. Protein expression in 
mammalian cells is ideal as it eliminates the mentioned inconveniences of the E.coli expression 
system, producing correctly folded and soluble protein. Typically, CD4 has been expressed from 
mammalian cell cultures (Kwong et al., 1998, Ryu et al., 1990). However, mammalian cell 
culture is tedious, time-consuming, costly and yields of protein tend to be relatively low (Yin et 
al., 2007). In this project, we have provided indications that a 2dCD4 expressed in E.coli is 
capable of being refolded into a native structure in vitro, and can be used as an immunogen for 
the generation of anti-CD4 antibody with anti-HIV properties. The generated CD4-MAbs 
ultimately were able to bind strongly to not only 2dCD4 variants, but to 4dCD4, and cognate 
epitopes within the individual CD4 domains 1 and 2 specifically. Moreover, together with the 
data described in Chapter 2, the finding that a set of antibodies elicited to a 2-domain CD4 
immunogen bind robustly to CD4 D2 provides further evidence that this protein is structurally 
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similar to CD4-D2 as it occurs in the context of the native CD4 structure,. These experiments 
have therefore reinforced our confidence in the expression of CD4 in E.coli host cells, which is 
much more economical and less time-consuming than using mammalian cell expression systems. 
Despite almost 30 years since the discovery of HIV/AIDS, an effective vaccine remains to be 
found. High mutation rates (Korber et al., 2001), glycosylation masking and inaccessible 
neutralising epitopes (Johnson et al., 2009, Poignard et al., 2001) on the envelope glycoprotein 
are some of the few reasons why the development of vaccine immunogens that can elicit 
neutralizing antibodies targeting HIV directly have not been successful. Targeting host cell CD4 
with an antibody to inhibit HIV infection could be a potential approach to overcoming such 
challenges and provide an alternate therapy. While the generation of anti-CD4 MAbs as potent 
viral inhibitors has been considered for some time, it remains a difficult task due to risk of 
compromising the critical physiological role played by CD4 in adaptive immunity (Cobbold et 
al., 1984, Goronzy et al., 1986, Dalgleish et al., 1984). Currently proceeding into phase III 
clinical trials, Ibalizumab is the only anti-CD4 MAb that inhibits HIV infection without causing 
immune suppression (Jacobson et al., 2009, Norris D, 2006, Khanlou H, 2011, 
TaiMed_Biologics_Inc, 2011). With Ibalizumab as a novel class of drug against HIV, we 
propose that several other undiscovered epitopes exist on CD4 which can be targeted by MAbs 
without mediating immunosuppressive effects. Moreover, with the emergence of HIV strains that 
are resistant to all existing antiretroviral therapies (Gupta et al., 2009), including Ibalizumab 
(Toma et al., 2011, Pace et al., 2013), there is an urgent ongoing need for the development of 
alternative antiviral therapies targeting different sites on both the virus and host molecules.  
Notwithstanding this, nearly half of the MAbs raised against the 2dCD4 immunogen were shown 
to target domain 2 of CD4. Furthermore, eight of these were able to inhibit viral infection as 
demonstrated from the pseudoviral assay (Figure 28). Non-immunosuppressive anti-HIV 
Ibalizumab was confirmed to bind to the domain 2 of CD4 (Song et al., 2010, Freeman et al., 
2010, Burkly et al., 1992), although its mechanism of action does not involve blocking of CD4-
gp120 binding (Burkly et al., 1992, Moore et al., 1992). Rather, the mode of action of 
Ibalizumab is suspected to involve inhibiting the conformational changes in either CD4 or gp120 
that ultimately lead to viral entry. We therefore have at our disposal an entire new panel of 
potentially novel CD4 domain 2 targeting antibodies with anti-HIV properties which are able to 
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restrict gp120 binding. This therefore indicates that epitopes of the MAbs generated in this study 
are different to those of Ibalizumab: these may be more proximal to or overlap with residues in 
D1, or these MAbs may bind to D2 via approaches that sterically inhibit gp120 binding. It is 
plausible that the Fc portion of the antibody has a role to play in obstructing gp120 binding. It 
would therefore be interesting to verify whether the gp120 inhibitory effect is still possible with 
the use of Fab fragments. 
It has been suggested that CD4 is susceptible to redox changes that affect its physiological role. 
For instance, CD4 has been observed to form disulphide-linked dimers during T-cell activation 
(Lynch et al., 1999, Moldovan et al., 2002). Whilst more research needs to be conducted, it has 
been reported that reduced, monomeric forms of CD4 represented the preferred state of the 
receptor for HIV entry (Matthias et al., 2010), since reduction of the disulphide bond in the 
second domain of CD4 supports higher levels of HIV infection. (Matthias et al., 2002, Cerutti et 
al., 2014). It is undoubtedly interesting to speculate whether HIV corrupts the CD4-redox 
physiology in order to enhance infection. With wild-type CD4 and a panel of Cys/Ala CD4 
mutants at our disposal, we therefore sought to find out whether we could identify any CD4 
Mabs that had specific binding preferences for distinct CD4 redox isomers. Based on the 
evidence of the importance of disulphide bonds in CD4, the discovery of a redox-dependent 
antibody would indicate that significant conformational changes occur in CD4 during redox 
alterations. Furthermore, such an antibody could potentially lock CD4 in a redox state that is not 
permissive to viral entry. Intriguingly, while the CD4-Mabs showed no difference in binding to 
either wild-type or D2 cysteine deficient two-domain CD4, the latter had reduced binding ability 
to a 2dCD4 in which all cysteines were ablated (2dCD4-CA). D1-specific MAbs did not show 
any binding to 2dCD4-CA.   
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CHAPTER 4: 
CONCLUSION 
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In this study we described the generation of recombinant bacterial expressed individual domains 
1(D1) and 2 (D2) of CD4. D1 and D2 were effectively expressed, purified and based on the 
several lines of biochemical evidence, were structurally and functionally intact. Reducing and 
non-reducing SDS-PAGE showed the occurrence of intact disulphide bonds in both of the 
recombinant proteins. Far-UV CD-spectrum showed preservation of the secondary structure. The 
biophysical assessment of stable mutant D1 (m1.1) showed consistency with the previous study 
on which this recombinant protein was based (Chen et al., 2011). The expression of recombinant 
wild-type D2, which has only been mentioned once in the literature (Matthias et al., 2010), 
indicated a correctly folded structure. For future studies, using these individual domains, it could 
be possible to further characterise the structural and functional roles of the domains of CD4 
independently. With our laboratory focusing on redox changes in the CD4 molecule, the 
individual domains of CD4 would provide insight for assessing the states of the disulphide bonds 
in 2dCD4. Future analyses, including time-dependent assays and determination of the redox 
potential would allow quantitative description of the disulphide bonds. With previous research 
indicating that the redox state the disulphide bonds influences viral infection (Matthias et al., 
2010, Matthias and Hogg, 2003, Matthias et al., 2002), these further experiments on individual 
domains D1 and D2, will provide insights into the role of CD4 structural dynamics during HIV 
viral entry and infection. 
Ibalizumab, currently in phase III of clinical trials, is the only recognised anti-CD4 MAb that has 
demonstrated effectiveness in inhibiting HIV infection. As such, the development of anti-CD4 
MAbs against HIV remains a mostly untapped field. With growing HIV resistance against 
Ibalizumab (Toma et al., 2011, Pace et al., 2013), the urgency of seeking novel anti-CD4 MAbs 
is further stressed. In the second part of the project, we have successfully generated a panel of 40 
anti-CD4 MAbs; all of which could inhibit CD4-gp120 binding and limiting pseudoviral 
infection in vitro. Undoubtedly, our research represents preliminary work – further analyses and 
experiments need to be conducted. Purifying and further characterising the epitopes and 
potencies of the MAbs needs to be undertaken. An important piece of work remains verifying 
whether the MAbs have any immunosuppressive effects. A basic PBMC assay allowing the 
detection of secreted INF-γ was begun (Appendix D). This represents a future platform for 
assessment of secreted cytokines, of which the levels are indicative of immunosuppression. 
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Additionally, with the use of the recombinant individual D1 and D2 domains of CD4, it was 
possible to define the domain specificities of each CD4-MAb. Ibalizumab targeting the domain 2 
of CD4, allows for gp120 binding to CD4, but limits viral entry by restricting the conformational 
changes that ensues. Here, whether targeting D1 or D2, the MAbs could actually inhibit gp120-
CD4 binding. Thus, these MAbs potentially signify alternate binding epitopes and mechanism of 
action in preventing viral entry. Our work therefore lays down the basis for development of these 
novel anti-CD4 MAbs therapies against HIV. 
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APPENDIX A 
 
a. For Bacterial Transformation/Culture/Plating: 
 
i. Ampicillin 1000x Stock Solution (per 10 mL): Weigh out 1 g Ampicillin (Sigma-
Aldrich, MO, U.S.A). Dissolve by vigourous agitation in 5 mL high-quality Millipore® 
distilled water and 5 mL 100 % ethanol. Store at -20
o
C. 
 
ii. Transformation Buffer (per 100 mL): Weigh out 1.4702 g CaCl2.2H2O (100 
mM) (Sigma-Aldrich, MO, U.S.A) and 0.3024 g PIPES-HCl (10 mM). Dissolve in 80 mL 
of high-quality Millipore® distilled water. Add 15 mL of glycerol (15 %). PH to 7.0 with 
NaOH (Sigma-Aldrich, MO, U.S.A). Make up to 100 mL with high-quality Millipore® 
distilled water. Sterilize by autoclaving on liquid cycle (121
o
C, 1kg/cm
2
, 20 minutes). 
Allow to cool and store at 4
o
C. 
 
 
iii. Luria Bertani (LB) broth  (per 1L): Weigh out 10 g tryptone (Sigma-Aldrich, 
MO, U.S.A), 10 g yeast extract (Sigma-Aldrich, MO, U.S.A) and 5.0 g NaCl (Sigma-
Aldrich, MO, U.S.A). Dissolve into 1L distilled water Sterilize by autoclaving on liquid 
cycle (121
o
C, 1kg/cm
2
, 20 minutes) and allow to cool. Store at room temperature. 
 
iv. Agar LB (per 200ml): Weigh out 2 g tryptone (Sigma-Aldrich, MO, U.S.A), 2 g 
yeast extract (Sigma-Aldrich, MO, U.S.A), 3 g agar and 1g NaCl ((Sigma-Aldrich, MO, 
U.S.A). Dissolve into 1L distilled water. Sterilize by autoclaving on liquid cycle (121
o
C, 
1kg/cm
2
, 20 minutes) and allow to cool. Store at room temperature. Melt before use. 
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b. For Agarose Gel Electrophoresis: 
 
i. EDTA 0.5 M Stock Solution (per 200ml): Weigh out 37.22 g EDTA ((Sigma-
Aldrich, MO, U.S.A). Dissolve in 150 mL high-quality Millipore® distilled water. PH to 
8.0 with NaOH. Store at room temperature. 
 
ii. Tris-acetate EDTA (TAE) Buffer, 50X stock (per 1L): Weigh out 242 g tris base. 
Add 57.1 mL glacial acetic acid (Merck, Darmstadt, Germany) and 100 mL 0.5 EDTA 
(Sigma-Aldrich, MO, U.S.A). Add 800 mL of distilled water. Adjust pH to 8.0 with HCl. 
Make up to 1 L with distilled water. Store at room temperature. 
 
iii. 1% Agarose gel: Weigh out 1g agarose powder (Sigma-Aldrich, MO, U.S.A). 
Add 100 ml of 1X Tris acetate EDTA (TAE) buffer and heat in a microwave until the 
agarose completely dissolved. Allow to cool at room temperature before the addition of 
7.5 µl Ethidium Bromide (0.5μg/ml) (Promega, U.S.A). Pour in a Bio-Rad Gel Chamber 
System (Bio-Rad) and allow to set. 
 
c. For SDS-PAGE: 
 
i. Monomer Solution (30.8 % T, 2.7 % Cbis), (per 200 mL): Weigh out 60 g 
acrylamide (Sigma-Aldrich, MO, U.S.A) and 1.6 g bisacrylamide (Merck). Dissolve in 
200 mL of distilled water. Store in the dark at 4
o
C. 
 
ii. Stacking gel buffer, 4X (0.5 M tris.cl, pH 6.8) (per 50 mL): Weigh out 3.0 g tris-
cl (0.5 M) (Sigma-Aldrich, MO, U.S.A). Dissolve in 40ml distilled water. Adjust pH to 
6.8 with HCl. Make up to 50.0 ml with distilled water. Store at 4
o
C in the dark. 
 
iii. Running gel buffer, 4X (1.5 M tris.cl pH 8.8) (per 200 mL): Weigh out 36.3 g 
tris-cl (Sigma-Aldrich, MO, U.S.A). Dissolve into 150ml distilled water. Adjust pH to 
8.8 with HCl. Make up to 200 ml with distilled water. Store in the dark at 4
o
C 
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iv. Loading Buffer, 2X (0.125M tris-cl, 4% SDS, 20% v/v glycerol, 0,2M DTT, 
0,02% bromophenol blue, pH6.8) (per 10ml): Weigh out 0.31 DTT (Sigma-Aldrich, 
MO, U.S.A). Add 2.5 ml 4x stacking gel buffer, 4.0 ml 10% SDS (Sigma-Aldrich, MO, 
U.S.A), 2.0 ml glycerol and 2 mg bromophenol blue. Adjust pH to 6.8 with HCl. 
Dissolve and make up to 10 ml with distilled water. Store 0.5 ml aliquots at -20
o
C. 
 
v. 10% SDS (per 100 ml): Weigh out 10g SDS (Sigma-Aldrich, MO, U.S.A). 
Dissolve in 100 ml distilled water. Store at room temperature. 
 
vi. 10% Ammonium Persulphate (per 1 mL): Weigh out 1 g Ammonium 
Persulphate (Sigma-Aldrich, MO, U.S.A). Dissolve in 1 mL of syringe-quality distilled 
water. Use immediately. Do not store. 
 
vii. Tank buffer, 10X (per 1L): Weigh out 30.28 g tris.cl (Sigma-Aldrich, MO, 
U.S.A), 144.13g glycine (Sigma-Aldrich, MO, U.S.A) and 10g SDS (Sigma-Aldrich, 
MO, U.S.A). Disolve into 1L of distilled water. Store at room temperature. 
 
d. For Coomassie Blue Staining and Western Blots 
 
i. Transfer buffer (per 1L): Add 200ml methanol into 800 mL of 1X Tank Buffer. 
 
ii. Coomassie Blue stain (per 1L): Add 500 ml methanol and 100 ml acetic acid into 
400 ml distilled water. Dissolve in 0.25g Coomassie R250. Store at room 
temperature. 
 
iii. Destain Solution (per 1L): Add 50 ml ethanol and 70ml acetic acid into 850ml 
distilled water. Distilled water is then added to make up to 1L. Store at room 
temperature. 
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iv. 10X TBS (per 1L): Weigh out 10 g NaCl (Sigma-Aldrich, MO, U.S.A), 30 g Tris 
(Sigma-Aldrich, MO, U.S.A) and 2.0 g of KCl (Sigma-Aldrich, MO, U.S.A). 
Dissolve into 950 mL of distilled water. Adjust pH to 7.4 with HCl. Make up to 1 
L with distilled water. Store at 4
o
C. 
 
v. T-TBS (0.05% Tween, per 1L): Add 500 µL of Tween® 20 (Sigma-Aldrich, MO, 
U.S.A) into 1L of 1X TBS. Dissolve. Store at 4
o
C. 
 
vi. BSA Blocking Solution (10 mg/mL): Weigh out 50 mg of BSA (Sigma-Aldrich, 
MO, U.S.A). Dissolve into 50 mL of 1X TBS. Use immediately. 
 
e. For Protein Isolation 
 
i. Solubilisation buffer (per 50ml): Weigh out 24.03g urea (8M) (VWR), 0.18766 
gylcine (50mM) (Sigma-Aldrich, MO, U.S.A), 0.068g imidazole (20mM) (Sigma-
Aldrich, MO, U.S.A), and 1.46 g NaCl (Sigma-Aldrich, MO, U.S.A). Dissolve in 
20 mL distilled water. Add 7.00µL β-mercaptoethanol (2 mM) (Sigma-Aldrich, 
MO, U.S.A). Adjust pH to 7.4 with HCl. Make up to 50 mL with distilled water. 
Store at room temperature. 
 
ii. Folding Buffer A (per 1 L): Weigh out 3.75 g glycine (50 mM) (Sigma-Aldrich, 
MO, U.S.A), 100 g sucrose (10 %) (Sigma-Aldrich, MO, U.S.A), 0.31 g GSH 
(Glutathione, reduced, 1 mM) (Sigma-Aldrich, MO, U.S.A), 0.061 g GSSG 
(Glutathione disulphide, oxidised, 0.1 mM) (Sigma-Aldrich, MO, U.S.A) and 240 
g Urea (4 M) (VWR International). Dissolve in 500 mL of distilled water. Add 
2.0 mL 0.5 M stock EDTA (Sigma-Aldrich, MO, U.S.A) and 7.8 mL of 2 M of 
stock NaOH (Sigma-Aldrich, MO, U.S.A). PH to 9.6 with HCl or NaOH. Make to 
1 L with distilled water. Chill before use (4
o
C). 
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iii. Folding Buffer B (per 1 L): Weigh out 1.59 g Na2CO3 (15 mM) ((Sigma-Aldrich, 
MO, U.S.A), 2.93 g NaHCO3 (35 mM) (Sigma-Aldrich, MO, U.S.A), 100 g 
sucrose (10 %) (Sigma-Aldrich, MO, U.S.A), 0.031 g GSH (Glutathione, reduced, 
0.1 mM) (Sigma-Aldrich, MO, U.S.A) and 0.006 g (Glutathione disulphide, 
oxidised, 0.01 mM) (Sigma-Aldrich, MO, U.S.A). Dissolve in 950 mL of distilled 
water. Add 2.0 mL 0.5 M stock EDTA (Sigma-Aldrich, MO, U.S.A). PH to 9.6 
with HCl or NaOH. Make up to 1 L wih distilled water. Chill before use (4
o
C). 
 
iv. Nickel Sulphate 0.1 M Stock Solution (per 10 mL): Weigh out 0.15476 g of 
NiSO4 (Sigma-Aldrich, MO, U.S.A). Dissolve in 10 mL of high-quality 
Millipore® distilled water. 
 
 
f. Wash buffers: 
 
i. Base solution (per 100 mL): Weigh out 48.05 g urea (8M) (VWR International), 
0.37532 g glycine (50mM) (Sigma-Aldrich, MO, U.S.A), 0.068g imidazole 
(20mM) (Sigma-Aldrich, MO, U.S.A) and 1.46 g NaCl (Sigma-Aldrich, MO, 
U.S.A). Dissolve in 40 mL distilled water. Add 14.00µL β-mercaptoethanol 
(Sigma-Aldrich, MO, U.S.A) (2 mM) and 10 mL of 10X PBS ((Sigma-Aldrich, 
MO, U.S.A). Make up to 100 mL with distilled water. Store at room temperature. 
Syringe/vacuum filter through 1 µL filter. Store at room temperature. 
 
ii. For 20 mM imidazole (per100ml): Dissolve 0.13616 g Imidazole (Sigma-
Aldrich, MO, U.S.A) into base solution. Adjust pH to 7.4 with HCl. 
 
iii. For 50 mM imidazole (per100ml): Dissolve 0.3404g Imidazole (Sigma-Aldrich, 
MO, U.S.A) into base solution. Adjust pH to 7.4 with HCl.  Store at room 
temperature. 
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iv. For 75 mM imidazole (per100ml): Dissolve 0.5106 g Imidazole (Sigma-Aldrich, 
MO, U.S.A) into base solution. Adjust pH to 7.4 with HCl.  Store at room 
temperature. 
 
v. For 100 mM imidazole (per100ml): Dissolve 0.6809 g Imidazole (Sigma-
Aldrich, MO, U.S.A) into base solution. Adjust pH to 7.4 with HCl. Store at room 
temperature. 
 
vi. Protein Elution Buffer (500 mM imidazole, per 50 ml): Dissolve 1.702 g 
Imidazole (Sigma-Aldrich, MO, U.S.A) into base solution. Adjust pH to 7.4 with 
HCl. Store at room temperature. 
g. For Tricine SDS-PAGE 
 
i. Anode buffer (per 1L): Weigh out 24.3 g tris base (Sigma-Aldrich, MO, U.S.A). 
Dissolve in 500 ml distilled water. Adjust pH to 8.9 with HCl. Make up to 1 L 
with distilled water. Store at 4
o
C. 
 
ii. Cathode buffer (per 1L): Weigh out 12.11g tris base (0.1M) ((Sigma-Aldrich, 
MO, U.S.A) and 17.19 g tricine (0.1M) (Sigma-Aldrich, MO, U.S.A), 1g SDS 
(0.1% w/v) (Sigma-Aldrich, MO, U.S.A). Dissolve in 1L distilled water. Do no 
adjust pH. Store at 4
o
C. 
 
iii. Tris.cl/SDS, pH 6.8 (0.5M tris.cl, 0.4% SDS) (per 100ml): Weigh out 6.05g tris 
base (Sigma-Aldrich, MO, U.S.A) dissolve in 40ml of distilled water adjust pH to 
6.8 with HCl, make up to 100ml with distilled water , syringe water through a 
0.45µm filter, dissolve in 0.4g SDS. Store at 4
o
C. 
 
iv. Tricine gel DTT-containing loading buffer, 6X (0.1 M Tris, 24 % w/v glycerol, 8 
% w/v SDS, 0.2 M DTT) (per 10ml): Weigh out 1 g SDS (Sigma-Aldrich, MO, 
U.S.A), 0.93 g DDT (Sigma-Aldrich, MO, U.S.A) and 1.2 mg Bromophenol blue. 
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Add 7 ml 4x tris.cl/SDS (pH 6.8) and 3.0 ml glycerol. Make up to 10 ml with 
distilled water. Store 0.5ml aliquots at -20
o
C. 
 
v. Tricine gel DTT-free loading buffer, 6X: Same as above, exclude DTT. 
 
h. For Mammalian Cell Cultures 
 
 
i. PBMC Culture Media 
RPMI-1640 Medium (with sodium bicarbonate, without L-glutamine) (Sigma-Aldrich, 
MO, U.S.A); supplemented with 1x Glutamax (2 mM), 1x P/S (100 units of Penicillin 
and 0.1 mg/ml of Streptomycin; Sigma-Aldrich, MO, U.S.A), 1x IL – 2 (3%) (Sigma-
Aldrich, MO, U.S.A), 10%/20% FCS (Biochrom Heat Inactivated, UK) 
 
ii. Freeze Media for PBMC (90% FCS, 10% DMSO) 
In 9 mL of FCS (Biochrom Heat Inactivated, UK), add 1 mL of sterile syringe-filtered 
cell culture grade DMSO (Sigma-Aldrich, MO, U.S.A). Mix before use. 
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APPENDIX B: Protocols 
 
a. Poly-Acrylamide Gels 
 
Mini-PROTEAN® Bio-Rad gel casting glass plates (12.5cm x 6.5 cm x 1.5 mm) were 
firstly washed with soapy water, rinsed with distilled water, and cleaned with 70% 
ethanol. The plates were assembled on the casting standing and it was ensured that there 
were no leaks. Running gels were prepared (described below), with Ammonium 
Persulphate (APS) (Sigma-Aldrich, MO, U.S.A) and Tetra-methyl-ethylene-
diamine (TEMED) (Sigma-Aldrich, MO, U.S.A) being added last. Running gel was 
poured into casting plates and topped with isopropanol in order to level the gels. Running 
gels was allowed to set. Once set, isopropanol was discarded and remaining isopropanol 
was allowed to air-dry. Stacking gels were prepared (described below), with APS and 
TEMED being added last. Stacking gels was poured onto set running gel. Combs were 
carefully placed to prevent air bubbles. Stacking gels were allowed to set. Gels could be 
used immediately or were wrapped in moistened paper-towels and stored at 4
o
C until use. 
 
Appropriate loading buffer was added to protein samples accordingly. If required, 
samples were incubated onto a water-bath at 100
o
C for 10 minutes. Casted gel plates 
were assembled into the electrophoresis cell. Appropriate buffer is added to 
corresponding chambers. Markers and gel samples are loaded into wells using a syringe. 
Gel electrophoresis is conducted (200 V, 15mA per gel) until proteins were resolved. 
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i. SDS-PAGE Gels (10% Running gels, 2 gels, 1.5 mm) 
 
Running Gel (10%)   Stacking Gel  
Monomer Solution 10.0 mL  Monomer Solution 0.88 mL 
4X Running Buffer 7.5 mL  4X Stacking Buffer 1.66 mL 
10% SDS 300 µL  10% SDS 66 µL 
Distilled Water 12 mL  Distilled Water 4.0 mL 
10% APS 150 µL  10% APS 33.4 µL 
TEMED 10 µL  TEMED 10 µL 
 
ii. Tricine Gels (15% Running gels, 2 gels, 1.5 mm) 
 
Running Gel (15%)   Stacking Gel  
Monomer Solution 4.9 mL  Monomer Solution 1.62 mL 
Tris.Cl/SDS 5.0 mL  Tris.Cl/SDS 3.10 mL 
Glycerol 1.59 µL  Glycerol - 
Distilled Water 3.5 mL  Distilled Water 7.78 mL 
10% APS 50 µL  10% APS 50 µL 
TEMED 10 µL  TEMED 10 µL 
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b. Plasmid extraction/Mini-Prep. (GenEluteTM Plasmid Miniprep Kit, Sigma-Aldrich) 
 
i. Pellet cells from 1 – 5 mL overnight culture (10 minutes, 2000 rpm). Discard 
the supernatant. 
ii. Resuspend in 200 µL of resuspension solution (RNAse-containing). Pipette 
gently to mix. 
iii. Add 200 µL of lysis solution. Invert gently to mix (4 – 6 times) and allow to 
clear (< 5 minutes). 
iv. Add 350 µL of neutralising solution. Invert gently to mix (4 – 6 times). Pellet 
debris by centrifugation at maximum speed. 
v. Attach binding column to collection tube. Prepare binding column by adding 
500 mL of column preparation solution to the binding column. Centrifuge 
(>12000 xg, 1 minute) and discard flow-through. 
vi. Transfer clear lysate to the binding column. Centrifuge (>12000 xg, 1 minute) 
and discard flow.through. 
vii. Add 750 µL of wash solution to column. Centrifuge (>12000 xg, 1 minute) 
and discard flow-through. 
viii. Dry-spin column. Centrifuge (>12000 xg, 1 minute) and discard collection 
tube. 
ix. Attach column to a new collection tube. Add 100 µL of elution buffer to 
column. Centrifuge (>12000 xg, 1 minute). Collect flow-through containing 
purified plasmid DNA. 
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c. Isolation and purification of DNA (High Pure PCR product purification kit, 
Roche®) 
 
i. Visualise under UV and isolate resolved bands of interest from agarose gel by 
cutting the desired band out. 
ii. Place cut agarose gel slice into sterile capped 1.5 mL microtube. 
iii. Add 300 µL of binding buffer per 100 mg of agarose to the microtube. 
Dissolve the agarose by incubating the microtube at 56
o
C for 10 minutes. 
Vortex every 2 – 3 minutes. 
iv. Add 150 µL of isopropanol to every 100 mg agarose gel. Vortex. 
v. Attach a High Pure ® filtration tube a to a collection tube. Pipette contents of 
microtube into the filtration tube (no more than 700 µL). Centrifuge 30 – 60s 
at maximum speed between 15 – 25 oC. Discard flow-through and reconnect 
the filter tube to the collection tube. 
vi. Add 150 µL of wash buffer to filter tube. Centrifuge at maximum speed for 1 
minute. Discard flow-through. Reconnect the filter tube to the collection tube. 
vii. Add 200 µL of wash buffer to filter tube. Centrifuge at maximum speed for 1 
minute. Discard the collection tube. Reconnect the filter tube to a new 1.5 mL 
collection tube. 
viii. Add 50 - 100 µL of elution buffer to filter tube. Centrifuge at maximum speed 
for 1 minute. Collect flow-through containing purified DNA. 
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APPENDIX C: Diagrams, Tables and Graphs 
 
a) Amino acid sequence alignment of D1 (m1.1) and D2 (WT) relative to 2dCD4. 
In green: Mutations; In yellow: Histidine tags 
1                                                                                                                                              50 
Two-domain_CD4     KKVVLGKKGD   TVELTCTASQ  KKSIQFHWKN  SNQIKILGNQ  GSFLTKGPSK 
Cd4_D1(m1.1)  MKKVV I GKKGD        TVELTCTASQ        KKSIQFHWKN     SNQIKILGNQ      GSFLTKGPSK 
Cd4_D2_(WT)         ----------------------------------------------------------------------------------------------------------- 
 
51                                                                                                                                      100 
Two-domain_CD4      LNDRADSRRS  LWDQGNFPLI  IKNLK  I   EDSD  TYICEVEDQK EEVQLLVFG 
Cd4_D1(m1.1)       LNDRVDSRRS  LWDQGNFPLI  IKNLKPEDSD TYICEVEDQK    EEVQLI VLG 
Cd4_D2_(WT)          ---------------------------------------------------------------------------------------------------MG 
 
101                                                                                                                                     150 
Two-domain_CD4       LTANSDTHLL QGQSLTLTLE SPPGSSPSVQ CRSPRGKNIQ GGKTLSVSQL 
Cd4_D1(m1.1)           HHHHHH----------------------------------------------------------------------------------------- 
Cd4_D2_(WT)          LTANSDTHLL QGQSLTLTLE SPPGSSPSVQ CRSPRGKNIQ GGKTLSVSQL 
 
151                                                                                                           190 
Two-domain_CD4       ELQDSGTWTC TVLQNQKKVE FKIDIVVLAF QKAS------------ 
Cd4_D1(m1.1)            ------------------------------------------------------------------------------------- 
Cd4_D2_(WT)          ELQDSGTWTC TVLQNQKKVE FKIDIVVLAF QKLEHHHHHH 
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b) In silico derived-data of D1(m1.1)and D2 (WT) relative to 2dCD4. 
 
D1 (m1.1) 
Analysis Entire Protein 
Length 108 amino acids 
Molecular Weight 12392.35 
1 microgram = 80.695 pMoles 
Molar Extinction Coefficient 12900 
A280 corr. to 0.96 mg/mL 
A280 corr. ff 1 mg/mL 1.04 AU 
Isoelectric Point 8.94 
Charge at pH 7 3.36 
    
Amino Acids Number count % by weight % by frequency 
Charged (RKHYCDE) 39 40.13 36.11 
Acidic (DE) 13 12.67 12.04 
Basic (KR) 16 16.92 14.81 
Polar (NCQSTY) 29 25.67 26.85 
Hydrophobic (AILFWV) 30 28.23 27.78 
 
 
 
 
Table 2: In silico derived-
data of D1(m1.1) 
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D2 (WT) 
Analysis Entire Protein 
Length 94 amino acids 
Molecular Weight 10358.12 
1 microgram = 96.543 pMoles 
Molar Extinction Coefficient 5930 
A280 corr. to 1.75 mg/mL 
A280 corr. of 1 mg/mL 0.57 AU 
Isoelectric Point 8.06 
Charge at pH 7 1.36 
 
Amino Acids Number count % by weight % by frequency 
Charged (RKHYCDE) 24 29.43 25.53 
Acidic (DE) 7 8.21 7.45 
Basic (KR) 8 10.18 8.51 
Polar (NCQSTY) 32 32.89 34.04 
Hydrophobic (AILFWV) 26 28.12 27.66 
 
 
 
 
 
Table 3: In silico derived-
data of D2 (Wt) 
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c) Ramachandran Plots 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Ramachandran Plots of D1 (m1.1) and D2. 
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d) Far-UV CD Voltage/Wavelength 
 
 
Figure 30: CD-Analysis (V/nm) 
During CD-analyses, the voltage experienced against wavelength was plotted in order to validate the region of the 
Far-CD UV plot (Figure 15) where stable measurements were made. Stable, constant voltage of ~400 V from 
~210nm represents valid measurements. Increasing voltage to 1000 V below 210nm represent non-valid 
measurements. 
e) Viral Inhibition with serum m79 
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Figure 31: Preliminary Analysis of 
CD4MAb-mediated inhibition of 
HIV-1 pseudovirus replication 
Serum m79, which was derived from 
rabbit immunized with gp120-CD4 
complex, had shown significant viral 
inhibition against both SF162 and 
ZM53.  
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f) Previous Expression of individual domains 1 and 2 of CD4 
 
Domain Reference 
Name of 
Domain in 
Original 
Publication 
Description and 
Mutations 
Expression Purification 
D1 
Chen et 
al.(2011) 
mD1.1 
L5I, A55V, 
I76P, L96I, 
F98L; 
C-terminal His-
tag 
HB2151 E. coli; 
Soluble fraction 
of periplasm 
Metal Ion 
Affinity (IMAC) 
using Ni-
nitrotriacetic 
acid (NTA); 
followed by size 
exclusion 
chromatography 
D1 
Chen et 
al.(2011) 
mD1.1 
L5I, A55V, 
I76P, L96I, 
F98L; 
C-terminal His-
tag 
HEK293; 
Soluble from 
supernatant 
Metal Ion 
Affinity (IMAC) 
using Ni-
nitrotriacetic 
acid (NTA); 
followed by size 
exclusion 
chromatography 
D1 
Chen et 
al.(2011) 
mD1.1 – 
CH2 
L5I, A55V, 
I76P, L96I, 
F98L; 
Fusion protein 
with IgG1 CH2 
domain 
HEK293; 
Soluble from 
supernatant 
Protein A 
Sepharose 4 Fast 
Flow; 
followed by size 
exclusion 
chromatography 
D1 
Chen et 
al.(2011) 
mD1.2 
L5I, A55V, 
I76P, L96I, 
F98L; 
C-terminal His-
tag 
E. coli; 
Soluble fraction 
of periplasm 
Metal Ion 
Affinity (IMAC) 
using Ni-
nitrotriacetic 
acid (NTA); 
followed by size 
exclusion 
chromatography 
D1 
Chen et 
al.(2011) 
mD1.2 
L5Y, S23N, 
I76P, L96V, 
F98V; 
C-terminal His-
tag 
HEK293; 
Soluble from 
supernatant 
Metal Ion 
Affinity (IMAC) 
using Ni-
nitrotriacetic 
acid (NTA); 
followed by size 
exclusion 
chromatography 
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D1 
Saha et al. 
(2011) 
CD4D1a 
L5K, G6A, 
L51I, V86L, 
F98T; 
N-terminal His-
tag 
E. coli; 
Insoluble 
fraction as 
inclusion bodies 
Solubilisation 
with 8 M 
guanidine 
hydrochloride in 
PBS, Ni-NTA 
affinity and 
imidazole 
elution, 
refolding by 
dialysis against 
PBS 
 
D1 
Sharma et al. 
(2005) 
CD4D1 
V3T, L5A, 
I76T, L96A, 
F98A 
N-terminal His-
tag 
E. coli; 
Insoluble 
fraction as 
inclusion bodies 
Solubilisation 
with 6 M 
guanidine 
hydrochloride in 
PBS, Ni-NTA 
affinity and 
imidazole 
elution, 
refolding by 
dialysis against 
PBS 
 
D2 
Commercially 
available from: 
ProSpec-Tany 
TechnoGene 
Ltd., Rehovot, 
Israel (Cat. No.: 
CYT-315) 
Matthias et al. 
(2010) 
CD-4 
Residues 125 – 
202; 
Histidine 
tagged 
E. coli 
Has not been 
publicly 
described 
 
Table 4: Previous Expression of individual domains 1 and 2 of CD4 
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a) Restriction Analysis 
 
 
  
Figure 33: Restriction Analysis of D1 and D2 in pET15b vector 
Molecular screening for successful ligation was confirmed by 1.5 % gel electrophoresis of BamHI and 
XbaI/EcorRI digested plasmids. Linearised plasmid (i.e. BamHI digestion) produced the expected single bands at 
about 6000 bp. The absence of any other DNA contaminants or un-ligated inserts is stressed. Inserts derived from 
XbaI/EcorRI restriction analysis were visualised (D1 (m1.1): 691 bp, D2: 649 bp). This confirmed success of 
ligation and isolation of pet15b – D1 and –D2 plasmids.  
ML: Molecular ladder (Thermo Scientific O'GeneRuler DNA Ladder Mix, SM1173) 
 
 
ML   BamHI linearised plasmids                               ML   XbaI/EcorRI digested plasmids 
 
         Pet15b   D1      D1      D2      D2       D1     D2             Pet15b   D1     D1     D2      D2      D1     D2 
 
Figure 32: Restriction Analysis of 4dCD4-Wt and 4dCD4-D2A in pET15b vector 
 Molecular screening for successful ligation was confirmed by 1.0 % gel electrophoresis. Control pET15b and 
ligated vector were linearised with XbaI (L). Single significant band was observed, with ligated DNA occurring at 
higher molecular weight compared to pET15b control. Digestion with XbaI/XhoI allowed for identification of 
insert (1226 bp) in the ligated products (I). Control pET15b, subjected to XbaI/XhoI produced expected fragment 
of 109 bp. EcoRI digestion essentially caused linearization of control pET15b (E). In the case of ligated products, 
EcoRI digestion produced two fragments, due to presence of extra EcoRI restriction site present in 4dCD4 insert.  
ML: Molecular ladder (Thermo Scientific O'GeneRuler DNA Ladder Mix, SM1173) 
 
 
 
ML          pEt15                     4dCD4-WT 
             L            I            L          I           E 
 
 
 ML            4dCD4-D2A      
             L          I          E 
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APPENDIX D: PBMC-based IFN-G Stimulation Assay 
 
a. Material and Methods 
 
i. PBMC cell isolation 
 
Human buffy coats (purchased from the South African National Blood Services), which had been 
separated from whole blood by initial hard-spin, were used for extraction of peripheral blood 
mononuclear cells (PBMC). Approximately 200 ml of human buffy coat was diluted with an 
equal volume of 1x PBS (Sigma-Aldrich, MO, U.S.A) (Total of 400 mL). Twenty-five millitres 
(25 mL) of the diluted buffy coat was then layered onto 20 mL Ficoll-Paque
TM
 (GE HealthCare, 
LifeSicences, UK) in a 50 ml centrifuge tube at room temperature. The tubes were centrifuged at 
800 g for 30 minutes at room temp (maximum acceleration, no brakes). The buffy layer was then 
carefully removed from on top of the Ficoll layer and diluted into PBS (25 mL PBS per tube).  
The PBMC were gently mixed and centrifuged at 3200 g for 20 minutes at 16
o
C (max. 
acceleration, brakes on). The supernatant was discarded and the pellet resuspended in 5 mL of 
PBS. A total of 50 mL of PBS was then added to the tubes, which were then centrifuged at 450 g 
for 10 min at 10
o
C (max. acceleration, brakes on). The supernatant was discarded, the cells 
washed again, and the PBMC pellet from each tube resuspended in 2 mL of PBS. The cells were 
counted by trypan blue (Gibco©, LifeTechnology, U.S.A) exclusion using a haemocytometer 
before being stored in cryogenic 2 mL microtubes in freeze media (10% DMSO and 90% FCS)  
at -80
o
C (10 million cells in 1.5 mL per vial). 
 
ii. PBMC culture and stimulation 
 
Twenty million PBMCs were quickly thawed and washed thrice with room temperature PBS by 
centrifuging (3200 g, 3 minutes, max. acceleration, brakes on) before resuspension in 5 mL of 
RPMI cell culture media (See Appendix A.g.i.) containing 20% Fetal Calf Serum (FCS) 
(Biochrom Heat Inactivated FCS, UK). In order to allow for the cells to settle following thawing, 
these were firstly seeded in a 75 cm
2
 culture flask (Easy Nunc, Nunclon D, Denmark) in a total 
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of 30 mL of cell culture medium and allowed to incubate at 37
o
C in a humidified atmosphere 
containing 5% CO2 (standard conditions) overnight. 
 
The PBMCs were then transferred to a 50 mL centrifuge tube and centrifuged at 3200 g for 15 
minutes at room temperature (max. acceleration, brakes on). The supernatant was discarded and 
the PBMC pellet resuspended in 5 mL of culture media containing 10% FCS (Biochrom Heat 
Inactivated FCS, UK). Cells were counted and plated into 24-well culture plates (10
6
 cells in 1 
ml of medium per well) (ThermoScientific
TM
 Nunc
TM
 MicroWell
TM
 24-Well Microplate/ 
Nunclon
TM
-D, Denmark). The cells were incubated for 48 hours under standard conditions prior 
to stimulation with Phytohaemagglutinin (Sigma-Adrich, MO, U.S.A) (PHA, 5 ug/mL). The 
cells then incubated for a further 48 hours. Supernatants were collected and clarified by 
centrifugation at 10000 g for 5 min and stored at -20
o
C. 
 
iii. Assessment of supernatant inhibition of INF-γ 
 
Into 96-well plates (ThermoScientific
TM
 Nunc
TM
 MicroWell
TM
 96-Well Microplate/ Nunclon
TM
-
D, Denmark), 10
5
 cells per well in a total of 200 µL of culture media, were plated. In order to 
assess data statistically, triplicates of experimental wells were used. The cells were incubated at 
37
o
C/5% CO2 for 48 hours prior to stimulation with PHA (Sigma-Adrich, MO, U.S.A) at 5 
µg/mL. Anti-CD4 antibody-containing mouse hybridoma supernatants were then added to the 
PBMC cultures at a dilution of 1:100. As a positive control for CD4+ T-cell activation 
inhibition, the mouse monoclonal anti-CD4 antibody mt310 (Santa Cruz Biotechnology, TX, 
U.S.A) was added to a final concentration of 1 µg/mL. An irrelevant antibody, the anti-HIV 
monoclonal antibody (IgG1b12), which binds the viral envelope glycoprotein (gp120), was 
added at the same concentration as a negative control. Reactions were performed in triplicate, 
and the plates incubated for a further 48 hours. The levels of INF-γ in supernatant samples from 
each well were analysed by the INF-γ detection assay described below. 
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iv. INF-γ detection 
 
Secretion of human INF-γ from PHA-stimulated PBMCs was used as a crude marker of T-cell 
activation, and this was detected by sandwich ELISA using the DuoSet® ELISA Development 
System from R&D Systems (cat. No.: DY285, MN, U.S.A). Reagents and a standard ELISA 
protocol provided by the manufacturer were used. In order to assess data statistically, triplicates 
of experimental wells were used. One hundred microlitres of anti-IFN capture antibody diluted in 
PBS at 4.0 µg/mL was added to wells of 96-well plate (Nunc©, MaxiSorp, Denmark). PBS blank 
controls were included. The plate was sealed and incubated overnight at room temperature. The 
coating solution was aspirated from wells and washed with wash buffer (1x PBS, 0.05% Tween) 
(Sigma-Aldrich, MO, U.S.A) thrice. The plates were then blocked with 300 µL of blocking 
buffer (10mg/mL BSA in PBS-T) (Sigma-Adrich, MO, U.S.A) for 1 hour. The blocking solution 
was removed and the wells washed 3 times before the addition of either 100 µL of thawed 
PBMC supernatant samples, or recombinant human INF-γ control (0 - 1000 pg/ml). Following a 
2 hour incubation at room temperature, the wells were aspirated and washed, and 100 µL of 
detection antibody diluted in reagent diluent at 50 ng/mL was added to the plate wells, which 
were incubated for a further 2 hours at room temperature. The plates were washed after removal 
of the detector antibody solution, and 100 µL of Streptavidin-HRP (1:200 in reagent diluents) 
was added. Following aspiration and washes, 100 µL of TMB-Ultra substrate (Thermo-Pierce, 
U.S.A) was added. Plate was incubated for 20 min at 37
o
C onto a rotary plate. Sulphuric acid, 
100 µL at 1 M, was added to wells to quench reaction. The solution optical densities were 
determined using a plate reader (Fast read, 570/450 nm measure filter, 37
o
C; Bio-Rad Model 650 
Microplate reader; CA, U.S.A). 
 
a. Results 
 
There was enhanced expression and secretion of INF-γ, indicative of robust PHA-mediated 
PBMC/T-cell activation (Figure 33). Based on standards, above 1 mg/mL of INF-γ was detected. 
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i. Preliminary analysis of inhibitory effects of CD4MAb1-40 on T-Cell activation 
 
After confirming the secretion of INF-γ, we set out to verify whether the CD4MAb1-40 had any 
effect in the PHA-stimulated assay. The experiment, as described above, was set up in 96-well 
plates instead (10
5
 cells per well). Supernatants (1:100) were added to corresponding wells and 
the plate was incubated for 48h prior to INF-γ detection. Additionally, mt310 (1ug/ml) and 
IgG1b12 (1µg/ml) were also included in the setup as controls. Mt310 is a known anti-CD4 
antibody (positive control), whereas IgG1b12 is an anti-gp120 antibody (Negative control). It 
was observed that none of the CD4-MAbs, mt310 and IgG1b12 caused any reduction in INF-γ 
secretion following PHA stimulation, indicative of maintenance of PBMC/T-cell activation 
(Figure 34). 
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Figure 34: Preliminary detection of INF- γ produced by PBMCs 
INF-γ detection in PHA stimulated and unstimulated PBMCs. Almost 6.5-fold more INF-γ was detected in 
the cell culture media of PHA stimulated PBMC (green) when compared to unstimulated cells (red), 
representing concentrations above 1 mg/mL INF-γ.  
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Figure 35: Preliminary Analysis of Inhibitory effects of CD4MAb1-40 on T-Cell activation 
PBMC Stimulation Assay with supernatant (1:100), background corrected. As opposed to PHA stimulated experiments, the absence of PHA did not result 
in PBMC stimulation and INF-γ was not overexpressed. Supernatants and antibodies did not have any observable effect on INF-γ expression. It is likely the 
effect of PHA as a mitogenic stimulant results in net PBMC activation that overshadows the influence of the supernatants and antibodies. NB: Samples 6 
and 16 were ignored due to excessive evaporation of media on the wells during incubation.  
Triplicates of experimental data were used for calculating means; error bars represent standard deviation (µ±1sd). Two-tail T-test of experimental versus 
PHA pos./IgG1b12 as control was conducted (in blue); * indicates significant differences (p<0.05) relative to PHA pos/IgG1b12. Whilst these might 
indicate statistically significant differences, these may not be biologically significant - theoretically, PHA acting as a mitogen promotes cellular activation 
irrespective of CD4MAb presence. M85 and M79, used as further controls, are sera from rabbits that were immunised with a gp120-CD4 complex that had 
shown potent pseudoviral inhibition in our laboratory. 
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APPENDIX E: Analysis of CD4MAb-mediated inhibition of CD4-gp120 
binding in vitro 
 
CD4MAb Supernatant dilution 1 2 3 4 5 6 7 
0.1 0.065 0.084 0.033 0.047 0.059 0.076 0.058 
0.01 0.218 0.197 0.131 0.153 0.161 0.151 0.205 
0.001 0.316 0.330 0.275 0.277 0.308 0.225 0.364 
0 0.403 0.436 0.466 0.420 0.415 0.429 0.522 
 
CD4MAb Supernatant dilution 8 9 10 11 12 13 14 
0.1 0.077 0.091 0.064 0.082 0.077 0.031 0.056 
0.01 0.231 0.243 0.255 0.218 0.116 0.129 0.147 
0.001 0.354 0.383 0.399 0.324 0.258 0.223 0.239 
0 0.536 0.568 0.522 0.533 0.538 0.364 0.413 
 
CD4MAb Supernatant dilution 15 16 17 18 19 20 21 
0.1 0.041 0.067 0.022 0.032 0.028 0.013 0.024 
0.01 0.115 0.154 0.103 0.101 0.106 0.104 0.084 
0.001 0.202 0.237 0.162 0.191 0.152 0.156 0.225 
0 0.392 0.420 0.222 0.275 0.269 0.222 0.239 
 
CD4MAb Supernatant dilution 22 23 24 25 26 27 28 
0.1 0.034 0.021 0.031 0.018 0.008 0.018 0.019 
0.01 0.077 0.094 0.108 0.088 0.105 0.076 0.099 
0.001 0.205 0.163 0.157 0.166 0.169 0.159 0.174 
0 0.237 0.219 0.226 0.229 0.218 0.213 0.234 
 
CD4MAb Supernatant dilution 29 30 31 32 33 34 35 
0.1 0.012 0.025 0.029 0.015 0.026 0.029 0.020 
0.01 0.099 0.232 0.219 0.108 0.121 0.115 0.090 
0.001 0.166 0.221 0.223 0.146 0.152 0.155 0.125 
0 0.245 0.243 0.242 0.198 0.207 0.195 0.147 
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CD4MAb Supernatant dilution 36 37 38 39 40 
0.1 0.030 0.021 0.014 0.017 0.025 
0.01 0.090 0.060 0.065 0.081 0.070 
0.001 0.136 0.121 0.122 0.127 0.118 
0 0.187 0.184 0.156 0.159 0.175 
 
Table 5: In vitro gp120 binding inhibition assay 
Inhibition of gp120 (200 ng/ml) binding to 4dCD4-Wt following pre-incubation with CD4-Mab-containing 
supernatants at dilutions of 0.1, 0.01, 0.001 and negative control (PBS). Absorbance readings (570 nm) reflect the 
level of gp120 binding. Triplicates of experimental data were used for calculating means. 
 
APPENDIX F: TCID50 Calculation 
 
The TCID50 of the frozen pseudoviruses stocks (produced and pre-determined by Dr. M. 
Killick) were as follows: 
ZM53:  3,906,250 TCID50 
SF162: 1,746,928 TCID50 
 
An initial two-fold dilution (in DMEM) of viral stocks was made: 
ZM53:  3,906,250/2 = ~1,950,000 TCID50 
SF162: 1,746,928/2 = ~873,000 TCID50 
 
Following determination of viral working concentration (see 3.3.2.1), the 1:500 dilution of 
pseudovirus was selected. Thus, working TCID50 of virus was follows: 
ZM53:  1,950,000/500 = 3900 TCID50 
SF162: 873,000/500 = ~1750TCID50 
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APPENDIX G: ETHIC WAIVER 
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